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General Introduction 
DeoxyriboNucleic Acid, DNA, a substance of high molecular weight, was identified in 1871 by a 
young Swiss scientist, Friedrich Miescher1. Decades later, in one of the culminating points in 
biology of all time, James Watson and Francis Crick cracked the DNA code2. The two strands of 
the double helix are anti-parallel, with a sugar phosphate backbone on the outside while bases 
on the inside form the rung of the ladder. Each rung is composed of two base pairs. Either an 
adenine-thymine (A-T) pair that form a two-hydrogen bond together, or a cytosine-guanine (C-
G) pair that form a three-hydrogen bond. 
Nearly forty years later, a new defining moment was attained when the Human Genome Project 
was initiated in 1990. It was successfully completed in 2003, a year which marks the 50th 
anniversary of the discovery of the double helix structure of DNA by Nobel Prize winners, James 
Watson and Francis Crick. The overall result was the generation of a high-quality reference 
DNA sequence for the human genome‘s 3.2 billion base pairs.    
Available to researchers worldwide, the human genome reference sequence provides a 
magnificent and unprecedented biological resource that serves as a basis for research and 
discovery and, ultimately, a number of practical applications. In 2002, it inspired a consortium of 
researchers to embark on the HapMap project to characterize all single nucleotide 
polymorphisms (SNPs) which are single base differences between individuals. By the end of 
2005, researchers had created a map of these patterns across the genome by determining the 
genotypes of one million or more sequence variants, their frequencies and the degree of 
association between them, in DNA samples from populations with ancestry from parts of Africa, 
Asia and Europe3. In 2007, this consortium reported the completion of over 3 million SNPs, 
which represents a third of the estimated 10 million SNPs in the human genome4. Together, 
these research milestones have successfully formed the foundation of current genetic and 
genomic concepts.  
The central goal of human genetics is to understand the inherited basis of human variation, not 
only in determining differences in phenotypes between individuals but also in elucidating 
predisposition to disease. With these tools in hand, we can now discover sequence variants that 
affect common disease, facilitate the development of diagnostic tools and enhance our ability to 
choose targets for therapeutic intervention. 
This thesis focuses on investigating genetic risk factors in rheumatoid arthritis (RA), an 
autoimmune disease with unknown etiology. While there is a clear genetic component to the 
development of RA5, unraveling the genes predisposing to this complex disease, as well as 
other autoimmune diseases, has been rather elusive. In this chapter, I will provide an overview 
on rheumatoid arthritis, its genetic basis and the genes identified prior to the start of our 
research.  
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Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) (MIM 180300 [OMIM] ) is a chronic autoimmune disease that affects 
approximately 0.5-1% of the adult population worldwide and is associated with significant 
disability and early mortality5. Patients suffer from inflammation of the synovial membrane that 
covers the joint. Joints become red, swollen and tender, and stiffness prevents their use. By 
definition, RA affects multiple joints. Most commonly, small joints of the hands and feet are 
affected, although larger joints like the shoulder and knee can also be involved, differing per 
individual. Eventually, synovitis leads to erosion of the joint surface, causing deformity and loss 
of function6. While the causes of early mortality in RA are not well-known, it may be explained 
by several factors, e.g chronic exposure to inflammation and cumulative toxicity of 
immunosuppressive drugs resulting in an increased risk to infectious, cardiovascular, 
gastrointestinal and respiratory disease7.  
Besides these deleterious consequences for the individual patient, there is a considerable 
socio-economic impact leading to direct and indirect costs of many billion Euros per year. The 
total cost of the disease in 2006 was estimated at €45 billion in Europe and €42 billion in the 
United States8. It is therefore of the utmost importance to understand the basis of this disease 
so as to prevent exorbitant socio-economic costs, but primarily to alleviate patient suffering.  
Diagnosis and Clinical phenotypes of RA 
The diagnosis of RA is based upon a set of clinical and laboratory measures as defined by the 
American College of Rheumatology (Table 1). Once a diagnosis is established, the disease 
course of RA patients remains highly variable, ranging from mild symptoms to chronic 
inflammation and extensive joint damage.  
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Criterion Definition 
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour before 
maximal improvement 
2. Arthritis o  3 or mo e joint 
areas 
At l ast 3 joint areas simultaneously have had soft tissue swelling or 
fluid (not bony overgrowth alone) observed by a physician. The 14 
possible areas are right or left PIP, MCP, wrist, elbow, knee, ankle, and 
MTP joints 
3. Arthritis of hand joints At least 1 area swollen (as defined above) in a wrist, MCP, or PIP joint 
4. Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 2) on 
both sides of the body (bilateral involvement of PIPs, MCPs, or MTPs is 
acceptable without absolute symmetry) 
5. Rheumatoid nodules Subcutaneous nodul s, over bony prominences, or extensor surfaces, 
or in juxtaarticular regions, observed by a physicia  
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum rheumatoid factor by any 
method for which the result has been positive in <5% of normal control 
subjects 
7. Radiographic changes Radiographic changes typical of rheumatoid arthritis on posteroanterior 
hand and wrist radiographs, which must include erosions or 
unequivocal bony decalcification localized in or most marked adjacent 
to the involved joints (osteoarthritis changes alone do not qualify) 
 
Table1. American College of Rheumatology (ACR) 1987 revised criteria for the classification of Rheumatoid Arthritis. 
A patient is diagnosed with rheumatoid arthritis if he/she has satisfied at least 4 of the 7 criteria described below. 
Crit ria 1 through 4 must have been present for at least 6 weeks. Patient  with 2 clinical diagnoses are not excluded.  
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RA patients who fulfill the ACR criteria can be divided into two main subsets; those who 
possess circulating autoantibodies “autoantibody positive” and those who do not “autoantibody 
negative”. In the context of this thesis, the term autoantibody positive or negative will refer to the 
presence or absence of either of the two autoantibodies that play a major role in RA, namely, 
Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). The classical 
autoantibody associated with RA is RF, an autoantibody directed against the Fc part of 
immunoglobulin G. RF is not unique to RA, and is present in other autoimmune diseases, 
infectious diseases and healthy (elderly) individuals. RF is found in 60-70% of RA patients9. In 
contrast, ACPAs are antibodies directed against citrullinated proteins. Citrullination is the post-
translational modification of protein-bound arginine into the non-standard amino acid citrulline. 
This process results in a small change in molecular mass and the loss of a positive charge10. 
These autoantibodies appear early in RA and can be detected years before disease onset11,12. 
While being found in 50–70% of patients, ACPAs display a unique specificity for RA and are 
rarely detected in other diseases or in healthy controls10,12,13. The relevance of these 
autoantibodies in disease is exemplified by the fact that patients harboring these autoantibodies 
generally have a more severe disease course14,15. However, whether either of these two 
autoantibodies are part of a mechanism of disease initiation is still unclear. In contrast, no doubt 
exists that these autoantibodies represent a very useful tool in both diagnostic and prognostic 
terms16, as well as in defining a more homogeneous subset of patients to enhance the discovery 
of risk factors involved17. 
The role of environment and genetics in RA 
RA is considered to be a complex disease, and although the full etiology remains unclear, it is 
widely accepted that interrelated contributions from environmental and genetic factors play a 
major role18. Interestingly, environmental risk factors so far encompass age, gender, smoking, 
pregnancy, infections, diet and weather19 (reviewed in Kobayashi et al). While there is an 
elevated incidence with an increase in age20, the female to male ratio of RA patients is ~3:15, 
and generally smokers have a higher propensity to develop RA21.  
There is however a rather large genetic component to RA. Evidence from twin studies 
demonstrates excess disease concordance between monozygotic (15%) when compared with 
dizygotic (3.6%) twins(22). From such studies, the genetic contribution to RA has been 
estimated between 50% and 60%23. The increased risk of disease in siblings of patients with RA 
compared with that of the general population ( s) has been estimated to be between 2 and 17 
fold24. These data altogether provide compelling evidence of the role of genetics in the 
development of RA.  
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HLA, the most prominent genetic risk factor in RA 
The most prominent genetic association is confined to the human leukocyte antigen (HLA) locus 
on the short arm of chromosome 6. HLA-DR gene variants have been consistently associated 
with RA across several populations and in microsatellite-based whole genome screens on 
affected sibling pair families in Europe, US, UK and Japan25-31. This method involves a search 
for increased sharing of particular genetic regions among affected siblings. The association of 
HLA with RA has been mapped to the third hypervariable region of DR -chains, especially aa 
70–74, encoding a conserved amino acid motif (QKRAA, QRRAA, or RRRAA). This 
susceptibility epitope, called the shared epitope (SE), is found in multiple RA-associated DR 
molecules, including DR1, DR4, DR10 and DR14 (i.e DRB*0101, DRB*0102, DRB*0401, 
DRB*0404, DRB*0405, DRB*0408, DRB*1001 and DRB*1402)(32). However, amino acids 
encoding the DERAA motif (i.e. DRB*0103, DRB *0402, DRB *1102, DRB *1103, DRB *1301, 
DRB *1302 and DRB *1304) at the same position have a protective effect on the development 
of RA33-36.  
The HLA region is gene-rich consisting of over 100 immune-related genes that could be 
potentially relevant to the pathogenesis of RA37-39. Therefore, understanding of the biological 
role of this region in RA remains to be discovered. However, since the association with the HLA 
region only accounts for approximately 30% of the genetic burden to RA, it implies that 
additional genetic risk factors play a role in RA40. 
Non-HLA genes in RA 
A number of markers outside the HLA region did emerge from these four microsatellite-based 
whole genome studies which were suggestive of linkage with RA, although the effect of the HLA 
region is by far the strongest. One problem is that such studies have weak power to detect 
modest effects. In contrast, because such studies are simultaneously testing a large number of 
regions which may be linked with disease, the likelihood of a false-positive result is very high. 
Regions of linkage also tend to encompass large genetic regions containing a large number of 
genes making it difficult for researchers to progress from the linkage region to the causal gene. 
It is therefore not surprising that studies often failed to replicate their results. 
One of the few success stories came from a Japanese group. Following indications of linkage 
from the overlapping locus on chromosome 1p36 among certain genome-wide scans, 
Yamamoto and colleagues observed that this genomic region contains a cluster of enzymes that 
is functionally associated with the production of rheumatoid arthritis–specific autoantibodies. 
These enzymes are the peptidylarginine deiminases (PADIs), which posttranslationally convert 
arginine residues to citrulline. Fine-mapping of this region containing four of these enzymes 
(PADI 1-4) located next to one another revealed that polymorphisms in the PADI4 gene are 
strongly associated with RA in the Japanese41. However, whether this gene is associated with 
RA in Caucasians remains a question of debate and so far, no conclusive evidence has been 
obtained42,43.  
Another major breakthrough, employing a large-scale approach did not come from classical 
linkage studies but association studies between patients and healthy individuals in 2004. 
Begovich and colleagues performed a large-scale screen utilizing putative functional SNPs and 
identified a non-synonymous SNP (R620W) in the gene, protein tyrosine phosphatase non-
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receptor type 22 (PTPN22) more frequently in patients than in healthy individuals44. Well 
powered studies have successfully replicated the same association of rheumatoid arthritis and 
the R620W polymorphism, in populations of European descent from the UK, Finland, Sweden, 
Germany, Netherlands, Spain and Canada45 (reviewed by Bowes et al, 2008). Such consensus 
was previously unprecedented. Intriguingly, both HLA-SE alleles and PTPN22 are associated 
with the development of ACPA positive disease(17). It is of note that the PTPN22 R620W SNP 
is not polymorphic in the Japanese population and a haplotype analysis of the region reveals no 
association46.  
The same PTPN22 polymorphism has also been associated with several autoimmune diseases 
in Caucasians including among others Juvenile Idiopathic Arthritis and Systemic Lupus 
Erythematosus, Graves disease and Addison’s disease47-49, indicating the genetic risk factors 
may not be unique to a specific disease but can be promiscuously associated with other 
autoimmune diseases.  
An alternative approach to genome-wide strategies is to use a candidate gene screen which 
takes a hypothesis-driven approach. While this strategy has generated a huge amount of 
literature, it has not been very fruitful in the identification of consistent and replicable risk factors 
for RA outside the HLA region. With the advent of new technologies in genotyping a large 
number of variants and the availability of SNP data from the HapMap consortium, considerable 
progress has been made in this field, enabling researchers to perform highly improved 
association studies.  
Outline of this thesis  
The identification of RA-associated genes outside of the HLA region has been a challenge. 
Although the expected effect of genetic factors outside the HLA region are modest, the 
identification of risk loci through human genetic studies offers prima facie evidence that a 
biological pathway is critical in disease pathogenesis. Therefore, the aim of this thesis was to 
take a candidate gene approach to identify risk factors involved in rheumatoid arthritis. It is 
divided into three parts in which part one is dedicated towards the investigation of a region of 
the genome  encompassing genes highly involved in the immune system, namely Tumour 
Necrosis Factor (TNF) Receptor associated factor 1/Complement component 5 (TRAF1/C5) on 
chromosome 9q33. In the second part, we have investigated the role of an immunoregulatory 
cytokine interleukin 10 (IL10) located on chromosome 1q32 and in part three we have 
investigated the role of additional genetic risk factors in RA.  
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In the first part of the thesis, we have investigated the role of the TRAF1/C5 region in RA as 
well as other autoimmune diseases. In chapter 2, we have described the TRAF1/C5 region as 
one of the few widely-replicated genetic risk factors for RA. Based on available information in 
mouse models50-52 and indications from human studies53, we hypothesized that the C5 region 
may play a role in the development and/or exacerbation of arthritis. By genetic fine-mapping 
studies, we identified the haplotype associating with disease and replicated our findings in 4 
different cohorts derived from three different populations from the Netherlands, US and Sweden. 
Intriguingly, a genome wide association study (GWAS) on SNPs performed by Plenge et al 
identified the same TRAF1/C5 region, in addition to the previously known HLA and PTPN22, as 
genetic risk factors for RA54.   
To further establish this risk factor, we have reproduced this association in trio families in which 
both parents are unaffected and one offspring affected with RA (Chapter 3). This locus 
represents the third genetic risk factor for which association is found in family-based studies as 
well. Together, these findings firmly establish the TRAF1/C5 region as the one of the confirmed 
genetic risk factors for RA. 
In the recent years, it has been suggested that there may be a considerable heritable 
component to autoimmune diseases55. While certain diseases such as RA tend to occur among 
several members of the same family indicating a genetic component to that specific disease, it 
is also common to observe different autoimmune diseases in various family members as well as 
in a particular individual, suggesting that certain individuals may have inherited a set of genetic 
risk factors predisposing them to the development of an autoimmune disease. Our work has 
now shown that the TRAF1/C5 region is not only relevant for RA but is also relevant in patients 
with a polyarticular form of juvenile arthritis (JIA) (Chapter 4). Behrens and colleagues have 
now also independently reported an association of a perfect proxy to JIA further supporting our 
findings56.  
To test whether this region predisposes to other diseases we also investigated its relevance in a 
well-powered study including four additional autoimmune diseases including Type I Diabetes 
(TID), Celiac Disease (CD), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE) 
patients and a common set of controls consisting of healthy unrelated individuals that were 
geographically and ethnically matched. We observe and replicate modest associations to both 
T1D and SLE and did not observe any evidence of association to CD and SSc (Chapter 5).  
With these studies, we have provided considerable evidence that the TRAF1/C5 region is not 
only relevant to RA but that the frequency of the same allele is increased in JIA, T1D and SLE. 
It is therefore highly likely that the TRAF1/C5 region is a genetic risk factor involved in a shared 
pathway underlying multiple autoimmune diseases. 
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The second part of this thesis addresses the role of interleukin 10 (IL10) genetic variants in 
regulating expression levels and their role in disease. IL10 is a cytokine with key regulatory, 
anti-inflammatory and immuno-stimulatory functions involved in the pathogenesis of various 
diseases57-60.  Interindividual differences in the production of IL10 have been extensively 
associated with polymorphisms and haplotypes of the IL10 gene61. The A allele of IL10-2849, a 
polymorphism located in the promoter region, is associated with decreased IL10 production as 
measured by lipopolysaccharide (LPS) stimulated whole blood cultures62. A low innate 
production of IL10 using the same assay is associated with an increased risk of familial 
osteoarthritis (OA)63. Therefore, in chapter 6, we investigate the role of IL10 in osteoarthritis 
and observe no association of 7 promoter SNPs with disease.  
While there is a direct correlation between IL10 mRNA and protein levels  and high and low IL10 
producers have similar mRNA halflife(64), little evidence existed that this variation in clinically 
relevant levels of IL10 is actually dictated by IL10 haplotypes. In chapter 7, by using the 
technique of allele-specific transcript quantification (ASTQ), the ratio between two alleles (A and 
G) of the IL10 gene was characterized in 15 healthy heterozygous individuals. We show that 
IL10 alleles are indeed differentially transcribed in cells from heterozygous individuals and that 
IL10 haplotypes likely dictate the production of IL10. These findings show, for the first time, that 
interindividual differences in IL10 protein levels could be partially explained at the allele-specific 
transcriptional level.  
In RA, the IL10-A2849 G allele has been shown to be associated with differences in titres of 
autoantibodies (RF and ACPA). Moreover the rate of joint destruction in RA patients from the 
early arthritis cohort was twice as high in patients that were –2849G carrier to those who were 
not (median rate per year 8 versus 4 SHS units on X-rays of hand and feet)(65). As the length of 
the haplotype block around IL10 is highly relevant to the search for the functional 
polymorphism(s), we characterized the level of linkage disequilibrium in a region of 217 kb, 
encompassing IL10 as well as its neighbouring homologues (IL19, IL20 and IL24). We showed 
that the neighboring genes are unlikely to harbor functional cis-acting variants (chapter 8). In 
this chapter we also report an association of IL10 polymorphisms with restenosis. Stenosis 
occurs when a coronary artery constricts or narrows. One way to widen a coronary artery is by 
using percutaneous coronary intervention (PCI, or balloon angioplasty). Some patients who 
undergo PCI have restenosis (renarrowing) of the widened segment within about six months of 
the procedure. Restenosed arteries may have to undergo another angioplasty. Inflammation is 
thought to play a key role in the development of restenosis and concordantly, we observed that 
patients with a lower innate ability to make IL10, favouring a pro-inflammatory environment, are 
at a high risk of undergoing restenosis. 
We further fine-mapped the immediate IL10 region. Six tagging SNPs have been genotyped in 
our extensive and clinically well-defined RA cohorts to determine their relevance to clinical 
remission and severity of RA (Chapter 9). While there is conflicting evidence that the IL10 gene 
is associated with the development of RA, there is no indication in our cohort of the involvement 
of IL10 in either clinical remission or the progression of joint destruction in RA.  
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In the third part of this thesis, the role of other genetic risk factors (besides IL10 and 
TRAF1/C5) is described. In chapter 10, the role of TNF  in predisposing patients towards a 
more severe disease course is investigated. While increased levels of TNF  are found in 
patients with RA18 and the treatment of patients with anti-TNF agents do provide beneficial 
effects66, very little evidence exists that variations in the gene predispose individuals to the 
development or progression of rheumatoid arthritis, implying that increased TNF production in 
RA patients is most likely due to other molecules in the signaling cascade leading to the 
enhanced production of TNF  protein. One such molecule TNF -induced protein 3 (TNFAIP3) 
on chromosome 6q23 has recently been associated with development of RA(67;68). TNFAIP3 
is a negative regulator of NF!B and as such is involved in inhibiting TNF-Receptor mediated 
signaling effects69. Interestingly, the initial association was detected in cohorts of patients with 
long-standing RA. However, no association was found in a Swedish early arthritis cohort. We 
therefore hypothesized that the 6q23 locus containing TNFAIP3 may be predominantly 
associated with a phenotype consistent with more severe disease. To determine whether this is 
the case, we set out in chapter 11 to analyze the effect of the 6q23 region on the rate of joint 
destruction in our large and well-described early RA cohort.  
One of the rare success stories for RA from the classical microsatellite-based linkage approach 
came in 2007, when candidate genes were investigated under a linkage peak on chromosome 
2q in the US study. The 13 candidate genes investigated revealed strong association at four 
strongly linked SNPs in an intron of the gene signal transducer and activator of transcription 4 
(STAT4)67. The data from STAT4 (Chr2q33) has already been consistently replicated in not only 
Caucasians but also in East Asians68-71. This is however not the case for the other signal 
observed under the same linkage peak in this study, namely cytotoxic T lymphocyte associated 
4 gene (CTLA4). Originally identified as a determinant of susceptibility to autoimmune diseases 
including Grave’s disease, Type 1 Diabetes and autoimmune hypothyroidism72, this locus has 
been a constant debate in RA42. In chapter 12, we perform independent replication and a meta-
analysis of three loci including STAT4, CTLA4 and the recently described 4q27 region 
containing the IL2 and IL21 genes73. We show a strong association with STAT4 and as 
previously described, no preferential association was observed with ACPA status. More 
importantly, we confirm the role of CTLA4 in RA, resolving a longstanding debate of whether 
does or does not predispose to RA. We additionally show for the first time that the association is 
restricted to ACPA positive individuals only. For the 4q27 locus, we provide independent 
replication of the data and indicate that for this locus, in contrast to previous findings, no 
differences in effects are seen in ACPA positive and ACPA negative individuals. However, these 
data have to be interpreted with caution due to a possible lack of power. Interestingly, we also 
observe an association between the 4q27 locus and juvenile arthritis as described in chapter 
13.  
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While most described genetic risk factors in RA either predispose to the autoantibody positive 
subset of patients or both, data is extremely scarce when it comes to patients who harbor none. 
One genetic risk factor in the HLA region, DRB*0301, has been consistently associated with 
ACPA negative disease74,75. In chapter 14, we describe the identification of the only non-HLA 
genetic factor, Interferon Regulatory factor 5 (IRF5), showing a predominant association with 
ACPA negative disease. A recent report confirmed these findings but also show a small effect in 
ACPA positive disease76.  
Chapter 15 provides an overview of novel genetic risk factors in ACPA positive RA, identified 
with the use of a meta-analysis of three well-powered GWAS studies from the US, Sweden and 
the UK. Simultaneously, the UK group confirmed 3 of the loci identified in the meta-analysis 
including MMEL1, PCRKQ and KIF5A80. Two additional loci surfaced in their study providing 
compelling evidence for IL2RB and suggestive evidence for IL2RA. In Chapter 16, we provide 
the first independent study replicating these two risk factors in a non-UK population, underlining 
the relevance of the IL2 pathway in RA. Finally in Chapter 17, I discuss the biological relevance 
and potential implications of all these identified RA loci, summarizing the recent explosion of 
genetic findings in RA.  
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Abstract 
Background  
Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting ~1% of the population. 
The disease results from the interplay between an individual’s genetic background and unknown 
environmental triggers. Although human leukocyte antigens (HLAs) account for ~30% of the 
heritable risk, the identities of non-HLA genes explaining the remainder of the genetic 
component are largely unknown. Based on functional data in mice, we hypothesized that the 
immune-related genes complement component 5 (C5) and/or TNF receptor-associated factor 1 
(TRAF1), located on Chromosome 9q33-34, would represent relevant candidate genes for RA. 
We therefore aimed to investigate whether this locus would play a role in RA. 
Methods and Findings  
We performed a multitiered case-control study using 40 single-nucleotide polymorphisms 
(SNPs) from the TRAF1 and C5 (TRAF1/C5) region in a set of 290 RA patients and 254 
unaffected participants (controls) of Dutch origin. Stepwise replication of significant SNPs was 
performed in three independent sample sets from the Netherlands (ncases/controls = 454/270), 
Sweden (ncases/controls = 1,500/1,000) and US (ncases/controls = 475/475). We observed a significant 
association (p < 0.05) of SNPs located in a haplotype block that encompasses a 65 kb region 
including the 3  end of C5 as well as TRAF1. A sliding window analysis revealed an association 
peak at an intergenic region located ~10 kb from both C5 and TRAF1. This peak, defined by 
SNP14/rs10818488, was confirmed in a total of 2,719 RA patients and 1,999 controls (odds 
ratiocommon = 1.28, 95% confidence interval 1.17–1.39, pcombined = 1.40 × 10
!8) with a population 
attributable risk of 6.1%. The A (minor susceptibility) allele of this SNP also significantly 
correlates with increased disease progression as determined by radiographic damage over time 
in RA patients (p = 0.008). 
Conclusions  
Using a candidate-gene approach we have identified a novel genetic risk factor for RA. Our 
findings indicate that a polymorphism in the TRAF1/C5 region increases the susceptibility to and 
severity of RA, possibly by influencing the structure, function, and/or expression levels of 
TRAF1 and/or C5. 
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Introduction 
Rheumatoid arthritis (RA) is characterized by chronic inflammation and destruction of the 
synovial joints leading to progressive joint damage and disability. The disease has a complex 
etiology, including a wide spectrum of clinical manifestations, variability in disease severity 
and/or progression, and differential response to a range of therapies. This heterogeneous 
phenotype suggests the involvement of both environmental and genetic factors [1], where the 
genetic component of RA has been estimated to be between 50%–60% [2,3]. Identification of 
disease-associated genes is important as it will guide our understanding of the biological 
pathways underlying polygenic diseases and the development of potential novel therapeutic 
targets. 
The most prominent genetic association in RA is confined to the human leukocyte antigen (HLA) 
locus. Although this association has been known for almost 30 years, and although the 
underlying mechanism is still not understood, it has been replicated in multiple studies [2,4]. The 
identification of RA-associated genes outside of the HLA region, however, has been a 
challenge. Recently one such gene, protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) (PTPN22), was identified in the first step of a large genetic-association study utilizing 
putative functional SNPs [5]. The gene product encoded by PTPN22 is, like the HLA locus, 
involved in T cell-mediated immune responses. However, other immune components are also 
thought to play a pivotal role in RA, as demonstrated by the beneficial effects of treatment with 
agents that block proinflammatory cytokines, such as tumor necrosis factor α (TNFα) [6]. 
Moreover, in several experimental animal models for RA, innate immune responses mediated 
by a diversity of players have been implicated in arthritis. In this respect, a prominent role for the 
complement system has been identified as mice deficient in complement factors are resistant to 
arthritis, and as it has been shown that targeting complement component 5 (C5) by antibodies 
prevents the onset of arthritis and reduces the clinical severity in mouse models for arthritis 
[7,8]. Likewise, the observation that high levels of C5a, a potent chemoattractant, are found in 
synovial fluid of RA patients combined with the fact that C5a receptor-deficient mice are also 
resistant to arthritis induction, indicate a central role for these mediators in arthritis [9,10]. A 
genome scan of mice that were or were not susceptible to antibody-induced arthritis revealed 
that the main genetic influence detected in this model maps to the C5 region [11].  
These functional data in mice inspired us to hypothesize that the C5 region would be a 
contributing factor in RA. Therefore, we searched for further evidence by first addressing the 
question of whether any genetic indications exist that implicate the involvement of this region in 
RA. A conventional linkage study using microsatellite markers identified a linkage peak in the 
vicinity of the C5 region [12]. Although this study provided weak evidence for linkage (logarithm 
of the odds score, LOD 1.8), it further boosted our interest in this region. C5 is located next to 
TNF receptor-associated factor 1 (TRAF1), an essential effector of the TNF signaling cascade. 
Since TNF blockade represents a powerful intervention in both mice and humans for the 
treatment of arthritis, it provided an additional rationale to explore this genetic region encoding 
C5 and TRAF1, which are adjacent to each other on Chromosome 9q33-34. We therefore 
sought to investigate whether these candidate genes, which are important immune mediators, 
would play a role in RA. 
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Methods 
Study Populations 
All RA patients in all sets in this study met the American College of Rheumatology 1987 revised 
criteria for RA [13]. Sample set 1 cases consisted of 290 RA patients consecutively included 
from the out-patient clinic of the Leiden University Hospital in 1994 [14] and 254 controls 
randomly selected by the section Immunogenetics and Transplantation Immunology of Leiden 
University Medical Center, Leiden, The Netherlands (ITI). 
Since 89% of the first set of RA patients were rheumatoid factor (RF) positive, we genotyped an 
independent sample set 2, which consisted of 454 RF-positive patients from two inception 
cohorts of early arthritis patients (EAC and BEST) and a second set of 270 randomly selected 
Dutch blood donors from ITI. Briefly, the EAC consists of patients included from 1993 onwards 
and originating from a health care region of about 400,000 inhabitants in the western part of The 
Netherlands. General practitioners were encouraged to refer patients directly when arthritis was 
suspected. Patients were included when the symptom duration was less than 2 y. Patients from 
the BEST study were recruited between March 2000 and August 2002 at 20 centers in the 
western part of The Netherlands. Patients had a maximum disease duration of 2 y, were at least 
18 y of age, and had active disease (defined as   six swollen joints,   six tender joints, and 
either an erythrocyte sedimentation rate of   28 mm/h or a global health assessment score of   
20 on a 100-mm visual analog scale, where 0 = best and 100 = worst). Only patients with a 
diagnosis of RA were included in the present study. These cohorts are further described in 
detail in other reports [15,16].Sample set 3 consisted of 1,500 RA patients (70% RF-positive) 
and 1,000 unaffected participants (controls) from the Swedish EIRA study as previously 
described [17]. Briefly, RA patients and controls aged 18–70 y during May 1996 to December 
2003 from a geographically defined area in the south and central regions of Sweden. Control 
participants were randomly selected from a continuously updated national population register, 
with consideration given to age, sex, and living area. If the selected control was not traceable, 
reported having RA, or refused to participate, a new control was selected using the same 
procedure. 
Sample set 4, obtained from the Genomics Collaborative, (GCI), comprised 475 RF-positive RA 
patients and 475 individually matched controls from the US and has been described in detail 
elsewhere [5]. In brief, all case samples were from white North Americans who were RF-positive 
and whose condition met the 1987 American College of Rheumatology diagnostic criteria for 
RA. Control samples were taken from a pool of healthy white individuals with no medical history 
of RA. A single control was matched to each case on the basis of sex, age (±5 y), and ethnicity 
(grandparental country/region of origin). 
Patients from sample sets 1 and 4 had considerably longer disease duration at inclusion (13.8 ± 
10.1 y and 11.7 ± 10.0 y, respectively) as compared to patients from sample sets 2 and 3 (<3 y) 
(Table S1). All controls were healthy unrelated white individuals originating from the same 
geographical area as the patients. There was no overlap between cases and controls across all 
studies. All protocols and recruitments were approved by national and/or local institutional 
review boards, and informed written consent was obtained from all participants. 
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SNP Selection and Genotyping  
We chose 40 polymorphisms spanning TRAF1/C5 and their flanking genes PHD finger protein 
19 (PHF19) and centrosomal protein 110 kDa (CEP110) for this study (Table 1). We selected 
haplotype tagging SNPs (htSNPs) from the International HapMap Project database 
(http://www.hapmap.org/index.html) as well as random SNPs from the University of California 
Santa Cruz database (http://genome.ucsc.edu/) to ascertain maximum haplotype information for 
each of the genes and intergenic regions that are likely to harbor regulatory regions. 
Chromosomal locations of the SNPs were extracted from SNPPER (http://snpper.chip.org/) 
Goldenpath hg17, dbSNP build 123. Genotyping across all studies was performed as described 
in detail in Protocol S1. Three of the 40 SNPs were excluded from further analysis after 
reviewing results from sample set 1, two of which (SNP13/rs4837803 and SNP27/rs10119768) 
were not polymorphic and one (SNP35/rs7856420) of which deviated from Hardy-Weinberg 
equilibrium. 
Statistical Analysis 
Single SNP and haplotype analysis 
Single SNP analysis and genetic model assessment was initially performed using SPSS version 
12.0 (SPSS, http://www.spss.com/) in sample set 1. We did not find evidence of a recessive 
model for any SNPs. Since all SNPs were in Hardy-Weinberg equilibrium and adhered to the 
additive model of association, we performed further tests using allelic comparisons. Single- and 
multilocus allelic analyses were performed using Haploview version 3.32 (MIT, 
http://www.broad.mit.edu/mpg/haploview/) [18] with 40 SNPs in sample set 1 followed by six 
significant SNPs in sample set 2, the three most significant SNPs in sample set 3, and the 
single best-associating SNP in sample set 4. Odds ratios were calculated using Epi Info v6 
(CDC, http://www.cdc.gov/epiinfo/). All p-values reported were two-sided. A p-value < 0.05 was 
considered significant. Based on the linkage disequilibrium (LD) structure in sample set 1, 
haplotype blocks were inferred under the algorithm of Gabriel et al. [19] in Haploview 3.32. To 
further minimize haplotypic uncertainty, we used the software TagSNPs version 1.0 (http://www-
rcf.usc.edu/~stram/tagSNPs.html) to identify eight htSNPs from block 2 and ten htSNPs from 
block 3 (global R2h > 98%) [20]. The R
2
h coefficient is the squared correlation between the true 
haplotype count (number of copies of a haplotype) and the haplotype count predicted by 
TagSNPs. We chose htSNPs so that haplotypes were predicted with a global R2h value of 0.95 
or above, indicating a high accuracy. Haplotype analyses using these htSNPs were performed 
in Haploview 3.32. Global p-values for haplotype associations were calculated using the 
software Haplo.Stats version 1.2 (http://mayoresearch.mayo.edu/mayo) used for estimating 
haplotype effects under the generalized linear model [21]. htSNPs from blocks 2 and 3 in 
sample set 1 were further investigated by sliding-window analysis in Haploview 3.32 to 
determine the basis of the associated haplotypes. 
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Combining datasets  
Odds ratios (OR)s from all sample sets were combined by the random model of the Cochran-
Mantel-Haenszel test as implemented in EasyMA [22]. A Breslow-Day test of between-stage 
heterogeneity was also performed in EasyMA to test for consistency across sample sets [23]. 
We observed evidence of heterogeneity for SNP rs4836834 at p < 0.05 (Table S2). 
Logistics regression  
Forward conditional logistics regression was performed using all six significant SNPs from sets 
1 and 2 in SPSS 12.0. Genotypes were coded as categorical variables 0, 1, and 2 with the 
nonassociated genotype as reference. No evidence of a recessive effect was observed, as 
detailed in Table S3. 
Population attributable risk  
Population-attributable risk (PAR) was calculated using the population prevalence of the 
exposure (P) and the relative risk associated with the exposure (R), as follows [24]. 
 
Autoantibodies 
Baseline laboratory parameters included IgM-RF (ELISA) and IgG-ACPA (ELISA, Immunoscan 
RA Mark2, Euro-Diagnostica, http://www.eurodiagnostica.com/). The cut-off for antibody 
positivity was set according to the manufacturer’s instructions. Since baseline ACPA status was 
not available for most samples from the BEST study, we restricted our analysis to the EAC and 
EIRA cohorts. Autoantibody (RF and ACPA) and genotype status were available from 419 
patients from the EAC (we additionally genotyped RF-negative and ACPA-negative patients in 
this cohort) and 1,395 patients from the EIRA study. 
Severity  
Radiographs of hands and feet were scored at baseline and 2 y (n = 278) using the Sharp–van 
der Heijde method (erosions and joint space narrowing of hands and feet) [25]. Data was 
available from 193 A carriers (AA+AG) and 85 non-A carriers (GG) from the EAC cohort. The 
prevalence of either RF (A carriers 0.9%, non-A carriers 56.5%, p = 0.485) or anti-citrullinated 
protein antibodies (ACPA) (A carriers 60.7%, non-A carriers 60.8%, p = 0.986) is not 
significantly different between the two groups analyzed. Differences in means between groups 
were calculated using sharp scores adjusted for baseline with a two-sided nonparametric Mann-
Whitney test. 
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Transcription Factor Binding Sites 
Transcription factor binding sites (TFBSs) were predicted using MAPPER 
(http://bio.chip.org/mapper/mapper-main), a latform that combines information from two well-
known TFBS databases, TRANSFAC and JASPAR. The prediction is generated from a hidden 
Markov model and is based on experimentally determined binding sites in multiple genomes 
[26]. 
Results  
The TRAF1/C5 Region Associates with RA  
To investigate whether the TRAF1/C5 region on Chromosome 9q33-34 associates with RA, we 
selected a total of 40 polymorphisms spanning these candidates and their flanking genes for 
genotyping. Tagging SNPs as well as random SNPs were included to ascertain maximum 
haplotype information for each of the genes and to ensure coverage of intergenic regions which 
may harbor regulatory polymorphisms. 
Single SNP analysis performed in the first set of RA patients (n = 290) and controls (n = 254) 
revealed significant association between six SNPs in the TRAF1/C5 region (SNPs 4, 7, 10, 14, 
15, and 16) and RA (p = 0.0104, 0.0153, 0.0080, 0.0039, 0.0039, and 0.0250, respectively) 
(Table 1). One SNP in PHF19 (SNP3/rs10985070) and one in CEP110 (SNP36/rs10818503) 
also showed moderate association with RA (p = 0.0387 and 0.0257, respectively). None of the 
SNPs investigated showed evidence of a recessive mode of association. 
To delineate the haplotypic architecture, we estimated the underlying haplotype block structure 
of the 32 SNPs with minor allele frequency > 5% in the controls. We identified a potential 
recombination spot at SNP3/rs10985070 and SNP24/rs7026551 that divides the region into 
three inheritance blocks, blocks 1, 2, and 3. Block 1 is 8 kb and encompasses the 3  end to 
intron 9 of PHF19; block 2 extends from TRAF1 through 24 kb of intergenic sequence to exon 
32 of C5; while block 3 (178 kb) contains the remainder of the C5 gene and CEP110 (Figure 
1A). The LD structure in the Dutch population was similar to the structure reported by the 
International HapMap Project (unpublished data). 
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Data in bold indicate significant SNPs. 
a. Chromosomal locations were extracted from SNPPER Goldenpath hg17, dbSNP build 123. 
b. Number of alleles were compared in cases versus controls: allele1:allele2 cases, allele1:allele2 controls. 
c. Frequency of the susceptibility allele. 
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 Figure 1. LD Structure and Haplotype Association across the TRAF1/C5 Region in Sample Set 1 (290 RA Patients 
and 254 Controls)  
(A) Haplotype block structure was predicted on the basis of the strength of pairwise LD, which is presented as a 2×2 
matrix; red represents very high LD.  (D’), white indicates absence of correlation between SNPs, and blue indicates 
high correlation with a low level of significance. SNPs that were chosen for haplotype analysis are indicated along the 
top by an asterisk.   
(B) Using htSNPs from each block, indicated by the asterisk in (A), haplotypes were inferred with a certainty of above 
98% as represented by the R
2
h value. 
¥
Comparisons were made between one haplotype versus all others in cases 
and controls. 
a
The protective haplotype that is significantly less frequent in cases. 
b
The susceptible haplotype that is 
significantly more frequent in patients. 
(C) Sliding window of the susceptible haplotype using consecutive two-SNP combinations of the htSNPs reveals that 
SNP14 and SNP15 account for most of the association observed. For each of the SNP pairs we show the –log10 p-
value. The dotted line indicates a nominal p-value of 0.005. 
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To further minimize haplotypic uncertainty and to identify the minimal combination of SNPs that 
provide maximum information content within each block, we scanned these two blocks 
independently using the software TagSNPs. In block 2 we identified a minimal set of eight 
htSNPs with a global R2h of 0.996, and in block 3 we found ten htSNPs with an R
2
h of 0.985, 
indicating that haplotypes can be inferred with >95% certainty. Haplotypes were predicted, and 
analyses from all blocks revealed that the association with RA was restricted to SNPs in block 2 
(Figure 1B), as demonstrated by the global p-value of association (p < 0.05) and suggesting the 
possible involvement of TRAF1 and/or the 3  end of C5.  
 
Of the four common haplotypes capturing > 95% of the variation, two significantly associated 
haplotypes were observed, one increased in RA patients (susceptible haplotypeb p = 0.039), 
and one over-represented in controls (protective haplotypea p = 0.012). By applying a two-
marker sliding window analysis, we observed a significant peak centered on SNP14/rs10818488 
and SNP15/rs2416808 (p = 0.0039) (Figure 1C). Using three- and five-marker windows did not 
alter the outcome, suggesting that the significance seen with the other TRAF1 SNPs (Table 1) 
may be due to LD. To explore this possibility, we analyzed the r2-values with respect to SNP14. 
We confirmed that the most significant SNPs, which are located in TRAF1 and the adjacent 
intergenic region, are highly correlated with SNP14 (r2> 0.90) (Figure 2). 
 
 
Figure 2. RA-Associated SNPs are Highly Linked to 
SNP14 
 
Pairwise LD (r
2
) between associated 
SNP14/rs10818488 and all other SNPs genotyped 
was calculated. For each of the SNPs listed along the 
x-axis we show the –log10 (y-axis) of the p-values for 
RA patients versus controls. Dotted lines indicate a 
nominal p-value of 0.005 and a maximal r
2
 value of 1. 
In a logistics regression model, only 
SNP14/rs10818488 remained statistically significant 
(p = 6.16 × 10!4). 
 
Replication in Three Independent Sample Sets from The Netherlands, Sweden, and the 
US 
Six tagging SNPs which were significant (p < 0.05) in the initial study were selected for 
replication in a fully independent set of Dutch cases and controls (sample set 2). Of these, only 
SNP14/rs10818488 and SNP15/rs2416808 were statistically significant (p < 0.05). Haplotype 
and a two-marker sliding window analysis localized the strongest region of association to 
SNP14 and SNP15, confirming the results from sample set 1 (unpublished data). Combined 
analyses of the data from sample sets 1 and 2 showed an even stronger association for SNP14 
(OR 1.34, 95% confidence interval [CI] 1.13–1.58; p = 5.56 × 10!4)  and SNP15 (OR 1.33, 95% 
CI 1.13–1.57; p = 6.65 × 10!4) (Table 2). Although the other four SNPs did not reach statistical 
significance in sample set 2, they were highly significant in the combined analysis (Table 2). To 
evaluate putative modes of inheritance, we calculated genotype-specific ORs in the combined 
dataset as detailed in Table S3. All SNPs were consistent with an additive model. On the basis 
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of forward conditional logistics regression, SNP14 remained in the model with a heterozygote 
(AG) OR of 1.38 (95% CI 1.04–1.83, p = 0.027) and a homozygote (AA) OR of 2.06 (95% CI 
1.42–2.98, p = 1.29 × 10 3). 
Similar replication of three SNPs in a cohort of Swedish patients and controls (sample set 3) 
confirmed association with SNP14/rs10818488 (p = 0.0078) (Table 2). A combined analysis of 
patients and controls of European origin (Dutch and Swedish) with 2,244 RA patients and 1,524 
controls (sample sets 1, 2, and 3) showed that the most significant associations could again be 
attributed to SNP14 (OR 1.24, 95% CI 1.11–1.38, p = 1.73 × 10 5) and SNP15/rs2416808 (OR 
1.23, 95% CI 1.09–1.40, p = 7.21 × 10 5) (Table 2). Additionally, these findings were further 
replicated in a case-control sample set from the US. Since LD analysis in the original three 
sample sets showed SNP14 and SNP15 to be highly correlated (r2 > 0.98) we genotyped only 
SNP14 and confirmed that the minor susceptibility allele was associated with RA risk (OR 1.36, 
95% CI 1.13–1.64; p = 0.001) (Table 2). Combined analysis of SNP14 in all four independent 
sets ((ncases/controls = 2,719/1,999) yielded a highly significant association ORcommon=1.26, 95% CI 
1.15–1.37, pcombined = 1.40 × 10
 8) and a PAR of 6.1% (95% CI 4.0–8.5). 
 
Data in bold indicate the p-value of the most significant SNPs. 
a. The allele frequencies between allele1:allele2 in cases was compared to allele1:allele2 in controls. Allele 1 refers 
to the susceptibility allele from Table 1. 
b. Mantel-Haenzel OR as calculated under the random model. Raw data can be obtained from Table S2. 
Association with Autoantibody-Positive Disease 
RA is a heterogeneous disease with a considerable variation in phenotype as evidenced by the 
fact that some patients are autoantibody-positive whereas others are not. Antibodies to 
citrullinated protein antigens, called ACPAs, have gained much interest as current data suggest 
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that ACPA-positive and negative RA may have different genetic risk factors [27]. To investigate 
whether the TRAF1/C5 region is associated with a specific phenotype of RA, we next stratified 
patients for autoantibody status from whom baseline ACPA and RF measurements were 
available (n = 1,814) Interestingly, SNP14/rs10818488 mainly predisposes to autoantibody-
positive disease when compared to controls (OR 1.25, 95% CI 1.11–1.40, p = 2.27 × 10 4) 
(Figure 3A). Although we also observed an increase in the frequency of the A allele in 
autoantibody-positive as compared to autoantibody-negative disease, this difference did not 
reach formal statistical significance (OR 1.15, 95% CI 0.98–1.34, p = 0.0789). These data 
therefore suggest that the current genetic risk factor may be predominant in the autoantibody-
positive subset of RA patients. 
Association with Severity 
Because the clinical course of RA can vary considerably ranging from nonerosive disease to 
rapidly progressive joint damage, we also analyzed whether the SNPs in the TRAF1/C5 region 
were involved with RA progression. Annual X-rays of the hands and feet of patients were 
assigned Sharp–van der Heijde units, a combined score for bone erosions and joint space 
narrowing. Carriers of the minor susceptibility allele of SNP14/rs10818488 had an almost 2-fold 
higher severe disease course at 2 y after inclusion as compared to the non-A carriers (Figure 
3B; mean ± SE score of A carriers/non-A carriers, 11.4 ± 1.4/7.1 ± 1.8; p = 0.008) indicating that 
the A allele predisposes not only to RA susceptibility, but also to severity. 
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Figure 3. The A Allele of SNP14 Is Associated with Distinct Phenotypes of RA. (Top, table) The frequency of the A 
allele of patients from whom baseline autoantibody status (ACPA and RF) were available was calculated. ORs and 
pvalues were calculated between each subgroup and controls, and indicated a predominantly higher frequency of the 
A allele in ACPA- and RF-positive patients. (Bottom, bar graph) Progression of joint damage in Sharp–van der Heijde 
units (‘‘Sharp score’’) is higher in the presence of the minor A allele of SNP14. Radiological data of 193 A carriers and 
85 non-A carriers were available, and differences between the groups were calculated based on disease severity 
after 2 y corrected for baseline. 
SNP14/rs 10818488 Is Located in a TFBS 
To investigate the potential functional effect of this SNP, we scanned for transcription factor 
binding sites using MAPPER [26]. The SNP14 susceptibility A allele encodes a potential binding 
site for EP300, a histone acetyl transferase that regulates transcription via chromatin 
remodeling. In the absence of this allele, the binding of EP300 to this region is predicted to be 
disrupted, potentially disturbing the epigenetic tag for transcriptional activation. We hypothesize 
that this putative transcription factor binding site may be involved in the regulation of the 
neighbouring TRAF1 and/or C5 gene. 
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Discussion 
Using a candidate-gene approach, we identified the TRAF1/C5 region on Chromosome 9q33-34 
as a susceptibility and severity factor for RA. This region was also associated with RA in a 
large-scale genetic association study (Schrodi et al., unpublished data). It is, therefore, 
intriguing to see that these independent studies, in which the process leading to results differed, 
give similar results, and in doing so provide strong evidence for the TRAF1/C5 region as a true 
RA-associated genetic variant. The recent genome-wide study performed by the Wellcome 
Trust failed to identify this region as a candidate for RA [28]. Although it is difficult to speculate 
why this region was not detected in the Wellcome Trust Case Control Consortium study, we do 
note that none of the SNPs showing strong association in our hands was genotyped by the 
Wellcome Trust. Additionally, in line with our finding that this genetic risk factor is predominant 
in the autoantibody-positive subgroup, substratifications of the specific RA phenotypes may be 
needed to detect significant association. 
The protein encoded by TRAF1 is a member of the TNF receptor-associated factor (TRAF) 
protein family, which associates with and mediates the signal transduction from various 
receptors of the TNF receptor superfamily, including the receptor for TNFα [29]. In addition to a 
direct role in TNFα signaling, TRAF1 has also been implicated in the activation and proliferation 
of T cells [30] and is expressed ubiquitously by other cells of the immune system including 
monocytes and B cells [31]. It is therefore possible that TRAF1 could play a role in RA by aiding 
the maintenance of the proinflammatory environment. Likewise, studies have also shown that 
perpetuation of inflammation coincides with increased levels of the anaphylatoxin C5a in the 
synovial fluid of RA patients [9]. Further studies in mice identifying C5 as a candidate gene and 
showing that C5 deficiency results in lower incidence and less-severe disease course support 
the role of this gene in inflammation [7,11]. It is therefore likely that although the primary 
function of the complement system is to protect the host from microorganisms, a deregulated 
activity of its central component, C5, can play a substantial role in inflammatory diseases as 
well. 
In order to capture the variation within these candidate genes and potential regulatory regions, 
we genotyped both SNPs that were intragenic and those located 5  and 3  of the genes. 
Interestingly, the strongest replicated association was observed with SNP14/rs10818488, which 
maps to an intergenic region ~10 kb from both TRAF1 and C5 and is present in a TFBS which 
may regulate the transcriptional activity of its neighbouring genes. However, formal testing of all 
known variation within this region, both genetic and biological, will be necessary to pinpoint the 
precise biological process that is altered by the RA-associated variant(s) present in this region. 
We found a strong association of this region in all four independent sample sets which represent 
varying disease durations (<3 to >10 y) as well as a correlation with disease progression. More 
importantly, these phenotypic data on joint destruction not only indicate that the TRAF1/C5 
region predisposes to RA, but also suggest that within the RA population, patients harboring the 
minor susceptibility allele of SNP14/rs10818488 tend to experience a more severe disease 
course. Although the above findings most likely exclude the possibility of a spurious association, 
especially since each case group was assigned an ethnically and geographically matched 
control group, background levels of population stratification as described by Cardon et al. [32] 
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may exist in the different populations under study. It is therefore conceivable that the slight 
variation in the observed effect between the four populations may partially be due to varying 
sample sizes and background levels of population admixture. RA is a common complex disease 
that results from the interaction of multiple genetic variants, each with relatively low penetrance, 
with an array of environmental triggers [33]. In advance of a genetic profile that can accurately 
pinpoint individuals at risk, identification of these genetic variants can provide insight into the 
underlying mechanisms of disease and the specific pathways associated with disease induction 
and/or progression. Understanding the function of these common disease-associated variants 
will be important to identify potential targets for intervention strategies that could prove useful to 
all patients, whether or not they carry the disease-associated variant. 
In summary, this study provides robust evidence from four independent sample sets (two of 
Dutch origin, one of Swedish descent, and one from the US) that genetic variants within the 
TRAF1/C5 region are associated with RA, indicating a possible role for these immune-related 
genes in the biological process underlying RA disease pathogenesis. 
Limitations of This Study 
Our study defines the TRAF1/C5 as a novel genetic region present in the human genome that 
predisposes to RA. However, the causative variation (SNP) or the biological mechanism 
explaining this association is not yet known. Although it could be that the current identified 
polymorphism is causative, other proxies in high LD with this SNP could also be responsible for 
this issue, which can be addressed in more detailed by functional studies. Furthermore, 
although our data indicate a predominant association with autoantibody-positive disease, our 
study is underpowered to exclude the possibility that the TRAF1/C5 region also predisposes to 
autoantibody-negative disease. By combining information obtained from other cohorts in which 
both the autoantibody and the TRAF1/C5 status are known, this question should be resolved in 
the future. As it has been indicated that distinct genetic risk factors underlie either autoantibody-
positive or autoantibody-negative disease, such additional information would provide more 
detailed knowledge on the genetic heterogeneity of these two distinct phenotypes of RA. 
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Abstract 
Objective 
We recently showed, using a candidate gene approach in a case-control association study, that 
a 65-kb block encompassing tumor necrosis factor receptor associated factor 1 (TRAF1) and 
Complement component 5 (C5) is strongly associated with rheumatoid arthritis (RA). Compared 
with case-control association studies, family-based studies have the added advantage of 
controlling potential differences in population structure and are not likely to be hampered by 
variation in population allele frequencies, as is seen for many genetic polymorphisms, including 
the TRAF1/C5 locus. The aim of this study was to confirm this association in populations of 
European origin by using a family-based approach. 
Methods 
A total of 1,356 western European white individuals from 452 “trio” families were genotyped for 
the rs10818488 polymorphism, using the TaqMan allelic discrimination assay. 
Results 
We observed evidence for association, demonstrating departure from Mendel’s law, with an 
overtransmission of the rs10818488 A allele (A = 55%; P = 0.036). By taking into consideration 
parental phenotypes, we also observed an increased A allele frequency in affected versus 
unaffected parents (A = 64%; combined P = 0.015). Individuals carrying the A allele had a 1.2-
fold increased risk of developing RA (allelic odds ratio 1.24, 95% confidence interval 1.04–1.50). 
Conclusion 
Using a family-based study that is robust against population stratification, we provide evidence 
for the association of the TRAF1/C5 rs10818488 A allele and RA in populations of European 
descent, further substantiating our previous findings. Future functional studies should yield 
insight into the biologic relevance of this locus to the pathways involved in RA. 
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Introduction 
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, affecting ~1% of 
the population worldwide. Environmental as well as genetic factors are thought to play an 
important role in both the onset and the progression of the disease (1). Because the genetic 
contribution to RA has been estimated to be 50-60%, the identification of genes contributing to 
the disease is important for the understanding of underlying biologic mechanisms (2).  
In addition to HLA, the first identified genetic risk factor (3), and 3 other replicated regions 
including the protein tyrosine phosphatase N22 gene (4), the 6q23 locus near the tumor 
necrosis factor (TNF)  induced protein 3 gene (5,6), and the STAT4 gene (7,8), we recently 
reported a new genetic locus associated with RA (9). This region encompasses the TNF 
receptor associated factor 1 gene (TRAF1) as well as the complement component factor 5 (C5) 
gene, both of which are immune regulators and potential perpetuators of inflammation. We 
identified 1 single-nucleotide polymorphism (SNP), rs10818488, located within a 65kb haplotype 
block, explaining most of the association signal in this region in several populations, including 
Dutch, Swedish, and US sample sets consisting of 2,719 patients with RA and 1,999 control 
subjects (odds ratio [OR] 1.28, 95% confidence interval [95% CI] 1.17-1.39, P = 1.40 x 10-8). 
Interestingly, the same genetic association was described in a recent whole-genome 
association study (10). 
Our data revealed that although the case-control allele frequency increase in different sample 
sets ranged from 4% to 9%, the population frequency ranged from 38% to 46% in populations of 
European ancestry. Given that association studies compare the frequencies in patients versus 
healthy individuals, unknown biases in control frequencies may lead to spurious associations. 
Thus, family-based association studies remain important to definitively establish association, 
especially when small effect sizes as well as variability in allele frequency in different 
populations are observed. Therefore, with the aim to further substantiate the association at the 
TRAF1/C5 locus, we took advantage of one of the largest reported European family resources 
dedicated to RA family-based studies. 
Patients & Methods 
Study population  
DNA was available from 452 white trio families from western Europe, through the European 
Consortium on Rheumatoid Arthritis Families. Each family consisted of 1 patient with RA and 
both of his or her parents. Ethnicity was determined by the origin of the grandparents. At the 
time of inclusion in the study, all patients with RA fulfilled the American College of 
Rheumatology (formerly, the American Rheumatism Association) 1987 revised criteria (11). All 
individuals provided written informed consent, and the study was approved by the ethics 
committees in each country.  
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For each patient, the characteristics collected were sex, age at the onset of RA, disease 
duration (years), presence of bone erosions on radiographs, presence of rheumatoid nodules, 
and seropositivity for rheumatoid factor (RF). RF status was not available for 9 of the patients 
with RA. Because the anti-citrullinated protein antibody (ACPA) status was available for only a 
small proportion of the patients (n  197), we did not perform further analyses for ACPAs. The 
452 families included 313 families from France, 53 from Italy, 37 from Spain, 22 from Belgium, 
13 from The Netherlands, and 14 from Portugal. The characteristics of the French and 
European sample sets are summarized in Table 1. None of the cases reported in this study 
overlap with our previous case-control study (9).  
Genotyping 
All DNA samples were genotyped using the TaqMan allelic discrimination assay according to 
the manufacturer's instructions (Applied Biosystems, Foster City, CA). At least 2 positive 
controls and 1 negative control were performed in each plate, and no inconsistencies were 
detected. Furthermore, the concordance rate between 10% random samples genotyped in 
duplicate was 99%. The genotyping success rate in the 452 trio families was 100% (parents and 
probands included).  
Statistical analysis 
The family-based analysis was performed using the basic transmission disequilibrium test (TDT) 
combined with parental phenotype information (parenTDT), as implemented in Haploview 4.0 
(12). The basic TDT compares, for a given allele, the transmission of that allele from 
heterozygous parents to a child with RA, to the expected 50% transmission according to 
Mendel's law. The parental discordance test is based on counting the number of alleles in 
affected versus unaffected parents, treating each nuclear family parental pair as a matched pair. 
These counts combined with the transmitted and untransmitted counts of the basic TDT give a 
combined test statistic (13).  
The current data set included 42 families with 1 affected parent. The control genotypes were 
derived from the untransmitted parental chromosomes, using Unphased version 3.0.10 (14). By 
combining the case-control data from the probands with parental data, genotypic OR were 
calculated using a conditional logistic regression model stratifying on matched pairs (each 
proband-pseudocontrol as a matched pair; each affected and unaffected parent as a matched 
pair). Robust standard errors were computed, taking into account the dependency between 
pairs from the same family. These analyses were performed using Stata version 9.0 software 
(www.stata.com). 
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Table 1. Characteristics of the patients with rheumatoid arthritis (RA) 
  All  French  European  
Characteristic   (n  452)  (n  313)  (n  139)  
Female sex, no. (%)   393 (86.9)  275 (87.8)  118 (84.9)  
Age at onset of RA, 
mean   
SD years  30.8 9.4  30.7 9.4  30.9 9.4  
Disease duration, mean SD years  10.3 7.9  12.0 8.1  6.6 5.9  
Bone erosions, no. (%)   340 (75.2)  246 (78.6)  94 (67.6)  
Rheumatoid factor positivity, no. (%)  321 (71.0)  221 (70.6)  100 (71.9)  
Nodules, no. (%)  72 (15.9)  55 (17.6)  17 (12.2)  
 
Results  
A total of 1,356 European individuals from 452 trio families (1 patient with RA and both parents) 
were analyzed. Three hundred thirteen families were of French origin, and 139 were from other 
continental western European countries (Table 1). No deviation from Hardy-Weinberg 
equilibrium was detected in parental genotypes (n = 904; P = 0.548). We observed deviation 
from Mendel's first law, with a 55% overtransmission of the A allele to the patients in the 452 
families (P = 0.036) (Table 2) along with an increased prevalence of the A allele in affected 
parents (64% increase versus unaffected parents). By applying a parenTDT test that takes into 
consideration both the transmission from parents to patients and the occurrence of alleles in 
discordant parents (discordant for both disease status and genotype), we obtained a combined 
statistic (P = 0.015). There were no differences between families of French origin and those 
from other continental western European countries (55% and 56% overtransmission, 
respectively) as well as no differences between paternal and maternal transmissions (56% and 
57% overtransmission, respectively).  
One of the advantages of family trio data is that such data provide perfectly matched control 
subjects for each patient investigated. Each patient chromosome transmitted by a given parent 
is perfectly matched for the population of origin with the untransmitted chromosome of each 
heterozygous parent. We observed an rs10818488 A allele frequency of 36% in control sub-
jects, increasing to 41% in the patients with RA (data not shown). Using conditional logistic 
regression for the combined data set of case-control and parental discordant pairs, we observed 
an allelic OR of 1.24 (95% CI 1.04-1.50) (Table 3).  
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Table 2. Family-based association of the TRAF1/C5 region with rheumatoid arthritis (RA) 
 
 
 
* TRAF1 = tumor necrosis factor receptor–associated factor 1; RF = rheumatoid factor. 
† Percent transmission of the rs10818488 A allele from heterozygous parents. 
‡ By standard transmission disequilibrium test (TDT), as implemented in Haploview 4.0. 
§ Percent of the rs10818488 A allele from the affected parents in discordant parent pairs. 
¶ Combined TDT with parental phenotype information statistic, as described by Purcell et al (13). 
Table 3. Case–control association of TRAF1/C5 rs10818488 with RA 
 
* TRAF1 _ tumor necrosis factor receptor–associated factor 1; RA = rheumatoid arthritis; RF = rheumatoid factor. 
† Genotype-specific odds ratios (ORs) (95% confidence intervals [95% CIs]), using GG as the referent. 
‡ Allelic ORs (95% CIs), using the G allele as the referent. 
 
Because RA is a heterogeneous disease, and distinct subsets of patients are characterized by 
the presence of autoantibodies such as RF and ACPAs, we also performed a stratified analysis 
for the presence or absence of RF (only limited data were available for ACPAs [see Patients 
and Methods]). In concordance with our previous findings, we observed an overtransmission (A 
transmitted 56%) as well as a higher prevalence of the A allele in affected parents (A 67%; P = 
0.0099, by parenTDT) in the 335 RF-positive families (Table 2). 
Among RF-positive individuals, harbouring 1 copy of the risk allele yielded an OR of 1.47 (95% 
CI 1.03-2.10), and homozygous individuals had an almost 2-fold increased risk of developing 
RA (OR 1.93, 95% CI 1.01–3.69) (Table 3). Interestingly, this effect was not detected in the RF-
negative subgroup, as reflected by transmission of 49% and an A allele frequency in affected 
parents of 40% in the 108 RF-negative families (P = 0.84) (Table 2), resulting in an allelic OR of 
1.00 (95% CI 0.69–1.45) (Table 3). 
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Discussion 
In the current family-based study, we observed evidence of association between RA and the 
TRAF1/C5 rs10818488 A variant in a western European sample set, replicating our initial 
findings. One of the advantages of the family trio design is that it provides accurate estimations 
of matched control subjects for each patient, an approach that is robust against population 
stratification. In this set of perfectly matched cases and controls, we observed a 5% increase in 
the A allele frequency in the overall sample set and a 6% increase in the group of RF-positive 
patients of western European descent. Because these differences are well within the previously 
observed effect in the Dutch (9%), Swedish (4%), and American (7%) populations, these data 
together indicate that the contribution of the TRAF1/C5 locus to RA is not likely caused by 
underlying stratification in populations of European descent, and that the effect size is modest 
(OR  1.3).  
Although we observed association in the overall sample set as well as in the RF-positive subset 
of patients with RA, we did not observe any overtransmissions in the RF-negative subset of 
patients with RA (49% versus the expected 50%), indicating that the effect of this genetic risk 
factor in the overall sample set is likely to be attributable to the RF-positive subset of patients 
with RA. Given the recent finding of this locus by a genomewide SNP association study in 
ACPA-positive patients with RA, the current evidence further substantiates the role of the 
TRAF1/C5 region in the autoantibodypositive subset of patients with RA. However, whether this 
association extends to the autoantibody-negative subset of patients remains to be determined, 
because our RF-negative sample set possesses only 26% power to detect small effect sizes 
(OR 1.3) at a significance level less than 0.05. Therefore, our data do not allow a conclusion 
regarding the (lack of) contribution of the TRAF1/C5 locus to autoantibody-negative RA. 
The currently identified polymorphism lies in an intergenic region between TRAF1 and C5. 
Because TRAF1 is involved in TNF-mediated signaling and C5 generates C5a, the most potent 
chemoattractant involved in inflammation, both genes possess characteristics relevant to the 
pathogenesis of RA. Linkage disequilibrium patterns have so far revealed that the haplotype 
block surrounding this polymorphism encompasses the TRAF1 gene as well as the 3region of 
C5. Interestingly, our group recently observed an association of this SNP with the polyarticular 
form of juvenile idiopathic arthritis (15). It is therefore plausible that the association of the 
TRAF1/C5 variant may not be restricted to RA as such but may be relevant for other diseases. 
Furthermore, because current HapMap phase II data suggest that the frequency of the 
rs10818488 A allele is high in Chinese, Japanese, and Yoruban populations (44±69%), it would 
be interesting to investigate whether this genetic risk factor is also relevant across various 
ethnic populations. 
In conclusion, this study provides evidence of the association of the TRAF1/C5 locus as one of 
the widely confirmed genetic risk factors for RA in white individuals of European descent. 
Endeavors to characterize the functional relevance of this polymorphism and/or others highly 
linked to it will yield insights into the biologic effects of this locus and will generate further crucial 
information on the pathways underlying disease.  
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Abstract 
Objective 
Juvenile idiopathic arthritis (JIA) is a chronic disorder in which both genetic and environmental 
factors are involved. Recently, we identified the TRAF1/C5 region (located on chromosome 
9q33–34) as a risk factor for rheumatoid arthritis (RA) (pcombined=1.4x10
-8). In the present study 
the association of the TRAF1/C5 region with the susceptibility to JIA was investigated. 
Methods 
A case-control association study was performed in 338 Caucasian patients with JIA and 511 
healthy individuals. We genotyped the single nucleotide polymorphism  rs10818488 as a marker 
for the TRAF1/C5 region. 
Results 
The A allele was associated with the susceptibility to rheumatoid factor-negative polyarthritis 
with an 11% increase in allele frequency (OR 1.54, 95% CI 1.09 to 2.18; p=0.012). This 
association was stronger when combining subtypes with a polyarticular phenotype (OR 1.46, 
95% CI 1.12 to 1.90; p=0.004). In addition, we observed a trend towards an increase in A allele 
frequency in patients with extended oligoarthritis versus persistent oligoarthritis (49%, 38% 
respectively); p=0.055. 
Conclusions 
Apart from being a well replicated riskfactor for RA, TRAF1/C5 also appears to be a risk factor 
for the rheumatoid factor-negative polyarthritis subtype of JIA and, more generally, seems to be 
associated with subtypes of JIA characterised by a polyarticular course. 
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Introduction 
Juvenile idiopathic arthritis (JIA) is defined as arthritis of unknown aetiology that persists for at 
least 6 weeks and begins before the age of 16 years. It is the most common chronic 
inflammatory rheumatic disease in childhood (1). In 1997 the International League of 
Associations for Rheumatology formulated criteria for the classification of seven different 
subtypes of JIA based on clinical and laboratory features (2, 3). 
Although the pathogenesis and aetiology are still poorly understood, JIA is thought to be an 
autoimmune disease in which genetic and environmental factors play a part. Evidence for the 
importance of a genetic component includes the ethnic variability in the incidence of different 
subtypes of JIA, a female preponderance, an increased sibling recurrence rate ( s) of 15 and 
the association with HLA and non-HLA genes (eg, PTPN22)(3–5).  Still little is known about 
which genetic factors are involved in the susceptibility to JIA and the severity of JIA. 
Identification of these genetic factors could help to understand the pathogenesis of JIA and 
could be of use to identify patients with an unfavourable prognosis in an early stage. 
Recently we identified the TRAF1/C5 region (located on chromosome 9q33–34) as a genetic 
risk factor for RA, using a candidate gene approach (6). A similar finding was made in a 
genome-wide study in RA (7). TRAF1 is encoding the tumour necrosis factor (TNF)-receptor-
associated factor 1 and C5 is encoding the complement component 5. Inspired by these results 
we have studied whether variability in the TRAF1/C5 region also affects the susceptibility to JIA. 
Materials & Methods 
A case-control association study was performed in 338 Caucasian patients with JIA from 
paediatric rheumatology centres in the Netherlands (54%), Belgium (24%) and Germany (22%). 
Genotype frequencies of 511 healthy unrelated Dutch adult controls were available of the 524 
controls previously described by Kurreeman et al due to random genotyping failure (6). All 
patients with JIA (72% female, 28% male) were diagnosed according to the revised International 
League of Associations for Rheumatology criteria(2).  The inclusion of patients focused on 
persistent (39%) and extended (14%) oligoarthritis and rheumatoid factor (RF)-negative (22%) 
and RF-positive (5%) polyarthritis because of their relative homogeneous phenotypes. Patients 
who were included in the study had a follow-up of at least 2 years. Informed consent from all 
patients and/or parents and approval from each institutional review board were obtained. DNA 
was isolated from blood samples (20%) or mouthswabs (80%). 
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One tagging single nucleotide polymorphism (rs10818488) was genotyped as it revealed the 
strongest association in RA and none of the other tagging single nucleotide polymorphisms in 
the 65 kb block provided additional information.6 Rs10818488 is highly linked with rs3761847 
(r2=1, data from HAPMAP) and rs2900180 (r2=0.66), which were associated with RA as well (7). 
Rs10818488 was genotyped by the polymerase chain reaction–restriction fragment length 
polymorphism method as described (6).  Each 96-well plate contained two positive and two 
negative controls. Eight per cent of the samples were run in duplicate and we observed a 
concordance rate >98%. 
Differences in genotype frequencies between cases and controls were assessed using the 
Cochran–Armitage trend test. Allelic odds ratios (OR) with 95% confidence interval (CI) as well 
as the genotype specific odds ratios were computed. Case and control genotype frequencies 
were in Hardy–Weinberg equilibrium. Statistical analysis was performed with SPSS 14.0. 
p<0.05 was considered statistically significant. 
Results 
JIA is a heterogeneous disease consisting of several subtypes. As it is best to investigate 
genetic risk factors in well-defined phenotypic groups, we have analysed the genotypes of the 
rs10818488 single nucleotide polymorphism in the different subtypes of JIA as well as in the 
overall group of patients with JIA as shown in Table 1. 
Frequencies in patients with persistent oligoarthritis, systemic JIA and in the overall patient 
group with JIA did not differ significantly fromthose in controls. In extended oligoarthritis and RF-
positive polyarthritis (the equivalent of RA) a trend towards an increased A allele frequency was 
observed (49%, 50% respectively vs 41% in controls). However, although we do observe an 8-
9% increase in the A allele, we possess limited power to detect significant differences. In RF-
negative polyarthritis patients we found a significant increase in the A allele by 11% (allelic OR 
1.54, 95% CI 1.09 to 2.18) when compared with controls. Homozygotes for the susceptibility 
allele (AA) had an OR of 2.51 (95%CI 1.23 to 5.14) compared with the homozygotes of the 
protective allele (GG), whereas heterozygotes had an OR of 1.50 (95% CI 0.81 to 2.77). Gender 
was not a significant covariate when performing a regression analysis (p=0.124). 
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As extended oligoarthritis, RF-negative polyarthritis and RFpositive polyarthritis have a 
considerable phenotypic overlap and share a polyarticular course of disease, we also analysed 
these subtypes grouped together to determine whether the TRAF1/C5 region predisposes to a 
polyarticular disease course. The A allele was significantly increased in this combined group 
(51% in cases, 41% in controls), with an allelic OR 1.46 (95% CI 1.12 to 1.90), a genotypic OR 
(AA vs GG) of 2.25 (95% CI 1.29–3.90) and a p value (Cochran–Armitage trend test) of 0.004, 
which remains significant after Bonferroni correction (p<0.013). 
As persistent and extended oligoarthritis are clinically similar at disease onset, but differ in their 
course and outcome, we tested the hypothesis that these two subtypes would also differ in their 
genetic predisposition. Intriguingly, we detected a borderline significant difference between 
these two subtypes when compared directly with each other (allelic OR 1.57, 95% CI 0.98 to 
2.51; p=0.055). 
Together, these data indicate that the A allele predisposes predominantly to subtypes of JIA 
characterised by a polyarticular course, indicating that this allele does not associate with JIA as 
such, but rather with a particular phenotype of JIA. 
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Discussion 
This is one of the first studies to report an association between the TRAF1/C5 region and JIA. 
The A allele of rs10818488 was significantly associated with the susceptibility to RF-negative 
polyarthritis. However, patients with RF-negative polyarthritis have a considerable phenotypic 
overlap with patients with extended oligoarthritis and RF-positive polyarthritis, in having a 
polyarticular course of disease. Intriguingly, rs10818488 seems to be associated with this 
polyarticular phenotype and this difference remained significant after Bonferroni correction for 
multiple tests (p<0.013). 
Although we cannot formally exclude the possibility that population stratification may play a role 
in this study, we did not observe any statistically significant differences in the minor allele 
frequencies of the patients from the Netherlands, Belgium and Germany. Additionally, analysing 
the Dutch population independently did not alter the results (eg, RF-negative polyarthritis versus 
controls: allelic OR 1.66 (95% CI 1.10 to 2.51), genotypic OR (AA versus GG) 3.05 (95% CI 
1.25 to 7.44). 
At the clinical level, it is also important to make a distinction between persistent oligoarthritis and 
extended oligoarthritis in order to predict the probability of the development of a polyarticular 
disease course and adjust the medical treatment accordingly. Comparison of patients with 
persistent and extended oligoarthritis revealed a borderline significant difference in A allele 
frequency. This may indicate that the TRAF1/C5 region may eventually be helpful in predicting 
the development of an extended course in patients with oligoarthritis. Extended studies of this 
polymorphism may confirm its relevance as a predictive marker. 
It is presently unclear how the association between the TRAF1/C5 region and disease 
susceptibility can be explained biologically. The associated polymorphism is highly linked to the 
TRAF1 gene as well as the 3’ untranslated region of the C5 gene. Activated complement 
component 5 acts as a strong chemoattractant for neutrophils, and a deregulated activity may 
contribute to the perpetuation of inflammation. In JIA, complement activation is occasionally 
observed, especially in active polyarthritis (8). On the other hand, TRAF1 plays an essential role 
in the intracellular TNF-signalling pathway and is possibly a negative regulator of TNF signalling 
(9). Evidence for the importance of TNF in JIA is suggested by the effectiveness of treatment 
directed against TNF , especially in subtypes with a polyarticular course. However, future 
research will be necessary to confirm the genetic association and investigate functional 
consequences of the associated allele and could reveal further insight in the pathogenesis of 
polyarticular disease in JIA. Apart from being a well replicated risk factor for RA, TRAF1/C5 also 
appears to be a risk factor for the RF-negative polyarthritis subtype of JIA and, more generally, 
seems to be associated with subtypes of JIA characterised by a polyarticular course. 
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Abstract 
Objectives 
The TRAF1-C5 locus has recently been identified as a genetic risk factor for rheumatoid 
arthritis. Since genetic risk factors tend to overlap with several autoimmune diseases, we aimed 
to investigate whether this region is associated with Type I Diabetes (TID), Celiac Disease (CD), 
Systemic Sclerosis (SSc) and Systemic Lupus Erythematosus (SLE). 
Methods 
We genotyped the most consistently associated SNP, rs10818488, in a total of 735 T1D, 1049 
CD, 367 SSc, 746 SLE and 3494 ethnically and geographically matched healthy individuals. 
The replication sample set consisted of 99 T1D, 272 SLE patients and 482 healthy individuals 
from Crete. 
Results 
We detected significant association of the rs10818488 A allele with T1D (OR 1.14, p=0.027) 
and SLE (OR 1.16, p=0.016) which was replicated in 99 T1D, 272 SLE patients and 482 
controls from Crete (OR 1.64, p=0.002; OR 1.43, p=0.002 respectively). Joint analysis of all T1D 
(N=961) and all SLE (N=1018) patients compared to 3976 healthy individuals yielded an allelic 
common OR of 1.19 (p=0.002) and 1.22 (P=2.6x10-4) respectively. However, combining our 
dataset with the T1D sample set from the WTCCC results in a non-significant association (OR 
1.06, p=0.087). In contrast, previously unpublished results from the SLEGEN study shows 
significant association of the same allele (OR 1.19, p=0.0038) with an overall effect of 1.22 
(p=1.02x10-6) in a total of 1577 SLE patients and 4215 healthy individuals.  
Conclusion 
We report significant association of the TRAF1-C5 locus in SLE implying that this region lies in a 
pathway relevant to multiple autoimmune diseases. 
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Introduction 
The region encompassing Tumour Necrosis Factor (TNF) receptor associated factor 1 (TRAF1) 
and complement component 5 (C5) has recently reported it to be a genetic risk factor involved 
in rheumatoid arthritis (RA)(1). The robustness of this association is demonstrated by its 
prevalent risk in Dutch, Swedish, Crete(2) and American populations and is further corroborated 
by both a genome-wide association study(3) and an extensive fine-mapping study we have 
undertaken(4). Interestingly one consistent RA association signal defined by rs10818488 or its 
perfect proxy (rs3761847 and rs7021049, Linkage Disequilibrium R2>0.98) has been identified 
in this region by three independent studies and has been further confirmed by a large European 
family-based study(5). Moreover, an association of the opposite allele of rs3761847 in RA has 
been reported in the Japanese population but no association has been found in a Korean 
population(6;7). Additionally, we and others have shown that this polymorphism is associated 
with juvenile (idiopathic) arthritis(JIA)(8;9), indicating its possible role in other autoimmune 
diseases. 
From a functional perspective, TRAF1 is likely to be a negative regulator of TNF Receptor 
signaling(10) and C5 is a central component of the complement pathway(11). Both molecules 
are potent immune mediators and so far the question remains whether this region is restricted to 
arthritis as such or whether it lies in a biological pathway common to other autoimmune 
diseases. In the present study we aimed to investigate this hypothesis further by considering the 
role of this locus in four diseases including Type 1 Diabetes (T1D), Celiac Disease (CD), 
Systemic Sclerosis (SSc) and Systemic Lupus Erythematosus (SLE). 
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Methods 
Sample sets 
DNA was obtained from cohorts of T1D, CD, SSc and SLE from The Netherlands and Spain as 
well as T1D and SLE patients from Crete. Control cohorts were matched to each specific 
population of origin. The T1D sample set consisted of 556 white Dutch and 306 Spanish 
patients. The CD sample set comprised 496 Dutch and 553 Spanish CD patients. The SSc 
sample set consisted of 138 Dutch and 229 Spanish Systemic Sclerosis patients. The SLE 
sample set included 161 Dutch and 585 Spanish patients. All patients were Caucasian. A 
common set of controls were used consisting of 1396 Dutch and 2098 Spanish geographically 
and ethnically-matched healthy individuals. The replication sample set consisted of 272 SLE, 99 
T1D patients and 482 geographically and ethnically matched controls originating from Crete. All 
patients were diagnosed using the appropriate classification criteria and are described 
extensively in the Supplementary Methods. Informed consent was obtained from all subjects, 
and the study was approved by the local ethics committee of each center. 
GWAS data 
Genotype counts were obtained for rs10118357 (R2=1 with rs10818488) from the publicly 
available WTCCC study(12) consisting of 1960 T1D patients and 2930 ethnically matched 
healthy individuals from the UK population. For the SLE sample set, genotyope counts were 
obtained from the SLEGEN study(13) for rs3761847 (R2=1 with rs10818488) from 720 SLE 
patients and 2337 healthy individuals. These sample sets are described in further detail 
elsewhere(12;13). 
Genotyping 
All samples were genotyped using the Taqman assay (Applied Biosystems) according to the 
manufacturer’s instructions. Each plate consisted of at least 8 positive and 8 negative controls. 
At least 10% of the samples were genotyped in duplo with no discrepancies observed. The 
Dutch control sets consists of 511 healthy individuals which were previously genotyped(1). An 
additional 535 Dutch healthy unrelated individuals were genotyped using allele specific kinetic 
PCR(14) as well as 715 Dutch controls from Utrecht using the Taqman assay. To compare 
genotyping methods at least 50 samples were genotyped on each platform (Taqman, allele 
specific kinetic PCR and RFLP) and revealed a concordance rate of >99%. 
Statistical analysis 
In the controls, the frequencies were in Hardy-Weinberg equilibrium as determined by the 
observed versus expected genotype counts. Genotype counts were analysed using SPSS 
version 12.0. Odds ratios and confidence intervals were calculated using Statcalc. Combining 
odds ratios across sample sets was performed using the Cochran-Mantel-Haenszel test as 
implemented in EasyMA and the meta package in R (15). No evidence of heterogeneity of risk 
effect was observed using the Breslow and Day method (P>0.05) when combining OR. All 
power calculations were performed using Quanto version 1.2 (http://hydra.usc.edu/gxe). P 
values below 0.05 were considered significant. 
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Results 
T1D, CD, SSc and SLE samples were genotyped from both the Spanish and Dutch populations 
for the strongest and most consistent association signal in the TRAF1-C5 region characterized 
by SNP rs10818488. Since the Dutch study was largely underpowered to detect modest effect 
sizes (OR~1.2) we opted for a combined analysis which consisted of a total of 3494 controls 
and 735 T1D, 1049 CD, 367 SSc, 746 SLE patients. This combined dataset enhanced power to 
 85% to detect effect sizes of 1.2 at P<0.05 with the exception of SSc which only achieved 64% 
power to detect an odds ratio of 1.2. 
The frequency of the rs10818488 A allele was significantly increased in T1D patients (OR 1.14; 
95% CI 1.02- 1.28; p=0.027, Table 1). Similarly we found a significant difference in the 
prevalence of the A allele in SLE patients resulting in an OR of 1.16 (95% CI 1.03-1.31, 
p=0.016). Patients harboring two copies of the A allele had a 1.3 fold (p=0.01) and a 1.4 fold 
(p=0.04) increased risk for T1D and SLE respectively as compared to those who carried none. 
We observed no association with CD (Allelic OR 1.07, 95% CI 0.97-1.18, p=0.18) and SSc 
(Allelic OR 1.02, 95% CI 0.87-1.19, p=0.84). While the possibility remains that the absence of 
association in SSc may be due to lack of power to detect OR of 1.2 or lower, the direction of 
association in the individual studies was opposite (Allelic OR, 95% CI; Spanish 1.16, 0.94-1.43; 
Dutch 0.85, 0.65-1.09), suggesting that the absence of association may be more likely. 
We then proceeded to replicate our significant findings in T1D and SLE in the genetically 
homogeneous population of Crete. Since this largest island of Greece consists of 650,000 
inhabitants who share the same genetic and cultural background as well as a common 
environment, it represents a “geographically isolated” gene pool which may enhance the 
detection of risk alleles that may be diluted in larger continental populations(16). We observed 
an 11% increase and an 8% increase in the A allele in T1D and SLE patients, respectively, 
when compared to controls (Table 2). This resulted in a 1.6 fold increased risk for T1D 
(p=0.002) and a 1.4 fold increased risk for SLE (p=0.002) in the Crete population. Overall 
analysis of T1D and SLE in all three datasets (Spanish, Dutch and Greek) reveals a common 
OR of ~1.2 (p=0.002 and p=2.6x10-4 respectively) for both diseases. 
We also analysed our data in combination with rs10118357 (perfect proxy of rs10818488, R2=1) 
for T1D obtained from the Wellcome Trust Case Control Consortium (WTCCC)(12) study as 
well as a meta-analysis of the effect of SNP rs3761847 (perfect proxy of rs10818488, R2=1) in 
the SLE Genetics consortium (SLEGEN) study(13) (Table 2). The WTCCC T1D dataset 
comprising 1960 patients and 2930 healthy individuals displayed no association with an OR of 
0.99 (95% CI 0.91-1.08, p=0.837). Combining all four datasets (2794 patients and 6906 
controls) generated an overall OR of 1.06 (95% CI 0.99-1.13, p=0.087) indicating that the effect 
size is very modest and that our study is largely underpowered to detect a significant effect. 
Previously unpublished data from the SLEGEN study in contrast, show a significant increase in 
the rs10818488 A allele frequency in 720 SLE patients (43%) as compared to 2337 healthy 
individuals (39%) (OR 1.19, 95% CI 1.06-1.35, p=0.0038), independently replicating the 
association of this locus with SLE. Combining all datasets consisting of 1577 SLE patients and 
4215 controls shows a significant association with OR 1.22 (95% CI 1.12-1.31, p=1.02x10-6). 
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Table 1. Association of rs10818488 in the TRAF1-C5 locus with autoimmune diseases. 
  Controls T1D CD SSc SLE 
 Initial  
Sample Set 
  
Spanish AA 169 45 84 38 101 
 AG 663 150 251 104 276 
 GG 564 111 218 87 208 
 A(%) 1001(36%) 240(39%) 419(38%) 180(39%) 478(41%)
    
Dutch AA 392 106 100 21 28 
 AG 1060 305 249 68 84 
 GG 646 145 147 49 49 
 A(%) 1844(44%) 517(46%) 449(45%) 110(40%) 140(44%)
    
 OR(95% CI)* - 1.14
(1.02-1.28) 
1.07
(0.97-1.18) 
1.02 
(0.87-1.19) 
1.16 
(1.03-1.31) 
 P - 0.027 0.181 0.842 0.016 
    
 Replication 
Sample Set 
  
Crete AA 32 1 26 
 AG 214 77 148 
 GG 236 21 98 
 A(%) 278(29%) 79(40%) 200(37%)
    
 OR 
(95% CI) 
 1.64 
(1.18-2.28) 
1.43 
(1.14-1.80) 
 P  0.002 0.002 
    
    
 Joint  
Sample Set 
  
    
 Combined OR
¥
 
(95% CI) 
 1.19 
(1.07-1.32) 
1.22 
(1.09-1.35) 
 P  0.002 2.6x10
-4
 
 
T1D – Type 1 Diabetes, CD- Celiac Disease, SSc- Systemic Sclerosis and SLE- Systemic Lupus Erythematosus. * 
Represents the combined allelic OR between the Dutch and Spanish sample set. ¥ Represents the combined allelic 
OR between Dutch, Spanish and Crete sample sets. All OR were combined using the Mantel-Haenszel fixed effects 
as implemented in EasyMA and the Meta package in R.  
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¥Table 2. Meta-analysis of rs10818488 in the TRAF1-C5 locus with Genome Wide Association Studies. 
                   WTCCC                   SLEGEN  
GWAS  
Data Set 
Controls T1D Controls SLE 
AA 362 598 339 138 
AG 1011 1410 1135 344 
GG 587 922 863 238 
A (%) 2930 (44%) 1960 (44%) 2337 (39%) 720 (43%) 
   
OR * 
(95% CI) 
 0.99
(0.91-1.08) 
1.19  
(1.06-1.35) 
P  0.837 0.0038 
   
Joint  
Sample Set  
  
Combined OR
¥
 
(95% CI) 
 1.06
(0.99-1.13) 
1.22  
(1.12-1.31) 
P  0.087 1.02x10
-6
 
 
T1D – Type 1 Diabetes and SLE- Systemic Lupus Erythematosus. * Represents the combined allelic OR between the 
cases and controls in the GWAS sample set. ¥ Represents the combined allelic OR between Dutch, Spanish, Crete 
and GWAS sample sets. All OR were combined using the Mantel-Haenszel fixed effects as implemented in EasyMA 
and the Meta package in R.  
Association of the TRAF1-C5 region on chromosome 9q33 with RA and autoimmunity 67
Discussion 
We report here for the first time reproducible association of the TRAF1-C5 region with SLE 
complementing the already consistent finding of this variant with RA and juvenile arthritis. 
Remarkably, the same allele that predisposes to RA and juvenile arthritis also predisposes to 
SLE lending support to the hypothesis that this region may contribute to a shared pathway 
involved in RA, JIA and SLE. While the possibility also remains that other additional alleles at 
this locus may be involved in these diseases, complementary studies undertaking further fine-
mapping as well as sequencing will yield further insight into the most likely causal alleles at this 
locus. 
We also observed a difference in allele frequencies in healthy populations of Dutch (44%), 
Spanish (36%) and Greek (29%) origins. To address this difference in population, each patient-
control sample set was geographically and ethnically matched. Data from HapMap 
(www.hapmap.org) support these observations with the G allele (minor allele in Caucasians) 
frequency of rs3761847 (perfect proxy of rs10818488) varying from 48% in Caucasians of 
European descent, 31% in Gujarati Indians in Texas, 42% in Japanese in Tokyo, 66% in 
Mexicans in Los Angeles, 59% in Yorubans in Nigeria and 74% in Luhya in Kenya. However, 
underlying population stratification is difficult to account for as panels of markers characterizing 
each population in our study thoroughly have not as yet been described. In our study, 
association of the TRAF1-C5 locus has been observed in more than one sample set 
considerably reducing the chances of false positive findings due to population stratification. 
The association of the TRAF1-C5 region has not been reported in the recently published 
genome-wide association studies (GWAS) in SLE(13;17;18) and the GWAS of T1D in WTCCC 
study(19). However, while an association with RA was initially not detected in the WTCCC , a 
follow-up report showed a significant association of the same allele in the UK population 
although with much a much lower effect size(20). In line with this observation, a meta-analysis 
of GWA studies in RA has recently illustrated that much larger sample sizes are required to 
detect the commonly observed low penetrance of genes in autoimmune diseases like RA(21). It 
is also not uncommon that modest effects are not detected in such largescale studies as 
exemplified by the association of TNFSF4, a gene identified by family-based association 
studies(22), that did not surface in the recently performed GWAS. Likewise BANK1, a gene 
identified in the GWA scan by Kozyrev et al was not identified by the other two GWA studies 
that employed 500K SNPs. However, while our study combined with the GWA of the WTCCC 
does not provide sufficient evidence of the role of the TRAF1-C5 locus in T1D, data obtained 
from the SLEGEN study confirms our findings of this locus in SLE. Interestingly, this association 
is absent in a well-powered Japanese case-control study and small study in the Columbian 
population(6;23). As with many genetic loci, it is highly likely that ethnic differences exist in the 
contribution of this locus to SLE. 
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TRAF1 has been reported to be a negative regulator of the TNF receptor signalling 
cascade(10;24) and high levels of TNF has been detected in both human and murine lupus, it is 
likely that a dysregulation of the function and/or expression of this molecule could be involved in 
the inflammatory processes in SLE(10;25). Currently, controlled clinical trials involving the 
blockade of TNF are being conducted(26). Although the haplotype block encompassing 
rs10818488 does not encompass the C5 coding region(4), this central component of the 
complement system is also a likely functional candidate in SLE. The prominent role of 
complement activation in humans and murine models of SLE as well as the beneficial effect of 
blocking C5 anaphylatoxin in murine lupus models point to the likely role of this molecule in 
SLE(27;28). In summary, we report here for the first time an association of the TRAF1-C5 locus 
with SLE which, in combination with previous findings of an increased risk to RA and juvenile 
arthritis, indicates that this region is likely to be part of a shared mechanism underlying several 
autoimmune diseases. 
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Abstract 
Objective 
The interleukin (IL)-10 single nucleotide promoter polymorphism (SNP) –2849A is associated  
with decreased IL-10 production as measured by lipopolysaccharide (LPS) stimulated whole  
blood cultures. A low innate production of IL-10 using the same assay is associated with an 
increased risk of familial osteoarthritis (OA). We investigated the association of 7 novel SNP 
located downstream of the IL-10 transcription start site: –2849,–2763, –1330, –1082, –819, and 
–592, constituting the 4 ancient haplotypes, with distal interphalangeal (DIP) OA. 
Methods 
The study population comprised consecutive patients with and without radiological DIP OA 
(Kellgren-Lawrence score of  2 in one joint) aged 40–70 years from a cohort of subjects with 
different types of arthritis in an early stage referred to an Early Arthritis Clinic (EAC). DNA typing  
for IL-10 SNP as well as radiographs of the hands were performed at clinic enrolment. Patients 
with rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathies, and psoriatic 
arthritis were excluded. 
Results 
The distribution of DIP OA and IL-10 SNP were comparable to representative samples of  the 
Dutch population. In the cohort of 172 subjects, 57 had DIP OA (33%) and 115 (67%) had no 
DIP OA. No significant association was found between DIP OA and IL-10 SNP and the 4 
common haplotypes IL10.1, IL10.2, IL10.3, and IL10.4. 
Conclusion 
Our data suggest that IL-10 SNP, including –2849, which is associated with differential 
production, do not play a major role in the susceptibility of DIP OA. 
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Introduction 
Distal interphalangeal (DIP) osteoarthritis (OA) is one of the most frequent subtypes of OA, 
causing pain and loss of function in the hands. Familial aggregation and twin studies have 
shown DIP OA to have a strong familial component(1–3). Despite studies focusing on the 
genetics of DIP OA, the genes involved have not been identified. Several chromosomal regions 
are reported to be associated with DIP OA, namely quantitative trait loci (QTL) on chromosomes 
2q, 7p, and 11q implicated by linkage studies (4), HLA-DR2 by candidate gene analysis in 
several populations (5,6), and further, a locus on chromosome 2 containing the matrilin-3 gene, 
by a genomewide scan in an Icelandic population (7). 
Loss of articular cartilage and changes in the subchondral bone and joint margins is a hallmark 
of OA. An increased matrix catabolism characterized by an upregulation of metalloproteinases 
(MMP) and the depletion of structural macromolecules such as proteoglycans contributes to the 
OA disease process (8). Increasing data support the role of cytokines in these processes. 
Although proinflammatory cytokines have been shown to play a pivotal role in the initiation and 
development of OA, a shift in the balance between the pro and antiinflammatory cytokines is 
believed to contribute to the loss of integrity of articular cartilage (9). 
Among the antiinflammatory cytokines, interleukin (IL)10 appears to be a crucial factor in 
inflammatory processes(10). In a mouse model of arthritis, IL-10 administration prevents 
cartilage destruction by reducing IL-1ß and tumor necrosis factor (TNF)-  mRNA expression in 
articular chondrocytes, while neutralizing anti-IL-10 antibodies accelerate the onset and 
enhance the severity of arthritis(11). 
The human IL-10 gene is highly polymorphic. Gibson, et al (12) identified 7 novel single 
nucleotide polymorphisms (SNP) in the distal region of the IL-10 promoter and found that certain 
haplotypes are significantly associated with high or low IL-10 production. Studies have shown 
that there are striking differences between healthy individuals in their ability to produce IL-10 
following lipopolysaccharide (LPS) stimulation of whole blood cultures ex vivo. Moreover it 
hasbeen shown that IL-10 haplotypes dictate IL-10 production as measured by this assay (13). 
Of the IL-10 promoter polymorphisms, –2849A, encoded on haplotype IL-10.01, has been 
shown to correlate best with protein production (13). Individuals with the AA genotype have a 
reduced IL-10 production in comparison to AG and GG individuals. 
Several studies have reported the clinical relevance of IL10 gene polymorphism in autoimmune 
diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)(12,14), 
and in infectious diseases (15). In an earlier study we found an increased risk of familial OA at 
multiple sites in subjects with a low innate production of IL-10, as measured by the same ex vivo 
whole blood assay using LPS stimulation(16) used in all previous studies (12,13). This finding 
implicating IL-10 in cartilage destruction led us to investigate whether genetic variation in IL-10 
contributes to the susceptibility of DIP OA. Our aim was to investigate whether IL-10 SNP –592, 
–819, –1082, –2763, –2849, and –3575 that constitute the 4 ancient IL-10 haplotypes are a risk 
factor for DIP OA. 
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Materials & Methods 
Study population 
The study population consists of subjects from the outpatient clinic of the Department of 
Rheumatology between the ages of 40 to 70 years with and without radiological DIP OA. This 
population, enrolled between 1993 and 2000, is part of an ongoing project, the Early Arthritis 
Clinic (EAC). Consecutive patients with arthritis in at least one joint with a short history of 
complaints are admitted to this clinic by general practitioners. Each patient subsequently 
undergoes full clinical, biochemical, and radiographic assessment. Diagnoses in the EAC are 
made according to international classification and if necessary revised up to 1 year of followup 
(17). Patients with a definitive EAC diagnosis after one year of followup were included in this 
study. Patients with RA, SLE, and spondyloarthropathies were excluded because these 
diseases have been associated with IL-10. Patients with psoriatic arthritis were also excluded 
since DIP involvement is common in psoriatic arthritis and could thus interfere with our readings.  
Reference populations 
Prevalence of radiological DIP OA and distribution of IL-10 promoter polymorphisms in the study 
population were compared to 2 reference populations representative of the general Dutch 
population. As a reference for radiological DIP OA, data were used from the Zoetermeer 
population, a population survey consisting of 3109 men and 3476 women (18) as described (5). 
A comparison between the frequency of radiological DIP OA in the present population in 
reference to the Zoetermeer population gave an observed-to-expected ratio of 0.96 (0.7–1.2). 
Distribution of IL-10 promoter polymorphisms was compared to its distribution in a random panel 
of the southwest region of the Netherlands (n = 321)(19). 
Radiographs and radiographic scoring 
Plain dorsovolar hand radiographs were taken routinely in each patient during the period of the 
first visit to the EAC. Only radiographs obtained at a maximum of 3 months before till 3 months 
after the first visit were included. Each of the radiographs was independently graded using the 
Kellgren-Lawrence scale for DIP OA by 2 out of 3 observers blinded to the underlying EAC 
diagnosis. This overall score distinguishes 5 degrees of severity of OA according to the 
presence of radiological features: osteophytes, joint space narrowing (JSN), subchondral 
sclerosis, cysts, and deformity. A patient was diagnosed with DIP OA if a Kellgren score of 2 or 
more was observed in at least one DIP joint. The inter-rater agreement for the presence or 
absence of DIP OA was 0.7 (Cohen’s kappa). In case of disagreement radiographs were re-
evaluated until consensus was reached. 
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Determination of IL-10 promoter polymorphisms  
Peripheral blood cells were lysed using sodium dodecyl sulfate and treated with proteinase K. 
DNA was isolated by phenol-chloroform extraction. A Perkin-Elmer thermal cycler Gene Amp 
9600 (PE-Cetus, Norwalk, CA, USA) was used to amplify the IL-10 promoter region by 
polymerase chain reaction. The primer combination and methods used have been described 
(20). 
Statistical analysis  
Means were compared using an independent sample Student’s t test. Odds ratios (OR) with 
95% confidence intervals (95% CI) were calculated to determine whether the distribution of IL-
10 promoter polymorphisms was comparable to the random panel by comparing the distribution 
of the minor allele grouped with the heterozygote [11 + 12] versus the major allele [22] in both 
sets of populations. OR were also used to assess the association between DIP OA and the 
different genotypes of IL10 promoter polymorphisms. Multiple locus haplotype frequencies 
(SNPHAP: a program for estimating frequencies of haplotypes of large numbers of diallelic 
markers from unphased genotype data from unrelated subjects (21) and the measures of 
pairwise linkage disequilibrium (LD) were determined using the HAPLO program (22). It uses an 
expectation-maximization algorithm to calculate maximum likelihood estimates of haplotype 
frequencies, given genotype measurements. The estimator of LD (where D = hpq– pq) indicates 
the difference in the observed (hpq) and expected (pq) frequencies of haplotypes. Its maximum 
value depends on the allele frequencies and whether the rare alleles are associated together on 
a haplotype (positive value of D) or whether the common allele is associated with the rare allele 
(negative value of D). |D| (Lewontins D’) is the fraction of D of its maximum (Dmax= p – pq) or 
minimum (Dmin = –pq) possible value. Power analysis was based on achieving 5% significance 
in order to detect a difference if IL-10 promoter polymorphisms or IL-10 haplotypes were 
associated with an almost 3-fold increased risk of DIP OA (OR = 2.7). This analysis was based 
on the frequency of the IL-10 A carriage rate in the SNP –2849 associated with differential IL-10 
production. 
Results 
Six hundred and one consecutive patients aged between 40 to 70 years visited the EAC. Sixty-
nine patients were excluded because no definitive diagnosis was made within one year, 281 
patients were excluded based on diagnosis of RA, systemic diseases, spondyloarthropathies, 
and psoriatic arthritis and 79 patients were excluded due to missing data. Of the remaining 172 
patients included in the study, 3 were not genotyped for the –3575, –2763, –1082, and –819 
SNP due to poor DNA quality and an additional 18 samples were missing at the time of 
genotyping the –3575 SNP.  
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Patient characteristics 
Because the patients in this study were included in the EAC, they had a broad variety of 
diagnoses independent of the presence or absence of DIP OA. Fifty-seven (33%) patients had 
DIP OA. As expected, the average age of patients with DIP OA was higher than patients with no 
DIP OA [58 yrs (range 43–70) vs 51 yrs (40–70); mean difference: 6.8 (4.1–9.1)]. The clinical 
characteristics of the study population are summarized in Table 1.  
Distribution of IL-10 promoter polymorphisms in comparison to controls 
In Table 2, the distribution of the minor allele grouped with the heterozygote is shown versus the 
major allele of the IL-10 promoter polymorphisms –3575, –2849, –2763, –1082, and –819 in the 
study population and in the random panel. No difference was observed in the distribution of 
these alleles in the 2 groups. The IL-10 promoter polymorphisms –1330 and –592 are in 
complete linkage disequilibrium with –1082 and –819 respectively; therefore, these variables 
were excluded from further analyses of single promoter polymorphisms. Genotypes did not 
show deviations from the Hardy-Weinberg equilibrium (data not shown) (23). 
Association of IL-10 promoter polymorphisms and haplotypes with DIP OA  
The association between DIP OA and genotypes of IL-10 SNP –3575, –2849, –2763, –1082, 
and –819 is shown in Table 3. No association was found between these polymorphisms and 
DIP OA. Since the interaction of 2 or more SNP in haplotypes may be more informative than 
single polymorphisms, a haplotype analysis was performed. No difference was observed in the 
distribution of the 4 extended haplotypes, IL-10.1, IL10.2, IL-10.3, and IL-10.4 in patients with 
and without DIP OA (p = 0.67). Data are presented in Table 4. In a separate analysis of the 
distal haplotype frequency (A–3575T, A–2849G, and A–2763C) and the proximal haplotype 
frequency (A-1330G, G-1082 A, T-819 C, and A-592 C) no difference was seen in the 
distribution in patients with and without DIP OA (data not shown). 
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 Table 1. Clinical characteristics of the study population: patients with and without distal interphalangeal (DIP) 
osteoarthritis (OA). 
 
Table 2. Distribution of the minor allele grouped with the heterozygote (11 +  12) versus the major allele (22) in single 
nucleotide promoter polymorphisms (SNP) of the interleukin (IL)-10 gene in the study population compared to a 
random panel in the south-west region of the Netherlands expressed as odds ratios (OR) with 95% confidence 
intervals (95% CI). 
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 Table 3. Summary of the association between DIP OA (n = 57) and the genotypes of the IL-10 promoter 
polymorphisms within the study population (n = 172) expressed as OR (95% CI). 
 
 
 
Table 4. Haplotype frequencies in patients with DIP OA (n = 57) and patients without DIP OA (n = 116). 
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Discussion 
We are the first to investigate the relationship between a highly genetic form of OA, namely DIP 
OA and promoter polymorphisms located downstream of the IL-10 transcription start site: –
2849, –2763, –1330, –1082, –819, and –592 constituting the 4 ancient IL-10 haplotypes. These 
SNP as well as the 4 haplotypes were not associated with a higher risk of radiological DIP OA. 
Association of DIP OA with IL-10 promoter polymorphisms in our investigation was studied in 
patients with a variety of underlying forms of arthritis. The consecutive patient population was 
collected in a prospective manner. Because the study population consisted of patients included 
in an EAC, the existing correlation between certain rheumatic diseases and the genetic 
variables under study was taken into consideration while selecting patients. All patients with 
diseases reported in the literature to be associated with the polymorphisms under study were 
excluded. Furthermore, patients with diseases that can lead to radiological damage of the DIP 
joints, such as psoriatic arthritis, were also excluded. However, radiological damage would not 
have been very likely since patients are seen in the EAC at a very early stage. Although patient 
selection in the EAC was outside our research question, we did find a patient population with a 
well-documented phenotype, i.e., radiological DIP OA with IL-10 and DIP OA distributions 
comparable to the general population. 
Among the IL-10 promoter polymorphisms under study, the SNP –2849A has been associated 
with low IL-10 production. We found an OR of one when comparing the –2849 AA versus –
2849AG and –2849GG. These data strongly suggest that the association is absent; although a 
type II error may have occurred given the power of the current study. We conclude that it is 
unlikely that the SNP –2849A has a large effect on genetic susceptibility to radiological DIP OA.  
Although the antiinflammatory role of IL-10 is recognized in arthritis, its role in OA is still 
undefined. Based on its biologic activity it is, however, conceivable that low IL10 production may 
contribute to a catabolic state in OA. IL10 is an important immunoregulatory cytokine in man 
(10) and plays a crucial role in inflammation and tissue destruction. In an arthritis model, mice 
lacking the gene for IL-10 experienced higher rates of clinical signs and more severe knee and 
paw injury compared to IL-10 wild-type controls. Furthermore, plasma levels of TNF-a, IL-1ß, 
and IL-6 were also enhanced in knockout compared to wild-type mice (24). 
IL-10 has been reported in vitro to be synthesized in increased amounts either spontaneously 
by synovial membrane and cartilage (25) or after stimulation of chondrocytes with IL-1ß or TNF-
  (8). IL-10 contributes to cartilage homeostasis through several pathways. In experiments on 
joint tissue, it has been shown that a lack of IL-10 can lead to joint destruction as a result of an 
increased expression of metalloproteinases (26). Upregulation of IL-1 receptor antagonist 
production by isolated monocytes has been found for IL-10 by human monocytes and 
neutrophils (27). Besides exerting antiinflammatory activity, IL-10 has been shown to directly 
stimulate proteoglycan synthesis by human chondrocytes in vitro (28).  
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In an earlier study (16), we investigated whether genetic variation in cytokine production 
contributes to OA susceptibility. The ex vivo production of cytokines in whole blood assays was 
used to classify subjects as “high” or “low” producers based on the distribution in controls. We 
observed that a low innate production of IL-10 using LPS production was associated with an 
increased risk of familial OA at multiple sites (defined as multiple sites in the hands or at 2 or 
more joint sites including the hands, spine, knees, and hips). The low innate IL-10 production in 
these patients is assumed to be partly caused by genetic variation at the IL10 locus (13,15), 
thus implicating that genetic variation of ex-vivo cytokine production upon LPS stimulation 
contributes to OA susceptibility. Therefore, we investigated whether IL10 SNP that constitute 
the 4 ancient IL-10 haplotypes, some associated with IL-10 production, are a risk factor for a 
predominant subtype of OA specifically in the DIP joints. Our results indicate that this is not the 
case. The discrepancy between findings in our earlier study and the present study may be due 
to different OA phenotypes: familial OA at multiple joint sites versus radiographically defined OA 
in DIP joints. Alternatively, not all of the genetic variation in IL-10 production is dictated by IL-10 
haplotypes (13). It may be that genetic factors that dictate inter-individual IL-10 production 
differences that are not located in the IL-10 locus are those relevant for DIP OA.  
In summary our current work suggests that the currently known IL-10 SNP do not exhibit a 
major effect on genetic susceptibility to DIP OA.  
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Abstract 
Background  
Interleukin-10 (IL10) is a cytokine with key regulatory and anti-inflammatory function involved in 
the pathogenesis of various diseases. Although the large interindividual differences in the 
production of IL10 have been extensively associated with polymorphisms and haplotypes of the 
IL10 gene, surprisingly little evidence exists that this variation is actually dictated by IL10 
haplotypes.  
Methods & Findings  
Using the technique of allele-specific transcript quantification, the ratio between two alleles (A 
and G) of the IL10 gene was characterized in 15 healthy heterozygous individuals. Two groups 
were identified whereby donors in group 1 exhibited a 1:1 ratio, whereas those in group 2 
exhibited a ratio > 1 (P < 0.0017). We found that donors heterozygous for haplotype IL10.2 (one 
of the four ancient IL10 haplotypes) were only prevalent in the group that showed higher allelic 
expression ratios.  
Conclusion 
In this study we show that IL10 alleles are indeed differentially transcribed in cells from 
heterozygous individuals and that IL10 haplotypes dictate production of IL10. These findings 
show that interindividual differences in IL10 protein levels can be explained at the transcriptional 
level.  
Introduction 
Interleukin-10 (IL10) has a key role in regulation of the immune response. Produced by a variety 
of cell types, including monocytes and B-lymphocytes, it is a potent upregulator of B-cell 
activation and differentiation (1), but has anti-inflammatory capabilities that can down-regulate 
TNFa, IL1, IL8 and IFNg (2,3). It has also been shown to be an essential growth factor for Tr1 
cells (4).  
Studies have shown that striking differences exist between healthy individuals in their ability to 
produce IL10 both at the constitutive level and following LPS stimulation of wholeblood culture 
in vitro. The relevance of these interindividual differences in IL10 secretion is supported by 
several studies. In the case of fertility, a 2-fold more prevalence of an IL10 genotype associated 
with low production (-2849AA) was observed among 73 women who remained childless as 
compared with the prevalence among 323 women with normal fecundity (5). In a study of first-
degree family members of patients with meningococcal disease, families characterized by high 
production of IL10 had a 20-fold higher chance of a fatal outcome in comparison with families 
with low production of IL10 (6). These data along with other studies point to a genetic origin of 
enhanced IL10 production that is clinically relevant. 
Around 50-70% of the interindividual differences in IL10 production can be attributed to genetic 
factors (6, 7). Polymorphisms in the promoter region of the IL10 locus exhibit functional 
relevance in a pleiotropy of diseases of infectious, autoimmune or immunosuppressive nature. 
Eleven promoter single nucleotide polymorphisms (SNPs) and two CA-repeat microsatellites 
(IL10.G and IL10.R) have been described. This has led to the identification of four common IL10 
promoter haplotypes (8). One interesting SNP is -2849A/G (relative to the transcription start 
site) in the IL10 promoter. Two previous studies from our research showed that carriers of the -
2849AA genotype (non-G carriers) produce significantly less IL10 than carriers of the AG and 
GG genotypes (G carriers) (5,9). The -2849AA genotype together with the IL10.R3 microsatellite 
tag the IL10.1 haplotype associated with low production of IL10. Interestingly, haplotypes of the 
IL10 promoter have been implicated in disease outcome as well. In a recent study, Lin et al. 
demonstrated that an IL10 promoter haplotype is an independent predictor of outcome of graft 
versus host disease after stem-cell transplantation (10). 
The genetic characterization of the IL10 production phenotype was based on results from 
whole-blood cultures stimulated with LPS. Different amounts of secreted IL10 in response to a 
constant amount of stimulus showed a high correlation at the mRNA level, while the mRNA half-
life between high and low producing donors was the same (8), indicating that secreted protein 
levels are regulated by differential transcription. However, the intraindividual variation in the 
amount of IL10 produced by one given individual is about 20% (11), and the associations 
between IL10 haplotypes and low or high producer phenotype are variable. Although current 
techniques, using statistic associations and artificial reporter constructs, may be effective in 
assigning a certain haplotype or a SNP as the marker of low/high IL10 production, we aimed at 
determining the exact nature of the relationship between IL10 production and cis-acting 
variations within the IL10 locus. 
In general, both copies of human autosomal genes are assumed to be co-dominantly 
expressed. However, exceptions do arise in the course of normal development or when 
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promoter utilization or RNA stability is altered (12). Allelic imbalances were previously studied in 
situations of genomic imprinting when both maternal and paternal alleles are present, but one 
allele is expressed while the other remains inactive (13). Recent surveys of human and mouse 
genes suggest that the occurrence of allelic expression differences are more common than 
previously expected (14,15). Although differential allelic expression may be a potentially 
important mechanism underlying human phenotypic diversity, no data is currently available 
showing a direct functional effect of allelic imbalances. Here, we report the first study of genetic 
variations in the IL10 gene aimed at analysing the intrinsic relationship between genotype and 
phenotype at the transcriptional level by quantifying the rate of RNA synthesis. 
Results 
To distinguish between alleles of the IL10 gene, a panel of 58 unrelated, healthy individuals was 
genotyped for a SNP at nucleotide position +4259 (position relative to the transcription start site) 
present on exon 5/3’UTR region (Supplementary Material, Fig. S1). Given that this SNP is 
located within a part of the gene that is transcribed, it is possible to discriminate between allelic 
transcripts in a +4259 heterozygous individual. Thus, 15 heterozygous unrelated individuals 
were selected for further analysis.  
To validate the allele-specific transcript quantification (12) procedure the intensities of the 
fragments in DNA mixtures with a known distribution of +4259A and +4259G alleles were 
measured along with genomic DNA controls. The ratio of the intensity of the bands equals the 
ratio in the DNA mixtures (Supplementary Material, Fig. S2a) with a high correlation factor (R = 
0.999). Genomic DNA yielded an equimolar ratio with a median of 1.00 (25th percentile 0.97-
75th percentile 1.035) as expected (Supplementary Material, Fig. S2b). Taken together these 
results show that any deviations from DNA equimolar ratio can be quantified as each allele acts 
as an internal control for confounding factors that alter the overall expression of that gene, 
including differences in tissue preparation, mRNA quality and environmental influences. 
Quantification of the respective IL10 +4259A and IL10 +4259G allelic RNA transcripts for 15 
individuals revealed that the median ratio of IL10 + 4259 A:G ranged from 0.93 to 1.13 (Fig. 1). 
In 33% of the individuals (2–6) both IL10 alleles contribute equally to the mRNA pool, whereas 
67% showed a preferential expression of allele G or A, respectively (individuals 1 and 7–15). 
Individual 1 showed preferential expression of allele G significantly different from genomic DNA 
(P < 0.0001). In individuals whose A allele was preferentially expressed (7–15), the ratio of the 
transcripts as compared with genomic DNA varied from 1.03 to 1.13 (P < 0.003). A:G ratios of 
samples derived from blood collected at a second time-point for individuals 3, 11 and 15 yielded 
a ratio of 1.01, 1.15 and 1.145, respectively as expected (data not shown), further supporting 
evidence for allele-specific expression.  
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We therefore characterized two predominant groups, group 1 which does not show a significant 
deviation from genomic DNA ratio and group 2 which includes individuals showing preferential 
expression of allele A by 3–12%. Moreover, upon examination of nuclear families of individuals 
13 and 14 (family 1 and family 2, respectively) exhibiting allelic variation in expression (Fig. 2), 
we observed that higher allele-specific expression in the IL10 gene is a heritable trait. 
 
 
Figure 1. Determination of the relative contribution of the IL10 +4259A and IL10 +4259G alleles in LPS-stimulated 
whole-blood cultures of 15 healthy individuals. Each dot represents a sample of DNA or cDNA. Data are 
representative of a minimum of three independent experiments. All individuals (1–15) were subjected to independent 
whole-blood cultures stimulated with LPS, followed by separate RNA purification and cDNA preparation. P-values 
refer to significance test for differences (Mann–Whitney U-test) between every individual RNA transcript ratio to 
genomic DNA ratio (significance P < 0.05). Individuals 2–6 yielded a median ratio not significantly different from 
genomic DNA (Mann–Whitney P > 0.2), whereas individuals 1 and 7–15 yielded a ratio of   1, significantly different 
from genomic DNA (P < 0.0017). Individually inferred haplotypes for each individual are indicated. 
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Figure 2. Inheritance pattern of altered IL10 allelic expression. The relative contribution of the IL10 +4259A and IL10 
+4259G alleles in whole-blood cultures stimulated with LPS was investigated in two pedigrees (families 1 and 2), as 
shown, in which the same trait is prevalent implying an underlying inheritance pattern. Each dot represents a sample 
of DNA or cDNA. Data are representative of a minimum of three independent ASTQ experiments. P-values refer to 
significance test for differences (Mann–Whitney U-test) between every individual transcription ratio to genomic DNA 
ratio (significance P < 0.05).  
 
 
Given the extensive associations between IL10 production and IL10 SNP genotypes, we 
hypothesized that the regulatory determinant could be one of the already characterized IL10 
SNPs found in the promoter region (16). Therefore, we analysed if one of the SNPs’ genotypes 
was always homozygous in the 1:1 donors and always heterozygous in the 1:   1 donors. Table 
1 shows that this is not the case. Although none of the SNPs show an individual effect, a 
combination of alleles may identify which haplotype dictates differential expression. Haplotype 
frequencies for the population comprising of 58 individuals were subsequently inferred using the 
estimation maximization (EM) algorithm in SNPHAP (Fig. 3). Two haplotypes were assigned to 
each heterozygous individual (P ! 0.9 were taken as true haplotypes). The level of linkage 
disequilibrium (LD) between all SNPs was very high, D’ values were close to 1 (data not 
shown), thus only 13 out of the 29 possible haplotypes were prevalent in the population. IL10.1 
to IL10.4 are the four most common haplotypes previously identified (17) and comprise 75% of 
total chromosomes.  
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 Table 1. IL10 genotypes and haplotypes of 15 unrelated individuals included in the ASTQ analysis and three family members (16–18) 
 
ND, not determined. Each individual’s A:G RNA ratio (1–18) is expressed as median. To determine if significant 
differences exist between RNA ratio and genomic DNA ratio, Mann–Whitney U-test was carried out (significance level 
P < 0.05). Nine IL10 SNPs including IL10 +4259 (exon 5/3’UTR), IL10 +1582 (intron 3); proximal promoter SNPs IL10 
-592, IL10 -819, IL10 -1082, IL10 -1330 and distal promoter SNPs IL10 -2763, IL10 -2849 and IL10 -3575 were 
genotyped, and haplotypes for each individual are indicated. L is assigned to the lower IL10 transcribing allele and H 
to the higher transcribing allele. 
 
 
Analysis of individual haplotypes in Table 1 shows that the IL10.2 haplotype is only present in 
the donors that exhibit a >1 ratio (P < 0.0017). IL10.2 is therefore proposed to be the ‘high’ 
haplotype, responsible for higher IL10 transcription and thus higher IL10 protein levels. 
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Figure 3. Haplotype frequencies of nine IL10 polymorphisms including seven promoter SNPs in 58 normal Caucasian 
individuals. SNPs were denoted respective to the transcription start site. In total, 13 haplotypes were inferred using 
EM algorithm in SNPHAP. Haplotypes IL10.1, 2, 3 and 4 are previously identified ancient haplotypes in the 
Caucasian population (17) and account for 75% of variation within our population. The proximal region of the IL10 
promoter shows less variation than the distal part. 
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Discussion 
IL10 is a crucial player in the immune system. Genetic differences in IL10 production have been 
associated extensively with the pathology and outcome of diseases. The aim of this study was 
to determine whether the mechanism driving these associations is differences in allelic 
expression. We show here for the first time that alleles of the IL10 gene are indeed differentially 
transcribed in LPS-stimulated whole-blood cultures of heterozygous individuals, a finding which 
supports the functional existence of transcriptionally distinct IL10 haplotypes in humans and 
questions the functional relevance of currently known SNPs. 
IL10.2 harbours a polymorphism that is associated with increased expression at the mRNA 
level. This implies that IL10.1 and IL10.7 harbour the SNP associated with lower transcription 
rate. By extrapolation, high or low phenotype has been assigned to each haplotype and 
indicated in Table 1. Our data can best be explained if the IL10.4 haplotype consists of two 
haplotypes, a haplotype associated with high and one associated with low allele-specific IL10 
expression. 
Our data are in accordance with previously published data on LPS-induced IL10 production. We 
observed that the -3575A/-2763A haplotype is associated with lower IL10 production (16). In our 
panel, this combination of -3575A/-2763A haplotype forms part of the larger haplotypes IL10.1, 
3 and 12, which are responsible for lower allele-specific IL10 transcription. We can therefore 
correlate these haplotypes to low IL10 protein levels, providing further evidence that this finding 
is in line with all data previously obtained. The -3575T/-2849G/-2763C haplotype, which tags 
IL10.2, IL10.4 and IL10.5, is associated with high IL-10 production, while the -3575A/-2849A/-
2763A haplotype, which tags IL10.1 and IL10.12, is associated with low IL-10 production. 
According to the data in Table 1, both IL10.1 and IL10.12 drive lower transcription of mRNA 
transcripts, and both IL10.2 and IL10.5 express higher allelic transcriptional levels, further 
supporting our analysis.  
Our finding that the IL10.4 haplotype may either be a low or a highly transcribed haplotype and 
the occurrence of an individual with ratio <1 suggests the presence of a bidirectional allelic 
imbalance that could result from allelic heterogeneity of one or more cis-acting regulatory 
polymorphisms present in the coding, intronic and/or other non-coding regulatory sequences 
(14,18) or from DNA methylation, histone acetylation and other epigenetic factors (19,20). 
Alternatively, the marker SNP could be detecting a single causal polymorphism that is actually 
responsible for the differential expression of IL10 RNA transcripts, but that does not show 
unidirectional allelic imbalance when it is not in complete LD.  
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Prime candidates are SNPs that are present in the regulatory region of the IL10 gene. However, 
our current knowledge of regulatory elements in the human genome is far from comprehensive 
and, beyond their coding sequences, most genes are not well annotated. As the positions of all 
regulatory sequences for any given gene are generally unknown, comprehensive direct 
analyses of such elements are currently impossible. Moreover, the SNPs used in this study 
span only about 8 kb of the IL10 gene, a region that does not cover the average length of a high 
LD block in world populations of similar origin (21). It would be interesting to determine the 
average length of the LD block surrounding the IL10 gene and attempt to identify regulatory 
sequences within.  
In summary, we propose that a common SNP in high but not complete LD with haplotype IL10.2 
dictates differences in IL10 expression. This cis-acting variation(s) may alter the functional 
motifs in the promoter region or work indirectly by modifying the activity of the gene product. 
However, the magnitude of difference in expression level that is likely to be biologically relevant 
is unclear. It is plausible that different cell types present in peripheral blood dilute the effect 
seen, such that investigating specific cell types would yield larger differences in IL10 differential 
transcription. However, in our system of LPS-induced whole-blood cultures, the main producers 
of IL10 are monocytes and macrophages, and so far no data exist to support monoallelic 
expression of monocytes. A more likely alternative, in our view, is that if a particular allele is 
always transcribing at a faster rate, subtle differences can have an exponential effect resulting 
in large changes in gene expression patterns. We therefore conclude the mechanism behind 
higher IL10 gene expression levels is caused by subtle differences in allelic expression 
regulated by cis-acting polymorphism(s) on distinct IL10 haplotypes. 
Materials and Methods 
Reagents 
All reagents were from Invitrogen, Life Technologies, Gaithersburg, MD, USA unless otherwise 
specified. 
Subjects/DNA isolation 
Blood samples were collected from 58 unrelated healthy Caucasian volunteers. DNA was 
isolated using a SOC-lysis and proteinase-K treatment of peripheral blood cells, followed by a 
phenol–chloroform extraction. From every heterozygous IL10 + 4259A/G (rs3024498) individual, 
two additional heparin-blood tubes were used to perform LPS-whole-blood stimulations, as 
described below. 
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Genotyping of IL10-polymorphisms (position relative to transcription start site) 
The IL10 -3575A/T (rs1800890), -2849A/G, -2763A/C, -1082A/G (rs1800896) and -819A/C 
(rs1800871) polymorphisms were typed as previously described (22). An amount of 25 ng 
genomic DNA was used per polymerase chain reaction (PCR) for all SNPs. -592A/C 
(rs1800872) and -1330A/G (rs1800893) are in complete LD (R2 = 1) with -819A/C and -
1082A/G, respectively. All SNPs were annotated relative to the transcription start site according 
to the public reference sequence U16720.  
The PCR for -592A/C genotyping was carried out using 0.6 U Taq polymerase with the buffer 
supplied by the manufacturer (Applied Biosystems), 2.5 mM MgCl2, 0.25 mM of each dNTP, 
100 µg/ml bovine serum albumin and 0.25 µM of each primer in a 30 µl reaction. Sense primers 
were 5’-CTC AGTTAGCACTGGTGTAC-3’ and antisense 5’-TGTTCCTA GGTCACAGTGAC-3’. 
DNA was denatured at 94°C for 5 min and cycling conditions were set at 94°C for 30 s, 60°C for 
30 s and 72°C for 30 s for 35 cycles and a final cycle of extension at 72°C for 7 min in a 
thermocycler (Applied Biosystems 9700). An aliquot of 10 µl of the PCR product was digested 
for 2 h with 1.5 U of Rsa I (MBI Fermentas) in a total volume of 25 µl at 37°C, yielding 480 bp 
for the C allele and 240 bp for the A allele. 
The PCR conditions for the +4259A/G SNP were the same as for the -592A/C and were run for 
40 cycles. Primers were sense 5’-ACTGAGCTTCTCTGTGAACG-3’ and antisense 5’-
AATAACAAGCTGGCCACAGC-3’. 12.5 µl PCR product was digested with 2.5 U per tube 
Fnu4HI (New England Biolabs) in a total volume of 50 µl yielding 416 bp for the A allele and 284 
+ 132 bp for the G allele.  
The conditions for the +1582T/C (rs1554286) SNP PCR were set at 1 min 94°C, 1 min 60°C 
and 1 min 72°C for 40 cycles with sense primer 5’-
CTACGGCGCTGTGTAAGTAGCAGATCAGA*T-3’ (modified nucleotides are marked) and 
antisense primer 5’-AACCCACAAATGACTCACAAAT-3’. An aliquot of 10 µl PCR product was 
digested with 2.5 U of Bgl II in a total volume of 25 µl yielding 157 + 105 bp for the T allele and 
130 + 105 + 27 bp for the C allele. 
Quality control 
Data for each SNP were reviewed independently to verify their quality. We considered each 
SNP to be validated and correctly genotyped for all individuals only if the genotype data met a 
series of strict criteria, including minimum signal intensity specifications and unambiguous 
genotype reading ability. No errors were detected in 10% of the samples that were randomly 
genotyped again. 
LD mapping and haplotyping across the IL10 gene 
GOLD (23) was used to determine pairwise LD between all SNPs. Haplotype frequencies were 
inferred using SNPHAP (http://www-gene.cimr.cam.ac.uk/clayton/software/). Crosschecking of 
the inferred haplotypes using available family data (data not shown) revealed that all haplotypes 
were accurate in areas of high LD (D’ close to 1). 
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LPS-whole-blood cultures/RNA isolation 
In total, 15 heterozygous unrelated individuals were selected for ASTQ on the basis of their 
heterozygosity with respect to the IL10 +4259 SNP. Approximately 20 ml of blood was collected 
at one time-point from each of 18 heterozygous IL10 + 4259A/G donors (15 unrelated and three 
family members, Table 1). Blood was collected from three individuals at a second time-point and 
an independent set of experiments was carried out.  
For each donor, five wells containing 3 ml of blood was immediately diluted once in 3 ml of an 
aliquot consisting of endotoxin-free RPMI 1640 medium (Gibco) with 10% fetal bovine serum 
(Bodinco BV), 5% pen-strep (Bio-Whittaker) and 30 mg/ml LPS from Salmonella typhosa 
(Sigma). As a control, one additional well was subjected to the same conditions in the absence 
of LPS. These aliquots were incubated for 17 h at 37°C with 5% CO2. 
RNA isolation 
The samples were harvested, red blood cells lysed, and centrifuged at 600g. Each cell pellet 
was washed once with 25 ml PBS, taken up in 1 ml RNA-Bee (Campro Scientific) and stored at 
-20°C for at least 18 h. These samples were thawed on ice and 100 µl chloroform was added. 
After the samples were vigorously shaken for 20 s, and incubated on ice for 60 min, they were 
centrifuged (13 200 rpm, 4°C) for 15 min. The upper aqueous phase was pipetted out into new 
tubes. An equal amount of isopropanol was added to each tube followed by incubation on ice for 
15 mins. RNA was precipitated by centrifugation (13 200 rpm, 4°C) for 15 min. The supernatant 
was discarded and the pellets were washed with 500 µl 70% ethanol. Samples were vortexed 
and centrifuged (13 200 rpm, 4°C) for 5 min. Supernatant was discarded and pellets were dried 
in air for 5–10 min. RNA was solubilised in 40–50 µl DEPC-treated water by incubation in a 
55°C water bath for 30 min. 
DNAse-treatment/RT-PCR 
RNA samples were treated with DNAse I, Amp. grade. Each DNAse-treated RNA sample was 
split into four equal volumes, each containing 2 µg RNA. Two fractions were reverse-transcribed 
into cDNA in a 40 µl volume at 37°C for 1 h using 400 U of M-MLV, 5x first-strand buffer, 0.1 M 
dithiotreitol, rRNAsin (Promega) 100 mM dNTP mix and either 1 µg of oligo dT12-18, or 1 µg of 
random primers. The remaining two fractions were used as negative controls. The reaction was 
inactivated by incubation at 95°C for 10 min. In total, each blood collection from each individual 
yielded six RNA samples which were reverse transcribed into 12 cDNAs. All cDNA samples 
were tested several times in independent ASTQ experiments as outlined below. Samples that 
were not stimulated with LPS were excluded from the analysis as the intensities obtained were 
too low to be quantified. 
Allele-specific transcript quantification 
This method is essentially the same as previously described (12) with the exception of the use 
of a marker (IL10 +4259) which is present in exon 5/3’UTR region of the IL10 gene, thus 
allowing the post-transcriptional analysis of the expressed alleles.  
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cDNA samples were amplified by PCR with the IL10 +4259A/G PCR. An aliquot of 20 µl 
amplicon was mixed with 4 µCi [ -32P]-dCTP (Amersham Biosciences) and 0.5 U Taq 
polymerase, followed by one PCR cycle with conditions set at 94°C for 5 min, 94°C for 1 min, 
60°C 1 min, 72°C for 1 min and 72°C for 7 min. An aliquot of 15 µl labelled amplicon was 
digested with 2.5 U Fnu4HI in a total volume of 50 µl and incubated at 37°C for 2 h. All samples 
were ethanol-salt precipitated, dissolved and separated on a 5% polyacrylamide sequence gel. 
After electrophoresis, the gel was dried for 3 h in a preheated vacuum gel-dryer and incubated 
for 7 days in a Phosphor imager (Molecular Dynamics) cassette at room temperature. The 
exposed screen was scanned and computer analysed (ImageQuant). 
Ratios of +4259A/+4259G transcripts were obtained by calculating the pixel values of digestion 
fragments of allele A (416 bp) versus allele G (284 bp). As the respective products are not of the 
same size, a correction factor was applied based on the respective GC content of each 
restriction product: GC content allele A = 168 bp; GC content allele G = 108 bp; Correction 
factor = 168/108 = 1.56 was applied to each cDNA ratio. As the values for these two bands 
reflect the synthetic products from a RT-PCR amplification of the same RNA preparation, 
controlling for variations in reaction conditions was unnecessary.  
Genomic DNA controls 
Each gel consisted of cDNA samples along with genomic DNA controls from six to eight 
independent individuals. As allele A and allele G are codominantly expressed at the genomic 
DNA level, A:G DNA ratio from heterozygous IL10 + 4259 individuals should be 1:1. The 
reliability of the cDNA data was determined by the average of the DNA ratios obtained. In each 
gel, RNA ratios were subjected to a correction factor equivalent to genomic DNA ratio to 
circumvent overestimation of differences. Gels with a genomic DNA ratio <0.95 and >1.05 were 
excluded from further analysis.  
Statistics  
Data were analysed using Graphpad prism and did not follow a normal distribution. The median 
value for RNA A:G ratio was calculated for each individual (Table 1) and a Mann–Whitney U-
test was performed to detect significant differences between RNA ratios and genomic DNA ratio 
(P < 0.05). 
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Abstract 
Genetic  factors appear to be important in the process of restenosis after percutaneous 
coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. An 
important mediator in the inflammatory response is interleukin (IL)-10. Our aim was to study 
whether genetic variants in IL-10 predispose to the risk of restenosis. The GENetic 
DEterminants of Restenosis (GENDER) study included 3104 patients treated with successful 
PCI. Target vessel revascularization (TVR) was chosen as primary end point. 
Genotyping of the -2849G/A, -1082G/A, -592C/A and +4259A/G polymorphisms of the IL-10 
gene was performed by MassArray platform. After adjusting for clinical variables, three 
polymorphisms significantly increased the risk of restenosis (-2849AA: relative risk (RR), 1.7, 
95% confidence interval (CI), 1.2–2.5; -1082AA: RR, 1.4, 95% CI, 1.1–1.8 and +4259GG: RR, 
2.0, 95% CI, 1.4–2.8). To further exclude possible involvement of neighboring genes due to LD 
in the IL-10 locus, additional polymorphisms were genotyped. The results reveal that 
association of the IL-10 gene with restenosis is independent of flanking genes.  
Our findings demonstrate that IL-10 is associated with restenosis and therefore support the 
hypothesis that anti-inflammatory genes also may be involved in developing restenosis. 
Furthermore, they may provide a new targeting gene for drug-eluting stents.  
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Introduction 
An important limitation of the treatment of atherosclerotic lesions by percutaneous coronary 
intervention (PCI) is the occurrence of restenosis(1,2). Inflammatory responsiveness, resulting 
in neointima formation, plays a pivotal role in the development of restenosis (3–5). Several 
inflammatory genes have already been reported to be associated with the development of 
restenosis (6,7). However, little is known about the involvement of anti-inflammatory cytokines, 
although they seem logic candidate genes in the process of restenosis. Interleukin 10 (IL-10) is 
one of these anti-inflammatory genes. It is an important immunosuppressor cytokine, involved in 
the regulation of many aspects of immune responses. Its effects are directed mainly against 
functions of mononuclear cells, T lymphocytes and polymorphonuclear leukocytes. Furthermore, 
IL-10 plays a role in inhibition of cell adhesion molecules, monocyte chemotactic protein-1, 
tissue factor, fibrinogen, matrix metalloproteinase-9, T-lymphocyte granulocyte–macrophage 
colony-stimulation factor, inducible nitric oxide synthase and smooth muscle cell proliferation 
(8–10). Several of these factors have been demonstrated to be involved in the restenotic 
process (5,11). The interindividual difference among individuals in their ability to produce IL-10 
appears to have a genetic origin (12–14). The heritability of the endotoxininduced IL-10 
production has been estimated to be 74% in studies on monozygotic or dizygotic twins and 
nonrelated individuals (15). The gene encoding IL-10 contains variable sites (polymorphisms 
and microsatellite markers) that have previously been associated with the level of IL-10 
produced, indicating that they may be associated with different responsiveness to regulatory 
signals. 
The aim of this study was to assess whether four different functional polymorphisms (three in 
the promoter, one in the 3’UTR) in the IL-10 gene are related to the risk of developing 
restenosis after PCI. 
Results 
A total of 3146 patients had a complete follow-up (99.3%) with a median duration of 9.6 months 
(interquartile range 3.9 months). Out of 3146 patients, 42 had an event in the first 30 days. 
These patients were excluded from further analysis, according to the protocol. Baseline 
characteristics of the population are shown in Table 1. Genotyping was successful in 2874 
patients for the -2849G/A polymorphism, in 2740 patients for the -1082G/A polymorphism, in 
2873 patients for the -592C/A polymorphism and in 2865 patients for the +4259A/G 
polymorphism. Allele frequencies were 0.72/0.28, 0.51/0.49, 0.76/0.24 and 0.73/0.27, 
respectively. The results of the remaining patients are missing owing to the lack of DNA or 
inconclusive genotyping. Patients who could not be genotyped did not differ in any characteristic 
from those who could be genotyped. The distributions of the genotypes are shown in Table 2. 
All polymorphisms showed no significant deviation from Hardy–Weinberg equilibrium (P>0.05), 
except for -1082G/A (P=0.01). 
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 Table 1 Demographic, clinical and lesion characteristics of 3104 patients with and without TVR 
 
 
Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; LAD, left anterior descending branch 
of the left coronary artery; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCX, circumflex 
branch of the left coronary artery;  VR, target vessel revascularization. Age is mean ±s.d.; other variables are 
percentage of patients. 
 
Of the 3104 patients, 304 (9.8%) patients underwent target vessel revascularization (TVR) 
during follow-up. Fifty-one (1.6%) patients died and 22 (0.7%) suffered from myocardial 
infarction (MI). After univariate analysis, -2849AA, -1082AA and +4259GG genotypes of the IL-
10 gene increased the risk for TVR significantly (P=0.005, P=0.03 and P=0.001,respectively) 
(Table 2). 
The effect of each polymorphism was adjusted for patient and intervention-related 
characteristics that were previously found to be related to TVR risk including diabetes, 
hypertension, stenting, residual stenosis >20%, current smoking and total occlusion, as well as 
age and gender. This analysis showed a significant association for the same three 
polymorphisms that were significantly associated with TVR in the univariate analysis. 
Furthermore, diabetes, stenting and total occlusion were significantly associated with TVR 
(Table 3a). Multivariable Cox regression analysis was performed, in which all four IL-10 
polymorphisms were included. Subsequently, we performed multivariable Cox regression 
analysis in which we included all four IL-10 polymorphisms, and adjusted for the same clinical 
risk factors and selected in a backward stepwise manner the polymorphisms that were 
independently associated with TVR risk. Polymorphisms were removed from the model when 
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their P-value was 40.10. A significant association was found for the IL-10 +4259GG genotype 
(P=0.001), implying that this polymorphism is an independent risk factor for TVR. Exclusion of 
the -1082G/A polymorphism, which was not in complete HW equilibrium, did not alter the 
outcome.  
As we found a strong correlation between the IL-10 polymorphisms and stenting, we stratified 
patients to a stented and a non-stented population. The use of intracoronary stents was carried 
out at the discretion of the operator. The stented population consisted of 2309 patients, of who 
203 (8.8%) patients had to undergo a TVR. Both the stented population and the non-stented 
population, consisting of 795 patients, demonstrated a significant association for the same three 
polymorphisms as described earlier when adjusted for clinical variables. Multivariable analysis 
including all polymorphisms demonstrated the +4259GG genotype of the IL-10 gene to be 
associated with TVR. Results of this analysis are shown in Table 3b and 3c. Furthermore, they 
show that the effect of the +4259GG genotype of the IL-10 gene was more pronounced in the 
non-stented population.  
 
Table 2 Distributions of the polymorphisms, including the univariate analysis of investigated polymorphisms in 
association with TVR 
 
 
Abbreviation: TVR, target vessel revascularization. 
*P-value determined by the Cox proportional regression model. 
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 Table 3 Relative risks (RR) of the univariate and multivariable analysis of the IL-10 polymorphisms in association with 
TVR for the 
(a) total population (N = 3104); (b) stented population (N = 2309) and (c) non-stented population (N = 795) 
 
Abbreviations: 95% CI = 95% confidence interval; IL, interleukin; NS, not significant; RR = relative risk; TVR, target 
vessel revascularization. 
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A high level of linkage disequilibrium exists between the polymorphisms in the IL-10 gene. In 
order to determine whether the three significant associated polymorphisms with TVR are acting 
synergistically to confer risk to TVR, we performed two haplotype analyses. We did not include 
the -592C/A polymorphism in the haplotype analysis, as it did not show a significant association 
with TVR. Furthermore, the R2 value for this polymorphism is much lower (pairwise linkage 
disequilibrium (LD) between -592 and +4259 has R2=0.12). 
 
 
 
Figure 1 IL-10 and haplotypes. Haplotypes are presented in the following order of polymorphisms: -2849G/A, -
1082G/A and +4259A/G. Of the eight possible haplotypes, only three haplotypes had relative frequency >1%, 
presented by the red bars. The blue bars present log hazard ratios. Differences were not statistically significant 
(P>0.05). 
 
We first performed a combined analysis with -2849G/A, -1082G/A and +4259A/G. Of the eight 
possible haplotypes, only seven were observed with relative frequency >0, and only three 
haplotypes had relative frequency >1%, namely ‘GGA’, ‘GAA’ and ‘AAG’ (Figure 1, red bars). 
The frequency of the GGA haplotype in patients with TVR was 0.47 compared to 0.51 for 
patients without TVR. For the GAA haplotype, the haplotype frequency was 0.22 for patients 
with TVR and 0.21 for patients without TVR. Furthermore, patients with TVR had a frequency of 
the AAG haplotype of 0.30 compared to 0.27 for patient without TVR. Compared to the wild-type 
haplotype (‘GGA’), the log hazard ratios of the other haplotypes were 0.094 and 0.098, 
respectively (Figure 1, blue bars). Differences were not statistically significant (P>0.05). 
Furthermore, as the -1082G/A polymorphism was not in HW equilibrium and the-2849G/A and 
the +4259A/G are in strong linkage disequilibrium (D’ = 0.96, R2=0.92 pairwise LD as calculated 
by haploview), we performed separate haplotype analysis for the -2849G/A and the +4259A/G 
polymorphisms. The combination of these two polymorphisms did not give an additive effect 
(data not shown). 
IL-10 is located in a cluster of IL-10 family genes on chromosome 1q32. As the extent of LD 
surrounding the IL-10 gene has not as yet been definitively characterized, we investigated 
whether the effect seen from the examined IL-10 polymorphisms could in fact be the result of 
LD with a neighboring gene. To this end, we genotyped polymorphisms in mitogen-activated 
protein kinase-activated protein kinase 2 (MAPKAPK2), IL-10, IL-19, IL-20 and IL-24 in a 
healthy population of unrelated Caucasian individuals (N=60). Haploview was used to assess 
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pairwise LD between polymorphisms of genes. Figure 2 reveals that the region spanning 217 kb 
is broken down into four blocks with a solid spine of LD. MAPKAPK2, IL-19, IL-20 and IL-24 
seem to be independent of the IL-10 gene itself. IL-19, IL-20 and IL-24 form combined blocks, 
indicating shared inheritance patterns of IL-20 with both IL-19 and IL-24. These data are in line 
with the haplotype blocks as defined by HAPMAP for a Caucasian population of European 
descent. In our study, this finding excludes the presence of cis effects of the IL-10 homologs or 
MAPKAPK2 on the IL-10 gene owing to ancestral recombination and reveals that the 
association of the IL-10 gene with restenosis is independent of flanking genes. 
 
Figure 2 Haplotype map of the IL-10 locus. The haplotype map is made by Haploview version 3.2 software. The 
basis of this graphical representation is pairwise linkage disequilibrium (LD) between polymorphisms. D’ values (%) 
are shown in the boxes. In the event of D’ = 100%, the boxes are empty. The region consists of four recombination 
blocks that encompass a 217 kb region between MAPKAPK2 and IL-24. Block 1 comprises the gene MAPKAPK2, 
block 2 comprises the best-known promoter polymorphisms of IL-10 and spans the whole IL-10 gene (-592C/A 
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Discussion 
Inflammation is known to play a pivotal role in the development of restenosis after PCI (4,5). 
Many inflammatory genes have already been investigated in relation to restenosis. However, 
the role of anti-inflammatory genes in restenosis is not fully understood. Therefore, we 
investigated in our large prospective GENDER study the effect of four different polymorphisms 
of the IL-10 gene in relation to restenosis, defined by TVR in our study. Different cell types, 
including human monocytes and T cells, produce IL-10. IL-10 inhibits the production of pro-
inflammatory cytokines, including tumor necrosis factor alpha (TNF ) (16). Furthermore, it 
interferes with the production of various chemokines (17). Treatment of IL-1- activated human 
endothelial cells with IL-10 results in lower surface densities of intercellular adhesion molecule-1 
and vascular-cell adhesion molecule-1 and reduced leukocyte adhesivity (18). In addition, IL-10 
enhances the production of an IL-1 receptor antagonist that has anti-inflammatory activity 
directed against the effects of IL-1 (19). 
After adjustment for clinical variables, we found the -2849AA, -1082AA and +4259GG 
genotypes of the IL-10 gene to be highly associated with restenosis after PCI. After inclusion of 
all four polymorphisms and clinical factors previously associated with TVR, only the +4259GG 
genotype showed a significant association. Possibly, the +4259A/G polymorphism has an effect 
on restenosis by influencing the mRNA stability. 
Haplotype analysis did not provide any additional information with regards to risk of TVR. As the 
-1082G/A polymorphism was not in complete HW equilibrium, and as we cannot be certain that 
this is due to selection of the population, or to genotype errors, we also performed multivariable 
analysis excluding this polymorphism. Exclusion of this polymorphism did not significantly alter 
the results. With the current chosen polymorphisms, we are able to characterize about 70% of 
the four common haplotypes in the IL-10 gene. However, we cannot exclude the possibility that 
less common haplotypes, characterized by further tagging polymorphisms (as provided by the 
HAPMAP project, www.hapmap.org), could provide more information with regards to the risk of 
restenosis. 
The results of our study reveal that association of the IL-10 gene with restenosis is independent 
of flanking genes, as cis-acting variations in neighboring genes are unlikely to play a role given 
that there are clear recombination points around the IL-10 gene, breaking the LD with 
neighboring genes. These findings are in line with the results of the HAPMAP project in a 
Caucasian population of European descent. 
Some studies found a relation between TNF  and IL-10 plasma levels (20). As we previously 
investigated the role of several polymorphisms in the TNF  gene (11) we analyzed whether 
those polymorphisms had an effect on our results. However, we did not find a significant 
association between the -238G/A and the -1031T/C polymorphisms of the TNF  gene and the 
four IL-10 polymorphisms we examined in this study. 
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The functional effect of the polymorphisms we examined has been described previously. Koss 
et al demonstrated that the A allele in the IL-10 promoter region at position -1082 was 
associated with decreased IL-10 production as measured by enzyme-linked immunosorbent 
assay (ELISA) in lipopolysaccharide (LPS)-stimulated whole blood in Crohn’s disease patients 
and healthy controls (P=0.005, P=0.015, respectively) (13). Furthermore, several studies have 
demonstrated that carriers of the -2849AA genotype have significantly lower IL-10 
responsiveness upon stimulation with endotoxin (12,21). In some individuals, allele G of the 
+4259 polymorphism produces less IL-10 transcripts as compared to the A allele (14), which 
points towards an allele-specific genetic regulation of protein levels of IL- 10. As we showed an 
increase in the risk of developing restenosis for the -1082AA, -2849AA and +4259GG 
genotypes, these data corroborate our hypothesis that lower levels of IL-10 may increase the 
risk of developing restenosis. However, the relevant stimulus and therefore the relevant 
transcription factor activating the IL-10 gene in the case of restenosis is largely unknown. 
Different transcription factors are known to either positively or negatively regulate the 
transcription of the IL-10 gene (22, 23). The current functional data available on the regulation of 
the IL-10 gene is thus a mere indication of plausible scenarios that may or may not provide 
explanations in the case of restenosis.  
Eefting et al. studied the involvement of IL-10 in neointima formation in a hypercholesterolemic 
mouse model of cuff-induced stenosis of the femoral artery by IL-10 knocking-out or 
overexpression procedures. Knocking out IL-10, in hypercholesterolemic ApoE*3-Leiden mice, 
resulted in a significant 1.9-fold increase of neointima surface as compared to ApoE*3- Leiden 
IL-10+/+ littermates (P=0.02). Conversely, a marked 45% inhibition on cuff-induced neointima 
formation was obtained after IL-10 overexpression (P=0.02) (24).  
Another study has examined the effect of recombinant human IL-10 (rhuIL-10) on intimal 
growth, after angioplasty or stent implantation, in hypercholesterolemic rabbits (25). The main 
findings of their study were that systemic administration of the anti-inflammatory cytokine rhuIL-
10 successfully inhibits intimal hyperplasia after balloon injury or stent implantation in 
hypercholesterolemic rabbits. This protective effect is associated with a major inhibition of IL-1b 
release by circulating leukocytes and reduced infiltration of the arterial wall by activated 
macrophages. RhuIL-10 has no apparent effect on lipid metabolism and no systemic toxicity in 
their animal model (25). It is therefore possible that an IL-10-releasing stent may contribute to 
lowering the development of restenosis. 
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Study limitations 
Circulating protein levels were not assessed in the present study. However, we believe that 
basal (pre-PCI) lasma levels of the gene product will not reflect the genetically determined 
differences in IL-10 increase after a trauma such as PCI. Moreover, local differences in 
response (in the vessel wall at the place of PCI) may not be reflected systemically. In humans, it 
is impossible to measure gene products locally in the acute phase of treatment or the following 
days, and several months later the causal trigger has probably already disappeared. 
Furthermore, the lack of data on the effect of the presently used drug-eluting stents on TVR and 
its relationship with the IL-10 polymorphisms is a limitation of our study. Another potential 
limitation is that we examined TVR as our primary end point instead of angiographic outcomes, 
such as late loss. However, in clinical practice, clinical restenosis is an end point much more 
valuable than angiographic restenosis. Finally, as our study was conducted in a sample of 
Caucasian patients, extrapolation of the data to other ethnic groups should be done with great 
caution.  
Conclusions 
The present study shows that the -2849AA, -1082AA and +4259GG genotypes of the gene 
coding for the anti-inflammatory cytokine IL-10 are a risk marker for the development of 
restenosis. Further investigation in other populations as well as the fine mapping of the IL-10 
gene will provide further insight into the precise role of IL-10 in restenosis. Based on our 
findings, screening patients for this genotype can lead to a better stratification of patients at 
increased risk for restenosis and thereby provide indications for improving individual tailor-made 
treatment, as it may be a new target point for drug-eluting stents. The results of this study lend 
support to the broader hypothesis that genetic programming of the inflammatory response plays 
a significant role in the development of restenosis. Given the explorative nature of this analysis, 
our results need to be reproduced in other studies.  
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Materials & Methods 
GENDER project 
Study design 
The present study population has been described previously (26). In brief, the GENDER project 
was designed to study the association between various gene polymorphisms and clinical 
restenosis. Patients eligible for inclusion were treated successfully for stable angina, non-ST-
elevation acute coronary syndromes or silent ischemia by PCI in four out of 13 referral centers 
for interventional cardiology in the Netherlands. Patients treated for acute ST elevation MI were 
excluded. Also excluded from analysis were patients suffering from events occurring within 1 
month after PCI, as these events were attributable predominantly to sub-acute stent thrombosis 
or occluding dissections, rather than to restenosis. 
PCI procedure 
Experienced operators, using a radial or femoral approach, performed standard angioplasty and 
stent placement. Before the procedure, patients received aspirin 300mg and heparin 7500 IU. 
The use of intracoronary stents and additional medication, such as glycoprotein IIb/IIIa 
inhibitors, were carried out at discretion of the operator. In case a stent was implanted, patients 
received either ticlopidin or clopidogrel for at least 1 month following the procedure depending 
on local practice. During the study, no drug-eluting stents were used. 
Follow-up and study end points 
Follow-up lasted for at least 9 months, except when a coronary event occurred. Patients were 
either seen in outpatient clinics or contacted by telephone. TVR, either by PCI or coronary artery 
bypass grafting (CABG), was designated the primary end point, as it is considered most 
relevant by regulatory agencies. An independent clinical events committee evaluated the clinical 
events.  
The study protocol meets the criteria of the Declaration of Helsinki and was approved by the 
Medical Ethics Committees of each participating institution. Written informed consent was 
obtained from all participating patients before the PCI procedure. 
Genetic methodology 
Blood was collected in ethylene diaminetetraacetate (EDTA) tubes at baseline and genomic 
DNA was extracted following standard procedures. In this population, we determined genotypes 
of the following polymorphisms in the IL-10 gene: -2849G/A (rs6703630), -1082G/A 
(rs1800896), -592C/A (rs1800872) and +4259A/G (rs3024498). These polymorphisms were 
selected from literature, and databases on the web, criteria used were frequency of the rare 
allele and a possible functional effect (8,10,13,14). To assay these polymorphisms, we used a 
MassArray platform according to manufacturer’s protocols. Two multiplex assays were designed 
using Assay designer software (Sequenom, Hamburg, Germany). After polymerase chain 
reaction (PCR), a primer extension reaction was performed to introduce mass-differences 
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between alleles and, after removing salts by adding a resin, ~15 nl of the product was spotted 
onto a target chip with 384 patches containing matrix. Mass differences were detected using an 
Autoflex (Bruker, Wormer, Netherlands) matrix-assisted laser desorption\ionization time-of-flight 
mass spectrometry (MALDI-TOF) and genotypes were assigned real-time using Typer 3.1 
software (Sequenom). As quality controls, 5–10% of the samples were genotyped in duplicate. 
No inconsistencies were observed. Positive and negative controls uniquely distributed in each 
384 wells plate were also consistent. Cluster plots were made of the signals from the low and 
the high mass allele. Two independent researchers carried out scoring. Disagreements or 
vaguely positioned dots produced by Genotyper 3.0 (Sequenom) as well as all wells that had 
50% or more failed SNPs were excluded from analysis.  
Statistical analysis 
Deviations of the genotype distribution from that expected for a population in HW equilibrium 
was tested using the χ2 test with one degree of freedom. Allele frequencies were determined by 
gene counting, the 95% CIs of the allele frequencies were calculated from sample allele 
frequencies, based on the approximation of the binominal and normal distributions in large 
sample sizes. 
Continuousvariables are expressed as mean± standard deviation and were compared by means 
of the unpaired, two-sided t-test. Discrete variables are expressed as counts or percentages 
and were compared with the χ2. In the first stage, the association between the IL-10 
polymorphisms and TVR was assessed using the Cox proportional regression model under a 
co-dominant genetic model. No adjustments for covariates were performed at this stage, so that 
we could assess their possible involvement in the causal pathway. 
All polymorphisms were also assessed using dominant and recessive models, and the model 
with the lowest Akaike information criteria was used in multivariable regression analysis (27). 
Multivariable regression analysis of the TVR risk was performed with all IL-10 polymorphisms, 
using a stepwise backward selection algorithm. In the final step, clinical variables associated 
with TVR, also including age and gender, were entered into the regression model. The IL-10 
polymorphisms were combined into haplotypes and the effect of haplotypes on restenosis risk 
was estimated according to the methods developed by Tanck et al (28). Evaluation of the 
neighboring genes of the IL-10 locus was performed by genotyping polymorphisms in the 
MAPKAPK2, IL-19, IL-20 and IL-24 genes in a panel of healthy individuals (N=60).  
Haploview software (http://www.broad.mit.edu/mpg/haploview) was used to perform LD 
calculations. Haplotype blocks were assigned under the algorithm of solid spine of LD as 
provided by the software. Statistical analysis was carried out using SPSS 12.0 for Windows 
(SPSS Inc., Chicago, IL, USA). A P-value <0.05 was considered statistically significant.  
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Abstract  
Objective  
Interleukin 10 has been previously identified as a genetic risk factor involved in the severity of 
joint destruction in Rheumatoid Arthritis (RA). However many studies provide conflicting results 
when investigating RA phenotypes such as radiographic damage or clinical remission. The aim 
of this study was to determine whether tagging SNPs in the IL10 locus are associated with RA 
disease outcomes in a well-defined clinical cohort.  
Methods  
RA patients enrolled in the Leiden Early Arthritis Clinic were genotyped for six tagging SNPs in 
the IL10 gene (n=594). Yearly radiographs were scored using the Sharp-van der Heijde method. 
Sustained DMARD-free remission (defined as no swollen joints for at least 1 year after 
discontinuing all DMARDs) was assessed in all patients. The extent of joint destruction between 
genotype as well as haplotype groups was compared using Kruskal-Wallis tests at each time 
point for a follow-up period of 5 years after inclusion. The association between genotype, 
haplotype groups and remission was investigated using Cox regression analysis.  
Results 
Patients did not show significant differences in the rate of joint damage and remission with 
respect to the genotypes and haplotypes they harbour for any of the six tag SNPs. No 
significant differences were also observed when stratifying for the presence or absence of anti-
citrullinated protein antibodies (ACPA).  
Conclusion 
IL10 polymorphisms most likely do not predispose to a higher rate of joint damage or clinical 
drug free remission in RA patients irrespective of their ACPA status. These data suggest that 
IL10 polymorphisms do not play a major role in RA disease outcomes. 
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Introduction 
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, affecting 1% of 
the population worldwide. Environmental as well as genetic factors are thought to play an 
important role in both the onset and the progression of the disease (2-5). Recent years have 
seen large progress in the identification of genetic risk factors involved in RA. To date, fifteen 
loci identified by genome-wide as well as candidate gene approaches have been implicated in 
RA. These loci include the HLA region with specific alleles conferring the largest effect size, 
PTPN22 now widely replicated as an autoimmune locus and many other loci with modest effect 
sizes(6;7).  
Such progress is however as yet unmet in dissecting genetic loci involved in mediating either 
clinical remission or inversely joint destruction in these patients. Genetic markers associated 
with these disease-classifying phenotypes are clearly of interest not only to generate more 
insight into the disease process but possibly also to serve as surrogate predictors of disease 
course. The sole genetic locus consistently correlated to a more severe radiographic damage is 
the HLA-shared epitope alleles in the presence of autoantibodies (8). While other loci have been 
reported, unequivocal replication in large well characterised datasets remains to be obtained.  
The interleukin-10 (IL10) locus on chromosome 1q32 has been previously suggested to be 
associated with RA as well as with a higher rate of joint damage in RA patients(9-12). Since 50-
60% of the variation in the level of this protein is likely to be attributed to genetic risk factors, 
IL10 promoter polymorphisms have been the prime candidates investigated(13-15). These 
polymorphisms as well as IL10 haplotypes have been widely correlated to IL10 mRNA and 
protein levels(16;17). Very recently, a novel inducible transcript with an extended 5’UTR has 
been described following lipopolysaccharide (LPS) stimulation of mononuclear cells(18). 
However extensive analysis of all available genetic variation has so far not been performed in 
most studies.  
Given the important role of this cytokine in mediating immunosuppressive as well as 
immunostimulatory effects, it remains an important candidate to examine in RA(19). However, 
the well-powered genome-wide scan performed by the Wellcome Trust Case-Control 
Consortium consisting of 2000 patients and 3000 healthy individuals has not reported the 
association of this region with RA. We observed only 54% coverage of this region using SNPs in 
a 200kb region around IL10 using a pairwise R2  0.8 and a coverage of 70% using a pairwise 
R2  0.5)(20). More recently a meta-analysis of all published genome-wide association studies 
also did not identify the IL10 region as a susceptibility locus for RA(7). These data suggest that 
the IL10 region is unlikely to play a major role in the predisposition to RA as such. However, it 
remains likely that genetic variants at this locus play a role in the various phenotypes of RA 
characterized by either joint damage or remission. The identification of genetic markers 
correlating with disease phenotypes remains a crucial question that may not only result in a 
better understanding of the disease process but also in improving treatment strategies for 
patients with a worse disease prognosis. 
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In this study, we have aimed to investigate the correlation of IL10 polymorphisms to the rate of 
joint damage and remission in RA patients by performing a comprehensive effort to capture 
most of the informative markers in the IL10 region known to date. Combined with the availability 
of a large number of RA patients and longstanding follow-up, we have determined the 
association of these SNPs with the progression of radiological joint destruction and remission in 
a prospective cohort of Early Arthritis patients (EAC).   
Patients & Methods 
594 RA patients from the population-based arthritis inception cohort (EAC)(21) were included in 
this study. All RA patients used fulfilled the American College of Rheumatology 1987 revised 
classification criteria for RA and were selected from a large prospective Early Arthritis Clinic 
(EAC) cohort that was started in 1993 at the Department of Rheumatology of the Leiden 
University Medical Center(22). Patients were referred to the EAC by general practitioners in the 
western part of The Netherlands when arthritis was suspected. The Leiden EAC is the only 
referral center in an area of ~400,000 inhabitants. Inclusion took place when arthritis was 
confirmed at physical examination and the symptom duration was less than 2 years. Written 
informed consent was obtained from all participants. The study and its protocols were approved 
by the appropriate local institutional review boards. All patients included in the study were of 
Caucasian origin based on self-reported ethnicity. Five hundred ninety four RA patients who 
were consecutively included and had DNA available were genotyped and the patient 
characteristics are summarized in Table 1. The number of patients with available radiographs 
varied per time point.     
At inclusion, blood samples were taken from every patient for routine diagnostic laboratory 
screening and stored to determine ACPA at a later time point. ACPA were measured by 
enzyme-linked immunosorbent assay (ELISA) (Immunoscan RA Mark 2; Euro-Diagnostica, 
Arnhem, The Netherlands). The cutoff level for positivity was set at 25 arbitrary units, according 
to the manufacturer’s instructions. Follow-up visits were performed on a yearly basis and 
included radiographs of hands and feet. Since the start of the EAC the treatment strategies 
have changed and four different strategies were applied depending on the inclusion period. 
Patients included between 1993 and 1995 were treated initially with analgesics and 
subsequently with chloroquine or salazopyrine if they had persistent active disease (delayed 
treatment)(23). From 1996 to 1998 RA patients were promptly treated with either chloroquine or 
salazopyrine (early treatment) (22;23). From 1998 to 2002 patients were promptly treated with 
either salazopyrine or methotrexate (early treatment) and patients included in 2002 or later were 
promptly treated with either salazopyrine or methotrexate combined with treatment adjustments 
based on the disease activity (early and disease activity based treatment). 
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Genotyping of IL10 polymorphisms and Haplotype block determination 
43 SNPs spanning the region around the IL10 gene encompassing 226kb were genotyped in 57 
unrelated healthy Caucasian individuals. Out of the 43 SNPs genotyped, 2 SNPs were not 
polymorphic (rs2945417 and rs17015763) and one SNP had a frequency  1% (rs4845140). 
Additional details are further described in Table S1. Haploview was used to determine the 
graphical representation of LD(24). 6 Tagging SNPs were selected and further genotyped in 
DNA from 594 RA patients. These 6 tagging SNPs captured 86% of all the alleles within the 
17kb block with an R2 threshold of 0.8. Rs3024505 was not tagged using either pairwise LD 
measures or 2 to 3 marker haplotypes.  
Standard quality control for genotyping was carried out. 10% of all genotypes were repeated 
and <1% errors detected. The success rate greatly exceeded 95% and varied per SNP. More 
specifically the success rate was 96% for rs6667202, 98% for rs6676671, 100% for rs6703630, 
98% for rs6693899, 99.7% for rs1800896 and 99% for rs1800871. All SNP genotypes were in 
Hardy-Weinberg equilibrium.   
Haplotypes per individual were inferred using plink(25). The most likely haplotypes were 
included in the analysis. The number of individuals with haplotype posterior probability <80% is 
26 indicating that uncertainty is minimal for the larger subset of RA patients.    
Radiographs 
Radiographs of hands and feet were taken on consecutive years starting at baseline and were 
scored according to the Sharp-van der Heijde method(26). Compared to another frequently 
used scoring method, the Sharp-van der Heijde method is the most sensitive on the individual 
patient level in early RA(27). To encompass a reliable sample size during follow-up, 
radiographic follow-up data were restricted to a maximum of 5 years. The number of available 
radiographs varied per time-point and was 509 at baseline which declined to 440 after 1 year of 
follow-up, 401, 340, 283, and 260 after 2 to 5 years of follow-up respectively. Due to the study 
design (an inception cohort) not all patients achieved a similar duration of follow-up. The cut-off 
after 5 years of follow-up was applied according to the criteria that at least 10 patients should be 
available per genotype group. All radiographs were scored by one experienced scorer who was 
blinded with respect to the patient’s autoantibody status, treatment, clinical outcome and 
genotyping results. Scoring was performed with known time order, which is more sensitive to 
change, compared to scoring with unknown time sequence(28). From the total number of 
scored radiographs, 499 radiographs were rescored by the same reader, consisting of 149 
baseline radiographs and 350 radiographs during follow-up belonging to 60 randomly selected 
RA-patients. Reliability of radiograph scoring was calculated and intraclass-observer correlation 
coefficients (ICC) were 0.91 for all scored radiographs, 0.84 for baseline radiographs and 0.97 
for the radiographic progression rate (van der Linden et al, Manuscript in press, A&R).  
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Remission 
Sustained DMARD-free remission was defined according to the following three criteria: 1) no 
current use of DMARDs, 2) no swollen joints and 3) classification as DMARD-free remission by 
the patient’s rheumatologist (Van der Woude et al, Manuscript in press at A&R). Corticosteroids 
were considered to be equivalent to DMARDs for the present study, while NSAIDs did not 
qualify as DMARDs. Patients had to fulfill all three criteria in order to be diagnosed with 
remission. To ensure that remission was not temporary, but rather sustained and long-lasting, 
the absence of swollen joints had to have been observed by a rheumatologist for at least one 
year after discontinuation of when DMARD-therapy. Patients with remission were discharged 
from the outpatient clinic if the absence of joint swelling had been observed for at least one year 
after the discontinuation of DMARDs. Most patients who achieved remission were followed-up 
longer than the minimum requirement of one year; the median time of observation after 
discontinuation of DMARDs in the absence of swollen joints was 2.5 years. Patients who had a 
recurrence of their arthritis after discharge, could easily return to the Leiden University Medical 
Center, the only referral center for Rheumatology in a health care region of approximately 
400.000 inhabitants. The frequency of relapse was recorded and patients with relapse (n=6) 
were included in the non-remission group. In contrast to previous analyses in which patients 
who presented to the EAC after 2003 were excluded, the current analysis contained all RA 
patients for whom IL10-genotyping information was available (n=594). This resulted in a slightly 
lower prevalence of remission (13.2%) than described previously (15%) (Van der Woude et al, 
manuscript in press at A&R). 
Statistical Analysis 
The association between genotypes and radiographic scoring data was analyzed using SPSS 
version 16.0 (SPSS Inc., Chicago, IL). As radiographic data were not normally distributed, the 
raw data on the Sharp-van der Heijde scores are presented using medians. The Kruskal-Wallis 
nonparametric test was used to compare median scores across genotype groups. Since six 
SNPs were evaluated a Bonferroni correction for multiple testing was applied and the p-value 
for significance was set at p<0.004.  
Summary statistics were generated to investigate the prevalence of the different IL10 genotypes 
and haplotypes in remission and non-remission patients. To avoid skewing of the results due to 
the difference in follow-up time, the present analysis used data from the first 10 years of follow-
up for all patients. To take into account the difference in follow-up times among patients, 
analyses were performed by Cox regression analysis, after verification that the proportional 
hazards assumption was satisfied. In Cox regression models the dependent variable is the 
“time-to-event”, which consisted of the time to remission for the remission patients, and the time 
to last follow-up (with a maximum of 10 years) for the non-remission patients. The time of 
remission was defined as the date at which DMARDs were discontinued due to remission. The 
analysis was also performed with a later date defined as the time of remission (date described 
above plus one year), which led to similar results. This indicates that the results were stable 
regardless of the exact date used to define remission. 
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Results 
Determination of LD in the IL10 locus 
In order to determine the extent of LD in the IL10 locus, 40 SNPs in the IL10 region spanning 
226kb were genotyped in 57 healthy unrelated Dutch Caucasian individuals. Under the 
algorithm of Gabriel et al, one haplotype block was inferred (Figure 1)(1). This block is restricted 
to 17 kb encompassing the coding region of the IL10 gene (5kb) as well as 5’and 3’ untranslated 
regions. Since we are primarily interested in identifying cis-variants predisposing to increased 
joint damage in RA patients, this block represented the most interesting region to look into. We 
used Tagger as implemented in Haploview to determine the tagging SNPs that provided the 
most information with regards to the haplotype variation(29). 6 tagging SNPs were chosen on 
the basis of pairwise comparisons with R2 0.8 and a multi-marker LOD threshold of 3. These 
SNPs captured 93% of all the alleles in the 17kb block. This block was comparable to the 
haplotype block in HapMap CEU (Figure S1).  
 
 
 
Figure 1. 17 kb LD Block around IL10 according to Gabriel et al(1). Paiwise linkage disequilibrium (LD) 
values (R
2
) are indicated. Strength of LD is positively correlated to color intensity. 
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Association of tagging SNPs and haplotypes with radiological joint damage in RA 
The study cohort consisted of 594 patients, whose characteristics at baseline are detailed in 
Table 1. None of the genotype distributions deviated from Hardy Weinberg equilibrium. Because 
Sharp-van der Heijde scores did not fit a normal distribution, we compared the median scores 
across the three genotypes per time point for all six SNPs using the Kruskall-Wallis non-
parametric test.  
 
Table 1. Patient characteristics from the Leiden Early arthritis cohort. 
Patient Characterisitcs N=594 
Age at inclusion, mean years (± SD) 56.6 (±15.5) 
Female N (%) 401 (67.7) 
ACPA positive 266 (56.1) 
IgM-RF positive 341 (58.3) 
 
Age and gender data were available for all RA patients. IgM-RF (rheumatoid factor) data was available from 585 RA 
patients. ACPA (anti-citrullinated protein antibodies) data was available from 474 RA patients 
 
None of the IL10 tagging SNPs showed a correlation with joint damage in time (Figure 2). Since 
more severe radiographic damage correlates with the presence of rheumatoid factor and anti-
citrullinated protein antibodies (ACPA), we have stratified our data according to the presence or 
absence of ACPA. No correlation was observed between genotype and joint damage in either 
stratum (Figure 3 and 4). While the data indicate that patients without ACPA and with 
rs1800871 TT genotype may have a higher rate of joint destruction, the medians are based 
solely on 7 individuals at baseline and 4 individuals after 5 years of follow-up. 
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 Overview of the raw Sharp-van der Heijde scores, expressed as medians, of all 6 SNPs per genotype for the total 
patient population. The number of individuals at inclusion (year=0) and after five years of follow-up (years=5) is 
given in the legend. For example the median sharp van der heijde scores originated from 102 GG, 233GT and 
119 TT patients at inclusion and declined to 52 GG, 118 GT and 83 TT after 5 years of follow-up.  
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Overview of the raw Sharp-van der Heijde scores, expressed as medians, of all 6 SNPs per genotype for ACPA 
positive RA patients. The number of individuals at inclusion (year=0) and after five years of follow-up (years=5) is 
given in the legend. For example the median sharp van der heijde scores originated from 46 GG, 101GT and 73 
TT patients at inclusion and declined to 30 GG, 72 GT and 51 TT after 5 years of follow-up.  
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Overview of the raw Sharp-van der Heijde scores, expressed as medians, of all 6 SNPs per genotype for ACPA 
negative RA patients. The number of individuals at inclusion (year=0) and after five years of follow-up (years=5) is 
given in the legend. For example the median sharp van der heijde scores originated from 36 GG, 85 GT and 52 
TT patients at inclusion and declined to 18 GG, 36 GT and 23 TT after 5 years of follow-up.  
The role of interleukin 10 (IL10) genetic variants in regulating expression levels and disease pathogenesis 129
Haplotypes were inferred for 586 individuals from whom genotype data was available in >50% 
of the SNPs. Haplotypes with a frequency lower than or equal to 2% were pooled into one 
category termed the rare haplotypes. Six common haplotypes (frequency >2%) capturing 88% 
of all haplotypes were detected in the total RA population. None of the haplotypes showed a 
correlation with joint damage in RA patients (Figure 5A). Stratifying RA patients according to 
ACPA status also revealed no significant correlation (Figure 5 B and C).      
 
 
 
 
Association of tagging SNPs and haplotypes with remission in RA 
Sustained DMARD-free remission was achieved by 13.3% of patients (N=79). Despite a trend 
towards association between some of the SNPs and sustained DMARD-free remission, none of 
these associations reached statistical significance (Table 2). Stratification of the RA patients by 
ACPA status also did not yield any statistically significant associations (Tables 3 and 4). 
Although there was a possible trend for association between the IL10 haplotypes and ACPA-
negative RA (Table 5), this association was not significant after correction for multiple testing. 
However, our data is largely underpowered to detect modest effects in this dataset.  
Overview of the raw Sharp-van der Heijde scores, expressed as medians, of all 6 SNPs haplotypes for (A) all RA 
patients (B) ACPA-positive RA patients and (C) ACPA-negative RA patients. The number of haplotypes at 
inclusion (year=0) and after five years of follow-up (years=5) is given in the legend. 
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Table 2. Association of IL10 SNPs with remission in RA patients ‡.  
Genotype Remission 
n=79 
No remission 
n=515 
Hazard Ratio  95% CI P 
      
rs1800871  CC 50 (71%) 269 (60%)    
                   CT 18 (26% 153 (34%)    
                   TT 2 (3%) 26 (6%) 0.66 0.42-1.04 0.075 
      
rs1800896  AA 13 (18%) 119 (26%)    
                   AG 37 (51%) 223 (48%)    
                   GG 22 (31%) 123 (27%) 1.20 0.91-1.57 0.28 
      
rs6693899   AA 11 (16%) 62 (14%)    
                    AC 33 (47%) 201 (45%)    
                    CC 26 (37%) 180 (41%) 0.92 0.70-1.22 0.64 
 
 
rs6703530*   AA 
 
 
8 (11%) 
 
 
45 (9.7%) 
 
 
  
                     AG 35 (49%) 177 (38%)    
                     GG 29 (40%) 241 (52%) 0.62    0.41-0.94 0.059 
      
rs6676671**  AA 18 (26%) 155 (36%)    
                     AT 38 (54%) 193 (44%)    
                     TT 14 (20%) 89 (20%)    
      
rs6667202    GG 18 (27%) 82 (19%)    
                    GT 34 (51%) 209 (48%)    
                    TT 15 (22%) 145 (33%) 0.73 0.55-0.97 0.064 
      
‡ The number and the percentage of patients are listed, relative to the total number of patients for whom information about the SNP 
under investigation was available. * Proportional hazards assumption not fulfilled because the small number of patients with 
genotype AA have an aberrant survival curve. HR therefore only applies to individuals with genotypes AG and GG. ** Proportional 
hazards assumption not fulfilled, therefore no HR was calculated.  
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Table 3. Association of IL10 SNPs with remission in ACPA-positive RA patients ‡.  
Genotype Remission 
n=9 
No 
remission 
n=264 
Hazard Ratio 95% CI P 
      
rs1800871        CC 7 (87%) 152 (62%)    
                          CT 1 (13%) 80 (32%)    
                          TT 0 15 (6.1%) 0.50 0.03-1.84 0.172 
      
rs1800896        AA 1 (11%) 60 (24%)    
                         AG 6 (67%) 122 (48%)    
                         GG 2 (22%) 70 (28%) 1.11 0.52-2.40 0.82 
      
rs6693899       AA 2 (25%) 34 (14%)    
                        AC 4 (50%) 112 (46%)    
                        CC 2 (25%) 98 (40%) 0.61 0.27-1.37 0.31 
      
rs6703530*     AA 1 (11%) 25 (9.9%)    
                        AG 5 (56%) 96 (38%)    
                        GG 3 (33%) 131 (52%) 0.46 0.14-1.53 0.29 
      
rs6676671**    AA 2 (25%) 84 (34%)    
                         AT 4 (50%) 110 (45%)    
                         TT 2 (25%) 51 (21%)    
      
rs6667202       GG 2 (22%) 46 (19%)    
                        GT 4 (44%) 117 (49%)    
                        TT 3 (33%) 77 (32%) 0.99 0.46-2.14 0.98 
      
‡ The number and the percentage of patients are listed, relative to the total number of patients for whom information 
about the SNP under investigation was available.* Proportional hazards assumption not fulfilled because the small 
number of patients with genotype AA have an aberrant survival curve. HR therefore only applies to individuals with 
genotypes AG and GG. ** Proportional hazards assumption not fulfilled, therefore no HR was calculated.  
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Table 4. Association of IL10 SNPs with remission in ACPA-positive RA patients ‡. 
Genotype Remission 
n=61 
No 
remission 
n=146 
Hazard Ratio 95% CI P 
      
rs1800871      CC 40 (72%) 72 (54%)    
                         CT 14 (26%) 55 (41%)    
                         TT 1 (2%) 7 (5.2%) 0.58 0.33-0.99 0.045 
      
rs1800896      AA 10 (18%) 36 (26%)    
                        AG 27 (48%) 71 (51%)    
                        GG 19 (34%) 32 (23%) 1.29 0.95-1.77 0.18 
       
rs6693899     AA 9 (16%) 17 (13%)    
                        AC 24 (44%) 63 (47%)    
                        CC 22 (40%) 53 (40%) 0.97 0.71-1.34 0.89 
      
rs6703530*   AA 7 (13%) 11 (8.1%)    
                        AG 26 (46%) 52 (39%)    
                        GG 23 (41%) 72 (53%) 0.66 0.41-1.05 0.14 
      
rs6676671**  AA 14 (25%) 47 (37%)    
                         AT 29 (53%) 57 (45%)    
                         TT 12 (22%) 22 (18%)    
      
rs6667202      GG 16 (31%) 19 (15%)    
                         GT 24 (47%) 64 (52%)    
                         TT 11 (22%) 41 (33%) 0.68 0.49-0.94 0.050 
‡ The number and the percentage of patients are listed, relative to the total number of patients for whom information 
about the SNP under investigation was available.* Proportional hazards assumption not fulfilled because the small 
number of patients with genotype AA have an aberrant survival curve. HR therefore only applies to individuals with 
genotypes AG and GG. ** Proportional hazards assumption not fulfilled, therefore no HR was calculated.  
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Table 5. Association of IL10 haplotypes with remission in all RA patients, ACPA-positive as well as ACPA-negative 
RA patients. 
 All Patients  ACPA-Positive Patients  ACPA-Negative Patients 
Haplotype No 
Remission 
Remission   No Remission Remission   No Remission Remission 
TAGCAC 224 (88&) 31 (12%)  122 (96%) 5 (4%)  64 (73%) 24 (27%) 
GTAAGC 193 (83%) 41 (17%)  101 (94%) 6 (6%)  58 (65%) 31 (35%) 
TAGCAT 187 (90)% 20 (10%)  99 (99%) 1 (1%)  62 (82%) 14 (18%) 
GTGAGC 80 (90%) 7 (8%)  45 (98%) 1 (2%)  23 (82%) 5 (18%) 
GTGCGC 44 (77%) 13 (23%)  30 (97%) 1 (3%)  9 (43%) 12 (57%) 
TAGCGC 52 (85%) 9 (15%)  27 (96%) 1 (4%)  18 (72%) 7 (28%) 
Rate (<2%) 100 (84%) 19 (16%)  66 (98.5%) 1 (1.5%)  24 (58.5%) 17 (41.5%) 
         
P (LogRank Test)*   0.07     0.59     0.02 
*The log Rank Test was performed since the proportional Hazards Assumption was not met. The log Rank Test 
assesses whether there is a significant difference in the survival curves estimated by the time to remission.   
Discussion 
IL10 is an important immunoregulatory cytokine with diverse effects on the immune system. The 
cytokine is produced by a range of immune cells, including B cells and regulatory T cells(19). 
Stimulation of human blood cultures with bacterial lipopolysaccharide (LPS) showed large 
interindividual variation in IL10 secretion, which has been shown to have a genetic component 
of 50-70%(13). Given the fact that IL10 is produced by a variety of different cells and recent 
evidence which suggests that the correlation of IL10 cis variants with IL10 protein levels can be 
cell and stimuli specific, it is highly plausible that its regulation is both at the cis (caused by 
variations with the gene region itself) and the trans (caused by other variations at other gene 
loci) level.  
Administration of IL10 to animals with collagen-induced arthritis reduces several parameters of 
the disease and would therefore suggest that high levels of IL10 are likely to result in less 
progressive disease(30). However, the precise role of IL10 is not clear, even in mouse models. 
One group recently highlighted this complexity. Hansson and colleagues showed that IL10-
deficient mice immunized with collagen type II (CII) develop a more severe disease than their 
heterozygous littermates(31).  
Previous findings in human genetic studies show that the presence of the G allele at IL10-2849 
(rs6703630) is correlated with enhanced IL10 protein levels in healthy individuals as well as 
increased levels of autoantibodies and more severe joint damage in RA patients(9). Marinou 
and colleagues have also recently suggested the involvement of IL10 polymorphisms in severity 
of RA(10). The authors suggest that in the absence of autoantibodies (RF or ACPA), patients 
with a IL10-592 (R2=1 with rs1800871) CC genotype have more severe joint damage in a Polish 
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population as measured by Larsen’s score. However, both studies were conducted in a cross-
sectional fashion with data available at one specific time point. The major strengths of the 
present study are the use of radiological data during long-term follow-up of five years. However, 
inherent to the design of an inception cohort, not all patients had achieved five years of follow-
up, so the number of missing data increased with longer follow-up.  
Our data suggests that six IL10 tagging polymorphisms do not influence radiographic joint 
damage in RA patients irrespective of the presence or absence of autoantibodies. In addition, 
haplotypes at this locus also do not show any correlation with severity of disease indicating that 
a large effect of known IL10 polymorphisms on joint destruction is unlikely. We have also 
investigated the role of the IL10 locus in relation to patients who achieved sustained DMARD-
free remission. Our data suggest that individuals with specific IL10 genotypes or haplotypes do 
not have a higher rate of remission, irrespective of their ACPA status. However, we cannot 
exclude that this locus may have a more modest effect on this phenotype. Large well-
characterised RA cohorts will be required to investigate the role of modest effect loci in relation 
to specific phenotypes in RA. 
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To the Editor: 
We read with interest the article by Khanna et al regarding the association between the tumor 
necrosis factor (TNFA) -308 polymorphism as well as the HLA–DRB1 shared epitope (SE) 
alleles and the level of radiographic damage in rheumatoid arthritis (RA) (1). The authors 
concluded that there is an association between the TNFA -308 A allele and the rate of 
radiographic joint destruction, but that the SE alleles are not associated with the level of joint 
damage in seropositive RA. In our opinion, both conclusions are questionable. First, Khanna et 
al investigated the Sharp scores of 189 rheumatoid factor (RF)–positive patients with early RA 
during 5 years of followup (completed by 45 patients) and compared the scores between 
patients with and those without SE alleles. The results depended on the method of analysis and 
on the subgroup of patients. In an analysis unweighted for the number of observations per 
patient, the presence of SE alleles was not associated with RA severity; in a weighted analysis 
assessing the total group of patients, the presence of SE alleles was associated with less 
severe disease; and in an analysis assessing the subgroup of white patients, the presence of 
SE alleles was associated with more severe joint destruction.  
The authors provided no explanation for these discordant findings. The most likely clarification is 
the fact that the authors selected a group of RF-positive patients. In RA, the presence of RF is 
highly correlated with the presence of anti–cyclic citrullinated peptide (anti-CCP) antibodies: 
only 13–18% of RF-positive RA patients are anti-CCP negative (2,3). Furthermore, we recently 
demonstrated that the SE alleles are primarily a risk factor for the presence of anti-CCP 
antibodies, and that the presence of SE alleles in RA patients with anti-CCP antibodies is not 
associated with the development of RA (4). In addition, our analysis on the association between 
the SE alleles in the presence of anti-CCP antibodies and the Sharp/van der Heijde scores 
during 4 years of followup was inconclusive; although a trend for more severe joint destruction 
among SE-positive, anti-CCP–positive patients compared with SE-negative, anti-CCP–positive 
patients was observed, the number of patients was too low to reach a definite conclusion (5).  
The anti-CCP antibody status of patients in the study by Khanna et al is not known, but 
considering the fact that all patients were RF positive, it is likely that the majority of the patients 
were anti-CCP positive. The fluctuating results on the absence or presence of an association 
between SE alleles and the rate of joint destruction in the study by Khanna and colleagues 
indicates that the sample size of that study was too small to conclude definitely on the 
association between the SE alleles and the severity of autoantibody-positive RA.  
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Second, Khanna et al examined whether the TNFA-308 G-to-A polymorphism was associated 
with radiographic joint damage in RF-positive RA. The total Sharp score and the frequency of  2 
erosions at baseline and during followup were not differently distributed between TNFA A and 
non-A carriers (1). However, when the rate of radiographic progression was derived from the 
slope of the regression line and weighted for the number of radiographic observations per 
patient, patients with genotype AA+AG had significantly higher Sharp scores than did patients 
with genotype GG (1).  
The authors also reported that the TNFA-308 A alleles are in strong linkage disequilibrium with 
HLA–DRB1*0301. Because it was recently reported in North American and Dutch patients that 
the HLA–DRB1*0301 allele (and the A1;B8;DR3 haplotype)is associated with anti-CCP–
negative RA (2,3), and, because anti-CCP–negative RA is associated with less severe joint 
damage, the observation that the TNFA -308 A allele is associated with a higher rate of joint 
destruction seems contrasting. Considering the linkage disequilibrium between the TNFA -308 A 
allele and HLA–DRB1*0301, the analysis on the association between this polymorphism and the 
rate of joint destruction should be corrected for the presence or absence of anti-CCP antibodies.  
Therefore, we determined the TNFA -308 polymorphism in 327 white patients who presented to 
the Leiden Early Arthritis Clinic between 1993 and 2000 and in whom RA was diagnosed during 
the first year after inclusion. Eight patients (2%) had genotype AA, 94 patients (29%) had 
genotype AG, and 225 patients (69%) had genotype GG. Anti-CCP antibodies were present in 
182 patients (56%). Radiographs were available for 267 patients after 1 year of followup, for 205 
patients after 2 years, and for 154 patients after 4 years of followup. The Sharp/van der Heijde 
scores were not significantly different between the RA patients who carried a TNFA -308 A 
allele and the patients who did not carry an A allele (Figure 1). Subsequently, this analysis was 
performed in subgroups of patients with and those without anti-CCP antibodies; the results 
revealed no significant differences. A linear regression analysis with the radiographic 
progression score as dependent variable and age, sex, TNFA _308 A/non-A carriership, and 
anti-CCP antibody status as possible explanatory variables revealed that only the presence of 
anti-CCP antibodies (regression coefficient 9.0, standard error 2.3, P <0.001) and age 
(regression coefficient 0.2, standard error 0.07, P < 0.003) were significantly associated with 
radiographic joint destruction. 
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In our opinion, because the TNFA -308 A allele is in linkage disequilibrium with HLA–DR3, 
which is reported to be associated with only anti-CCP–negative RA, and RA patients without 
anti-CCP antibodies generally experience a less severe disease course compared with RA 
patients who have anti-CCP antibodies, the analysis of the association between the TNFA -308 
A allele and the rate of joint destruction should be corrected for the presence or absence of anti-
CCP antibodies. Therefore, we analyzed white RA patients who were included in the Leiden 
Early Arthritis Clinic, and we did not observe an association between the TNFA -308 A allele 
and radiographic joint destruction in RA patients, neither in the presence nor in the absence of 
anti-CCP antibodies. 
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Abstract 
Background 
Two novel genetic polymorphisms on chromosome 6q23 are associated with susceptibility to 
rheumatoid arthritis (RA). Both polymorphisms (rs6920220 and rs10499194) reside in a region 
close to the gene encoding tumor necrosis factor  -induced protein 3 (TNFAIP3). TNFAIP3 is a 
negative regulator of NF!B and as such involved in inhibiting TNF-Receptor mediated signalling 
effects. Interestingly, the initial associations were detected in patients with long-standing RA. 
However, no association was found for rs10499194 in a Swedish early arthritis cohort. As this 
could be caused by overrepresentation of patients with severe disease in cohorts with long-
standing RA, we analyzed the effect of the 6q23 region on the rate of joint destruction. 
Methods and Findings 
Five single nucleotide polymorphisms (SNPs) in 6q23 were genotyped in 324 Dutch patients 
with early RA. Genotypes were correlated to progression of radiographic joint damage for a 
follow-up time of 5 years. Two polymorphisms (rs675520 and rs9376293) associated with 
severity of radiographic joint damage in ACPA+ patients. Importantly, the effects were present 
after correction for confounding factors such as secular trends in treatment 
Conclusions 
Our data associate the 6q23 region with the rate of joint destruction in ACPA+RA. 
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Introduction 
Recent whole genome association scans have revealed novel genetic polymorphisms 
associated with susceptibility to ACPA+ RA.[1,2] Among those, two single nucleotide 
polymorphisms (SNPs), rs6920220 (A allele) and rs10499194 (C allele), were found to 
independently associate with ACPA+ disease. Both SNPs map to a single linkage disequilibrium 
block spanning ~60 kb in a region on chromosome 6q23 that lacks known genes or transcripts. 
The closest genes are oligodendrocyte lineage transcription factor 3 (OLIG3) and tumor 
necrosis factor  -induced protein 3 (TNFAIP3). The latter is of potential importance to RA 
pathogenesis, as the protein TNFAIP3 acts as a negative regulator of NF-!B.[3] So far, 
however, functional relevance of the reported polymorphisms is unknown. 
Rs6920220 was initially identified in ACPA+ RA patients (minor allele OR 1.38) originating from 
the United Kingdom (UK).[1] It was further replicated in an extended UK based case-control 
study.[4] Rs10499194 was initially identified in North American ACPA+ patients (the Brigham 
Rheumatoid Arthritis Sequential Study, BRASS; minor allele OR 0.67).[2] Replication was 
successful in two additional US cohorts selected from the North American Rheumatoid Arthritis 
Consortium (NARAC). Replication failed, however, in ACPA+ patients of a Swedish population-
based inception cohort (the Epidemiological Investigation of Rheumatoid Arthritis cohort, 
EIRA).[2] This latter finding is of interest, as both BRASS and NARAC are cohorts of patients 
with long-standing RA (mean disease duration BRASS: 15.4 ± 12.8 years [5]; NARAC: 14.3 ± 
11.1 years [6]). The EIRA study, however, was designed to identify incident cases of RA as 
soon as possible after disease onset, resulting in an estimated mean disease duration at 
inclusion of only 10 months.[7]  
Association of a genetic polymorphism in cohorts of patients with longstanding disease but 
absence of this association in an early arthritis cohort led us to hypothesize that the 6q23 region 
would associate with disease severity in ACPA+ patients. Very little information is currently 
available on the effects of genetic variation on outcome measures in RA [8]. Therefore, we 
genotyped five SNPs in a Dutch early arthritis cohort (the Leiden Early Arthritis Clinic, EAC) and 
correlated genotyping data to progression of radiographic joint damage for a maximum follow up 
of 5 years. 
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Patients & Methods 
Patients 
The Leiden EAC is a population-based inception cohort that includes patients with self-reported 
symptom duration of   2 years.[9] DNA samples of 324 patients consecutively included between 
1993 and 2003 were used for analysis. For further details see supplementary file 1. 
SNP selection and genotyping 
Five SNPs (rs1878658, rs675520, rs9376293, rs10499194 and rs6920220) were selected 
based on a haplotype analysis across the 6q23 locus published previously.[2] All SNPs are in 
imperfect linkage disequilibrium to one another (supplementary table 1). Genotyping was 
performed using pre-designed Taqman allelic discrimination probes (Applied Biosystems). 
Each 384 well plate contained 10 ng sample DNA per well and at least 8 negative and 6 positive 
controls. Genotype calls and clusters were manually checked for discrepancies and doubtful 
calls were rejected. No SNP deviated from Hardy-Weinberg equilibrium. Genotyping call rates 
were 96.5 % (rs1878658), 98 % (rs675520), 95 % (rs9376293), 94 % (rs10499194), and 98.1 % 
(rs6920220). 
Serology and Radiographs 
Serum samples were tested for citrulline-specific IgG antibodies using a commercially available 
ELISA kit (Immunoscan Mark2, Eurodiagnostica, The Netherlands). Radiographs were scored 
according to the Sharp van der Heijde method [10] with known time order by one blinded, 
independent trained reader (supplementary file 1). 
Statistical Analysis 
Association between genotypes and radiographic scoring data was analyzed using SPSS 
version 16.0 (SPSS Inc., Chicago, IL). P-values < 0.05 were considered significant. All p-values 
reported are two-sided. 
Two approaches were chosen for statistical analysis. First, the average increase in Sharp van 
der Heijde scores during the follow-up period was estimated per person by regression analysis. 
Subsequently, the average increase (slope) of scores per genotype was compared non-
parametrically using the Mann-Whitney rank-sum test.  
We observed an influence of the time of inclusion (1993-2003) on the progression of 
radiographic joint damage reflecting most likely an improvement of treatment intensity during 
this 10 year time period. In order to account for this effect, we performed, as a second 
approach, a mixed model analysis described in detail in supplementary file 1. 
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Results 
Radiographic scores of 324 Dutch RA patients (181 ACPA+, 143 ACPA-) were available for 
analysis. At least five radiographic follow-up observations were available in 57% of patients. A 
dominant model was chosen for analysis, as the frequency of patients homozygous for the 
minor allele of rs1878658 (G), rs10499194 (T) and rs6920220 (A) was   5%. Figure 1 depicts 
the influence of genotypes on radiographic joint damage. ACPA+ and ACPA- subgroups were 
analyzed separately. Median scores and interquartile ranges (IQR) are provided for ACPA+ 
patients in table 1 (for ACPA- patients see supplementary table 2). 
No influence of genotypes on radiographic joint damage was observed in ACPA- patients (figure 
1). In ACPA+ patients, however, two polymorphisms showed reproducible association with 
disease progression over time. Presence of the G allele of rs675520 was found to associate 
with increased Sharp van der Heijde scores, as a significant difference was observed when the 
average increase (slope) in radiographic scores over time was compared with G as the 
dominant allele (median slope AG/GG = 4.6, AA = 2.3; Mann-Whitney p = 0.007). In order to 
account for an effect of improving treatment strategies on radiographic progression during the 
10 year period in which patients were included into the study, we next performed a mixed model 
analysis. This analysis identified the year of inclusion as a significant variable influencing the 
extent of radiographic joint damage (p = 0.005). After correcting for the year of inclusion, 
however, we still observed a significant influence of the G allele of rs675520 (AG/GG vs. AA, p 
= 0.026). 
Similar to the G allele of rs675520, we noted an influence of the C allele of rs9376293 on 
progression of radiographic joint damage (figure 1). The average increase (slope) in Sharp van 
der Heijde scores over time was significantly higher for C allele carriers as compared to T 
homozygotes (median slope CC/CT = 4.5, median slope TT = 3.0, Mann-Whitney p = 0.021). 
After correcting for the year of inclusion as described above a trend effect of the C allele 
remained (p = 0.097).  For rs1878658, rs10499194 and rs6920220, no significant influence of 
individual genotypes on radiographic joint damage was noted. 
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Figure 1. Development of median Sharp van der Heijde scores plotted according to genotype/allele in ACPA+ (left 
column) and ACPA- (right column) RA patients. Year 0 equals baseline-values. Regression analysis was performed 
in order to estimate the average increase (slope) in Sharp van der Heijde scores over time. Slopes were 
subsequently compared using the nonparametric Mann-Whitney test (for the ACPA+ subgroup: p = 0.37 (rs1878658); 
p = 0.007(rs675520); p = 0.021 (rs9376293); p = 0.05 (rs10499194); p = 0.76 (rs6920220)). 
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Discussion 
The 6q23 region has recently been associated with disease susceptibility in RA. This region 
contains no known transcripts. The closest genes with known function are OLIG3 and TNFAIP3. 
TNFAIP3 encodes protein A20, a TNF-  induced negative regulator of NF-!B.[3,11] Decreased 
levels of A20 lead to uncontrolled NF!B-activity, resulting in increased inflammation. This 
observation makes TNFAIP3/A20 and the 6q23 region interesting candidates that could 
modulate inflammation also in RA.  
We were intrigued by recent differential findings for rs10499194, a SNP on chromosome 6q23 
close to TNFAIP3, in cohorts with differing disease duration. The major allele (C) was found to 
associate with disease susceptibility in ACPA+ RA patients in three cohorts with long-standing 
disease, but not in an early arthritis cohort.[2] This indicated a potential impact of the 6q23 
region on disease severity. In order to test for such an impact, five SNPs were genotyped in a 
cohort of Dutch patients with early RA. These SNPs had previously been shown to identify 
common haplotypes in 6q23.[2] We identified two SNPs for which presence of alleles was 
associated with increased joint destruction in ACPA+ patients. Carriers of the G allele of 
rs675520 developed increased Sharp van der Heijde scores over time. A similar effect, although 
weaker, was found for the C allele of rs9376293. Interestingly, no association was found for any 
of the SNPs in ACPA- individuals. Although this does not exclude a contribution of the 6q23-
region to disease severity in ACPA- disease, the latter observation is in line with recent reports 
detecting an association of the 6q23 region with disease susceptibility in ACPA+ patients 
only.[4] No effect on disease severity was observed for rs10499194 and rs6920220. Based on 
our data we cannot rule out the possibility that either SNP exerts a weak effect that requires 
larger sample numbers for detection or that cannot be observed during the first years of 
disease. Interestingly, we observed nominally higher scores for the risk conferring A allele of 
rs6920220 without reaching statistical significance. The discrepancy between SNPs associating 
with susceptibility and radiographic progression also indicates that the causal variant at this 
locus has not yet been identified. Given the large area of linkage disequilibrium surrounding 
these SNPs, further fine-mapping and functional characterization will have to be performed. 
Data linking newly identified genetic polymorphisms to disease outcome in RA are only 
beginning to emerge. Our data are unique, as they cover a long period of radiographic follow-up 
and have been scrutinized for artefacts such as secular trends in treatment intensity. Albeit 
based on relatively low patient numbers, our data indicate a contribution of the 6q23 region to 
the rate of joint destruction in ACPA+ RA, thereby further refining our understanding of the 
effects exerted by this locus. Replication of our findings in other cohorts is needed. 
Nonetheless, this is the first study demonstrating such an effect for genetic polymorphisms 
located outside the HLA-region in ACPA+ RA patients. 
C
h
a
p
t
e
r
 
1
1
152
References 
(1) Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of 
seven common diseases and 3,000 shared controls. Nature 2007;447(7145):661-678. 
(2) Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J et al. Two independent alleles 
at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39(12):1477-1482. 
(3) Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S et al. Deubiquitination and 
ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430(7000):694-
699. 
(4) Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J et al. Rheumatoid arthritis association at 
6q23. Nat Genet 2007; 39(12):1431-1433. 
(5) Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE et al. Associations between 
human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of 
autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 2008; 
67(3):358-363. 
(6) Jawaheer D, Lum RF, Amos CI, Gregersen PK, Criswell LA. Clustering of disease features within 
512 multicase rheumatoid arthritis families. Arthritis Rheum 2004; 50(3):736-741. 
(7) Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L et al. Quantification of the 
influence of cigarette smoking on rheumatoid arthritis: results from a population based case-
control study, using incident cases. Ann Rheum Dis 2003; 62(9):835-841. 
(8) van der Helm-van Mil AH, Padyukov L, Toes RE, Klareskog L, Huizinga TW. Genome-wide 
single-nucleotide polymorphism studies in rheumatology: Hype or hope? Arthritis Rheum 2008; 
58(9):2591-2597. 
(9) van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld FC. The Leiden Early Arthritis 
Clinic. Clin Exp Rheumatol 2003; 21(5 Suppl 31):S100-S105. 
(10) van der Heijde DM. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their 
reliability and applicability. Baillieres Clin Rheumatol 1996; 10(3):435-453. 
(11) Opipari AW, Jr., Boguski MS, Dixit VM. The A20 cDNA induced by tumor necrosis factor alpha 
encodes a novel type of zinc finger protein. J Biol Chem 1990; 265(25):14705-14708. 
Other candidate genes in Rheumatoid and Juvenile Arthritis 153

Chapter 12 
Confirmation of STAT4, IL2/IL21, and CTLA4 Polymorphisms in 
Rheumatoid Arthritis 
N.A. Daha 
F.A.S. Kurreeman 
R.B. Marques 
G. Stoeken-Rijsbergen 
W. Verduijn 
T.W.J. Huizinga  
R.E.M. Toes 
Leiden University Medical Center, Leiden, Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arthritis Rheum. 60, 1255-60 (2009) 
Abstract 
Objective 
Recent advances have led to novel identification of genetic polymorphisms that are associated 
with susceptibility to rheumatoid arthritis (RA). Currently, 5 loci (HLA, PTPN22, TRAF1/C5, 
TNFAIP3, and STAT4) have been consistently reported, whereas others have been observed 
less systematically. The aim of the present study was to independently replicate 3 recently 
described RA susceptibility loci, STAT4, IL2/ IL21, and CTLA4, in a large Dutch case-control 
cohort, and to perform a meta-analysis of all published studies to date and investigate the 
relevance of the findings in clinically well-defined subgroups of RA patients with or without 
autoantibodies 
Methods 
The STAT4, IL2/IL21, and CTLA4 gene polymorphisms (rs7574865, rs6822844, and rs3087243, 
respectively) were genotyped in 877 RA patients and 866 healthy individuals. A meta-analysis 
of all published studies of disease association with these polymorphisms was performed using 
the Mantel-Haenszel fixed-effects method.  
Results 
An association of STAT4, IL2/IL21, and CTLA4 with RA was detected in Dutch patients (odds 
ratio [OR] 1.19 [P = 0.031], OR 0.84 [P = 0.051], and OR 0.87 [P = 0.041], respectively). Results 
from the meta-analysis confirmed an association of all 3 polymorphisms with RA in Caucasians 
(OR 1.24 [P = 1.66 x10-11], OR 0.78 [P = 5.6 x 10-5], and OR 0.91[P = 1.8 x 10-3], respectively). 
The meta-analysis also revealed that STAT4 predisposed to disease development equally in 
patients with autoantibodies and those without autoantibodies, and that CTLA4 enhanced the 
development of anti–citrullinated protein antibody (ACPA)-positive RA as compared with ACPA-
negative RA. 
Conclusion 
Our results replicate and firmly establish the association of STAT4 and CTLA4 with RA and 
provide highly suggestive evidence for IL2/IL21 loci as a risk factor for RA. Given the strong 
statistical power of our meta-analysis to confirm a true-positive association, these findings 
provide considerable support for the involvement of CTLA4 in distinct subsets of RA patients. 
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Introduction 
Rheumatoid arthritis (RA) is a common autoimmune disease with unknown etiology. 
Nonetheless, it is known that both genetic and environmental factors play a role in the 
pathogenesis of the disease. The strongest known genetic association with RA is with particular 
alleles of the HLA locus (1). In recent years, continuing advances in genotyping techniques 
have led to discovery of a large number of potential genetic associations outside this region (2–
4). Some of these newly identified susceptibility loci represent true associations, whereas others 
still remain to be conclusively investigated. 
Follow up replication studies in different populations are needed to resolve this issue. However, 
although some follow up studies have shown robust associations, others have yielded 
encouraging, but inconsistent, results. This could be due to insufficient power to detect modest 
effects in some of these studies. To overcome this limitation, data from previously published 
studies can be systematically evaluated by a meta-analysis. Furthermore, since RA is a 
heterogeneous disease and data indicate that different risk factors predispose to autoantibody-
positive disease as compared with autoantibody-negative disease (5), further investigation in 
these disease subsets remains to be performed in large data sets. In the present study, 3 
previously described susceptibility loci in patients with RA, i.e., rs7574865 (for signal transducer 
and activator of transcription 4 [STAT4]), rs6822844 (for interleukin-2/interleukin-21 [IL2/IL21]), 
and rs3087243 (for cytotoxic T lymphocyte– associated antigen 4 [CTLA4]), were investigated 
for association with the disease and for association with autoantibody status.  
The association of STAT4 with RA was first described in 2007, followed by a vast number of 
replication studies in both Caucasian and East Asian populations, all of which yielded results 
that were consistent across the studies (3,6–11). In contrast, the second polymorphism in this 
study, namely, rs6822844 in the IL2/IL21 region, has only been described in one study thus far, 
indicating that further replication is needed (4). The third variant that we aimed to investigate 
maps to the CTLA4 region. Various replication studies have shown encouraging, yet 
inconsistent, results for this locus (12–17). Plenge et al provided evidence that the differences 
between studies could be due to insufficient power in some of the studies (15). 
Thus, the aim of our study was to replicate 3 previously described risk factors for RA and further 
study their association by a meta-analysis. Additionally, we examined whether the association 
was restricted to clinically relevant disease subsets that were characterized by autoantibody 
status. 
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Patients & Methods 
Patients  
A total of 877 RA patients whose diagnosis met the American College of Rheumatology 
(formerly, the American Rheumatism Association) 1987 revised criteria for RA (18) were 
recruited in 1994 from hospitals in the western part of The Netherlands, of whom 602 patients 
were from 2 independent cohorts of patients with early arthritis, the EAC and BeSt cohorts, and 
275 were from the outpatient clinic of the Leiden University Medical Center. For both early 
arthritis cohorts, anti–citrullinated protein antibody (ACPA) status and rheumatoid factor (RF) 
status were obtained. For the patients from the outpatient clinic, only the RF status was 
obtained. Patients’ characteristics have been described previously (19). As healthy controls, 866 
subjects were randomly selected from the Immunogenetics and Transplantation Immunology 
section of Leiden University Medical Center. All patients and controls gave their informed 
consent to participate in the study, and the study was approved by the local ethics committee of 
the participating hospitals.  
Genotyping methods 
Genotyping of STAT4 rs7574865, IL2/IL21 rs6822844, and CTLA4 rs3087243 was performed 
using MassArray matrix-assisted laser desorption ionization– time-of-flight mass spectrometry, 
according to the protocols recommended by the manufacturer (Sequenom, San Diego, CA). 
SpectroCaller software, which was supplied by the same manufacturer, was used to 
automatically identify, i.e., call, the genotypes. Each 384-well plate consisted of 8 positive 
controls and 8 negative controls, all of which were indeed shown to be positive or negative. 
Clusters were evaluated and all doubtful calls were checked; after manually evaluating the 
spectra of each cluster, the genotypes were accepted, recalled, or rejected. At least 10% of the 
genotypes were assessed in duplicate, with an error rate of <1%.  
Statistical analysis 
Allele distribution was analyzed for association with RA using a chi-square test with 1 degree of 
freedom. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using the 
Statcalc module of Epi Info software (Centers for Disease Control and Prevention, Atlanta, GA). 
P values less than 0.05 were considered significant. Genotype frequencies in cases and 
controls did not deviate from Hardy-Weinberg equilibrium at a significance level of P < 0.05.  
A meta-analysis of published reports describing disease associations with STAT4, IL2/IL21, and 
CTLA4 was performed using the Mantel-Haenszel method of combining ORs. Reports 
published up to July 31, 2008 were included in the analysis. Heterogeneity of the ORs across 
sample sets was analyzed using the Breslow-Day test.  
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Since no significant heterogeneity was observed among the studies, the ORs and 95% CIs were 
calculated using a fixed-effects model, and P values less than 0.05 were considered significant. 
(Genotype frequencies are available upon request from the corresponding author.) The meta-
analyses had >80% power to detect allele associations both for association with RA and for 
association with autoantibody status, at ORs of  1.18 (at a significance level of P < 0.05) for all 
3 polymorphisms, except for the association of the IL2/IL21 locus with autoantibody status, in 
which the meta-analysis had 67% power to detect an OR of 1.20 (at a significance level of P < 
0.05). 
Results 
Replication of STAT4, IL2/IL21, and CTLA4 loci in an independent Dutch cohort 
The polymorphisms STAT4 rs7574865, IL2/IL21 rs6822844, and CTLA4 rs3087243 were 
genotyped in 877 RA patients and 866 healthy controls. Both STAT4 and CTLA4 showed an 
association with RA in the Dutch cohort, while a clear trend toward association was observed for 
the IL2/IL21 locus (Table 1). The results had the same direction of association as has been 
reported in previous studies (3,4,6,9–12,14,15,17).  
Stratification by autoantibody status 
For a better understanding of disease etiology, we investigated whether the associations were 
restricted to a specific subset of disease, defined by either ACPA positivity or RF positivity. In 
these subsets, no differential association could be observed for either the STAT4 polymorphism 
or the IL2/IL21 polymorphism (Table 1). The CTLA4 polymorphism, however, did show a 
significant association with ACPA-positive RA in patients as compared with healthy controls (OR 
0.80, 95% CI 0.66–0.96, P = 0.015), but showed no association with ACPA-negative RA in 
patients as compared with healthy controls (OR 0.90, 95% CI 0.70–1.12, P = 0.325). 
Furthermore, an increase in frequency of the G allele was observed in patients with ACPA-
positive RA (60%) as compared with patients with ACPA-negative RA (57%), but the difference 
was not significant. 
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Meta-analysis of STAT4, IL2/IL21, and CTLA4 loci 
Association with RA overall.  
To systematically assess the contribution of the 3 studied polymorphisms in RA, a meta-
analysis of all published studies to date was performed. This analysis provided an overall OR for 
the widely and consistently replicated STAT4 locus in the Caucasian population (OR 1.24, 95% 
CI 1.17–1.33, P = 1.66 x 10-11) (Table 2). Evaluation of both studies dealing with IL2/IL21 
provided additional evidence of an association of IL2/IL21 with RA in Caucasians (OR 0.78, 
95% CI 0.69–0.88, P = 5.6 x 10-5). Examination of the 6 previously published studies on 
rs3087243 in CTLA4 confirmed an overall association of this region with RA in Caucasians (OR 
0.91, 95% CI 0.85–0.96, P = 1.8 x 10-3) (Table 2).  
Association with RA stratified by autoantibody status.  
Results from our meta-analysis indicated that STAT4 was associated with both autoantibody-
positive and autoantibody-negative disease in the Caucasian population (OR 1.00, 95% CI 
0.89–1.14, P = 0.97) (Table 3). Moreover, IL2/IL21 showed a significant association with RF-
positive disease in Caucasian patients as compared with healthy controls (OR 0.78, 95% CI 
0.68–0.90, P = 6.9 x 10-4), but IL2/IL21 showed no significant association with RF-negative 
disease in Caucasian patients as compared with controls (OR 0.82, 95% CI 0.66–1.03, P = 
0.083). However, the effect sizes of both associations were of the same extent. Furthermore, 
the effect size of RF-positive disease compared with RF-negative disease was limited, 
indicating an association of IL2/IL21 in both disease subsets (OR 1.02, 95% CI 0.81–1.29, P = 
0.86) (Table 3). Interestingly, in the meta-analysis, CTLA4 in the Caucasian population was 
found to predispose to ACPA-positive disease only, and not to ACPA-negative disease (OR 
0.86, 95% CI 0.78–0.96, P = 4.7 x 10-3) (Table 3). 
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Discussion 
In the present study, 2 genetic risk factors for RA were replicated in an independent Dutch 
population, with a third genetic risk factor showing a clear trend toward association. All 3 loci 
were further confirmed in a well-powered meta-analysis. Interestingly, these polymorphisms 
have been described in several autoimmune diseases, varying from type 1 diabetes to systemic 
lupus erythematosus (3,4), which further emphasizes their role in autoimmunity. In RA, previous 
studies have suggested that genetic risk factors predispose to specific subsets of the disease, 
characterized by autoantibody status. For example, both the HLA shared epitope and PTPN22 
loci have been shown to be associated with a clear predisposition to ACPA-positive disease 
only. At a biologic level, classifying these genetic risk factors will ultimately enable a better 
understanding of the disease processes involved. Although STAT4, IL2/IL21, and CTLA4 have 
been found in association with ACPA-positive disease (20), they have not been investigated 
extensively in autoantibody-negative patients.  
In this study, we did not observe a difference in effect size between the autoantibody strata for 
either STAT4 or IL2/IL21. Our results are consistent with recent findings for STAT4. Zhernakova 
and colleagues (4) have shown an association of IL2/IL21 in RF-positive patients as compared 
with controls, but no conclusive difference could be established between the 2 subgroups. In 
support of these findings, our combined data sets also indicated that IL2/IL21 predisposes 
individuals to both autoantibody-positive and autoantibody-negative disease. However, 
additional replication in independent cohorts will still be necessary to tease apart the precise 
role of IL2/IL21 in these disease subsets.  
The results from several studies previously suggested that CTLA4 is associated with RA in an 
autoantibody-dependent manner. However, we provided, for the first time, conclusive evidence 
that CTLA4 is associated with ACPA-positive RA, but not with ACPA-negative RA. In 
conclusion, this study provides independent replication of an association of STAT4, IL2/IL21, 
and CTLA4 with RA, as well as substantial evidence of the involvement of CTLA4 in ACPA-
positive disease only, as compared with the involvement of STAT4 and IL2/ IL21, which 
predisposes to both disease subsets.  
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Abstract 
Objective 
Juvenile idiopathic arthritis (JIA) is characterized by chronic arthritis and an autoimmune 
etiology. In several autoimmune diseases, including rheumatoid arthritis (RA), an association 
with the 4q27 locus has been reported. We undertook this study to investigate the possible role 
of the 4q27 locus in JIA. 
Methods 
A case-control association study was conducted, with a total of 655 Caucasian JIA patients and 
791 healthy controls divided into 2 independent sample sets. The rs6822844 marker in the 4q27 
locus was genotyped. 
Results 
In the first and larger sample set, a 5% decrease in T allele frequency was observed in patients 
compared with controls (allelic odds ratio [OR] 0.72 [95% confidence interval 0.55–0.95], P 
=0.019), and in the second set, a 3% decrease was observed (allelic OR 0.81 [95% confidence 
interval 0.61–1.09], P =0.169). The combined data set generated an OR of 0.76 (95% 
confidence interval 0.62–0.93, P=7.08 x10-3). When the different JIA subtypes were analyzed 
individually, significant decreases were seen in the subtypes with a polyarticular course of 
disease (extended oligoarthritis [P = 0.019] and rheumatoid factor–negative polyarthritis [P = 
0.038]). 
Conclusion 
Our findings suggest that the 4q27 locus, previously reported to be associated with RA, type 1 
diabetes mellitus, celiac disease, and psoriatic arthritis, is also associated with susceptibility to 
JIA. 
Introduction 
Juvenile idiopathic arthritis (JIA) is a group of heterogeneous disorders characterized by chronic 
arthritis diagnosed in children younger than 16 years of age (1). Seven different subtypes of JIA 
can be distinguished according to the International League of Associations for Rheumatology 
(ILAR) classification (2). The subtypes oligoarthritis (both persistent and extended) and 
rheumatoid factor (RF)-negative polyarthritis are considered the most homogeneous subtypes, 
with shared phenotypic features. Systemic JIA has a more distinct phenotype resembling an 
autoinflammatory syndrome. Although the precise etiology is still unknown, JIA is considered to 
be an autoimmune disease.  
Genetic studies in autoimmune diseases have revealed the presence of shared common 
autoimmune susceptibility loci (3). In JIA, associations with the major histocompatibility complex 
locus, PTPN22, and TRAF1/C5 have been described (4–6). The 4q27 locus, a region of strong 
linkage disequilibrium that includes IL2 and IL21 (the genes encoding interleukin-2 [IL-2] and IL-
21, respectively), has been associated with celiac disease, rheumatoid arthritis (RA), type 1 
diabetes mellitus (type 1 DM), and psoriatic arthritis (7–9). To determine whether the 4q27 locus 
is also associated with JIA, we genotyped rs6822844 (which can be used as a proxy for the 
4q27 haplotype that is associated with autoimmune disease [8]) in JIA patients and controls. 
Patients & Methods 
Patient population 
A case-control association study was conducted in 2 independent sample sets. These sample 
sets consisted of Caucasian JIA patients (recruited from pediatric rheumatology centers in The 
Netherlands [n =327], Belgium [n= 96], Germany [n=95], and Switzerland [n =137]) and healthy 
Dutch adult controls, who were part of the DNA panel of the Immunogenetics and 
Transplantation Immunology section at Leiden University Medical Center and consisted of 
randomly selected unrelated individuals and blood donors.  
The first sample set consisted of 328 JIA patients and 465 healthy controls, and the second 
sample set consisted of 327 JIA patients and 326 controls. In all patients (69% female and 31% 
male), JIA was diagnosed according to the ILAR revised classification criteria (2). The patients 
with JIA who were selected for inclusion in the study were primarily those with the oligoarthritis 
(both persistent and extended) or RF-negative polyarthritis subtype, because of their 
homogeneous phenotypes. 
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Forty-four percent of the patients in the overall JIA patient group had persistent oligoarticular 
disease, 13% had extended oligoarticular disease, 24% had RF-negative polyarticular disease, 
3% had RF-positive polyarticular disease, 11% had systemic JIA, and 5% had other JIA 
subtypes. Because of the small sample size of patients with RF-positive polyarticular JIA and 
patients with types of JIA categorized as “other,” these groups were excluded from the subtype 
analysis described below. All patients were of self- or parent-reported European Caucasian 
ethnicity. Written informed consent was obtained from all patients and/or their parents, and the 
institutional review boards from all participating centers approved the study. 
DNA and Genotyping 
To test for an association of the 4q27 region with JIA, rs6822844 was typed in both sample sets. 
DNA was collected through either a blood sample (12% of JIA patients and all controls) or a 
mouth swab (88% of JIA patients). Genotyping was performed using high-throughput MassArray 
matrix-assisted laser desorption ionization time of flight mass spectrometry, according to the 
protocols recommended by the manufacturer (Sequenom, San Diego, CA). 
Each of the 384-well plates contained 8 positive controls (DNA obtained from the Centre 
d’Etude du Polymorphisme Humain, Paris, France), 8 negative controls, and 10% duplicates. 
The error rate was <1%. Random genotyping failure occurred in 3% of JIA patients and 1% of 
controls, decreasing the total number of subjects in the analyses to 635 patients and 783 
controls. 
Statistical analysis 
Because of the adherence to an additive model and the lack of evidence for a recessive model, 
we compared cases and controls using an allelic odds ratio (OR) and 95% confidence interval 
(95% CI). The common OR of the 2 independent sample sets combined was calculated using 
the Mantel-Haenszel test. There was no heterogeneity between the 2 sample sets (P >0.05 by 
Breslow-Day test). Case and control genotype frequencies did not deviate from Hardy-Weinberg 
equilibrium. All statistical analyses were performed with SPSS, version 14.0 (SPSS, Chicago, 
IL). P values less than 0.05 were considered significant. 
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Results 
In the first and larger sample set, the T allele frequency was significantly decreased, from 20% 
in controls to 15% in JIA patients (allelic OR 0.72 [95% CI 0.55–0.95], P = 0.019) (Table 1). A 
similar decrease in T allele frequency (from 18% in controls to 15% in patients) was observed in 
the second sample set, although it did not reach statistical significance (allelic OR 0.81 [95% CI 
0.61–1.09], P = 0.169). The common OR in sample sets 1 and 2 combined demonstrated a 
positive association with JIA (P = 7.08 x 10-3).  
 
 
 
Because of the importance of investigating genetic risk factors in homogeneous, well-defined 
phenotypic groups, we also analyzed association in the selected JIA subtypes (Table 2). 
Although a trend toward a decreased T allele frequency was observed among patients with 
persistent oligoarthritis and systemic JIA, only the subtypes with a polyarticular course of 
disease (extended oligoarthritis and RF-negative polyarthritis) showed a significant decrease in 
T allele frequency (P = 0.019 and P = 0.038, respectively). 
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Discussion 
This study demonstrates, for the first time, a positive association of the 4q27 locus (rs6822844) 
with JIA; a JIA-protective effect of the T allele was observed. When the different JIA subtypes 
were tested individually, a decrease in T allele frequency was observed in all subtypes. 
Interestingly, this decrease was significant only in the JIA subtypes that share a polyarticular 
phenotype. Similar observations have been made regarding the recently identified association 
with the TRAF1/C5 region (4), indicating a common genetic constitution underlying the 
polyarticular JIA phenotype.  
In studies of patients originating from different European countries, population stratification 
cannot be ruled out completely. However, no significant variance in allele frequency in control 
populations from Western Europe has been reported (7,8), and the allele frequency observed in 
our control population was very similar to previously reported frequencies. In addition, when 
allele frequencies in patients originating from the various European countries were compared, 
no significant difference was found (P = 0.77). Moreover, the degree of underrepresentation of 
the minor T allele and the 4q27 effect size were similar to those described in studies of other 
autoimmune diseases, such as RA and type 1 DM (8).  
The 4q27 locus consists of a large region of strong linkage disequilibrium encoding the genes 
KIAA1109, TENR, IL2, and IL21. Both IL2 and IL21 are likely candidates for association with 
susceptibility to JIA, since both cytokines are involved in immune activation and regulation 
pathways.  
The IL-2 pathway, in which the interaction between IL2 and IL2 receptor   is central, is involved 
in T cell proliferation and regulation (10). In mice deficient in IL2, T cells have impaired 
proliferation and effector function in vitro, and lethal autoimmunity develops (11). In addition to 
the 4q27 locus, the IL2RA locus has been associated with several autoimmune diseases 
(12,13), indicating an important role of the IL2 pathway in immune regulation and maintenance 
of self-tolerance.  
IL21 is also involved in a wide range of immunologic processes. It appears to play a role in 
autoimmunity by influencing the cellular immune response through both inhibition of 
suppression by CD4+ regulatory T cells and generation of Th17 cells, as well as by influencing 
the humoral response (14).  
Further analysis of the immunologic pathways involved in JIA may be helpful in identifying the 
causal gene in this locus. Moreover, sequencing, fine-mapping, and extensive testing of variants 
of this region will be required to narrow down the region of association and identify the 
associated gene. Functional testing of all the linked variants associated with disease is also 
needed.  
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In conclusion, like RA, type 1 DM, celiac disease, and psoriatic arthritis, JIA is associated with 
the 4q27 locus. The identification of the 4q27 locus as a risk factor for JIA contributes to the 
accumulated evidence that one of the genes in this region plays a role in autoimmune diseases 
in general. In addition, our data indicate that the 4q27 locus contributes to genetic susceptibility 
to JIA, warranting further research into the biologic pathways that would help to explain this 
association. 
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Abstract 
Objective 
To determine whether genetic variants of the interferon regulatory factor 5 (IRF-5) and Tyk-2 
genes are associated with rheumatoid arthritis (RA).  
Methods 
Five single-nucleotide polymorphisms (SNPs) in IRF5 and 3 SNPs in Tyk2 were analyzed in a 
Swedish cohort of 1,530 patients with RA and 881 controls. A replication study was performed 
in a Dutch cohort of 387 patients with RA and 181 controls. All patient sera were tested for the 
presence of autoantibodies against cyclic citrullinated peptides (anti-CCP).  
Results 
Four of the 5 SNPs located in the 5' region of IRF5 were associated with RA, while no 
association was observed with the Tyk2 SNPs. The minor alleles of 3 of the IRF5 SNPs, which 
were in linkage disequilibrium and formed a relatively common haplotype with a frequency of 
~0.33, appeared to confer protection against RA. Although these disease associations were 
seen in the entire patient group, they were mainly found in RA patients who were negative for 
anti-CCP. A suggestive association of IRF5 SNPs with anti-CCP–negative RA was also 
observed in the Dutch cohort. 
Conclusion 
Given the fact that anti-CCP–negative RA differs from anti-CCP–positive RA with respect to 
genetic and environmental risk factor profiles, our results indicate that genetic variants of IRF5 
contribute to a unique disease etiology and pathogenesis in anti-CCP–negative RA.  
Introduction 
The type I interferons (IFNs) comprise a large family of cytokines that are typically produced 
during viral infections, mainly by plasmacytoid dendritic cells (1). In addition to direct antiviral 
effects, type I IFNs have many important immunomodulatory functions (1). For instance, they 
cause maturation of dendritic cells, promote T cell activation, and stimulate B cell development 
and production of antibodies. Data from previous studies indicate that the type I IFN system 
plays a pivotal role when self tolerance is broken and autoimmune reactions develop (2). 
Accordingly, the type I IFN system is activated in many autoimmune diseases, including 
systemic lupus erythematosus (SLE) (2), pri-mary Sjogren’s syndrome (3), psoriasis (4), 
polymyositis (5), and type 1 diabetes mellitus (6). 
In a previous report we described a strong association between SLE and 2 key genes from the 
type I IFN signaling system, namely the Tyk-2 and interferon regulatory factor (IRF-5) genes (7). 
The association of the single-nucleotide polymorphisms (SNPs) in the IRF-5 gene with SLE has 
recently been convincingly replicated in 4 independent case–control studies (8). A causative 
role of type I IFN in the initiation and maintenance of autoimmunity is suggested by the finding 
that up to 19% of IFN=-treated patients with a malignant disease ultimately developed an 
autoimmune disorder (2). Development of rheumatoid arthritis (RA [MIM no. 180300]) during 
IFN  treatment has been reported (9), providing evidence that the type I IFN system may be 
involved in the pathogenesis of this disease.  
RA is a common autoimmune disease characterized by chronic arthritis with progressive joint 
destruction, and if left untreated RA can lead to severe disability. RA affects women 2–3 times 
more frequently than it affects men, and both genetic and environmental components are 
involved in the etiopathogenesis of the disease (10). A majority of RA patients are positive for 
autoantibodies against the Fc portion of the IgG molecule (rheumatoid factor [RF]). The 
presence of RF in patients correlates with a severe form of RA (11), but RF can occasionally be 
detected in normal healthy individuals and in patients with conditions other than RA (12). 
It has been shown that RA patients also produce antibodies against cyclic citrullinated peptides 
(anti-CCP), and that anti-CCP antibodies are rarely detectable in healthy individuals (13). They 
are thus a more specific disease marker for RA than is RF. Anti-CCP antibodies can be 
detected years before the appearance of any clinical RA symptoms (14), and they are 
prognostic indicators of a greater degree of inflammation and more destructive disease (15). 
Recent data on gene–environment interactions also show that the major environmental risk 
factor, smoking, is associated with anti-CCP–positive RA, but not with anti-CCP–negative RA 
(10,16). Furthermore, anti-CCP antibodies display a strong association with specific alleles at 
the HLA–DRB1 gene (10), which are collectively known as shared epitope alleles. In contrast, 
the HLA–DR3 allele is associated with anti-CCP–negative RA, which suggests that the 
syndrome called RA may consist of at least 2 distinct diseases (anti-CCP positive and anti-CCP 
negative), each with different risk factors and pathogenetic pathways (17). Genetic variants of 
several non–major histocompatibility complex (MHC) genes have also shown an association 
with RA (18), and among them the most convincing evidence for association has been observed 
for variants of the PTPN22 (MIM no. 600716) (19), PADI4 (MIM no. 605347) (20), and CTLA4 
(MIM no. 123890) (21,22) genes.  
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The PTPN22 allele, which has shown the most consistent association with RA in previously 
published studies, is associated with anti-CCP–positive RA (18). So far, no genetic risk factor 
outside the HLA locus has been identified for anti-CCP–negative disease. 
The role of the type I IFN system in RA has not been extensively investigated, but expression of 
IFN  (23) and the type I IFN–inducible protein myxovirus resistance protein A (24) has been 
detected in RA synovial tissue, along with increased levels of IFN  in synovial fluid (25). 
Furthermore, plasmacytoid dendritic cells are recruited to inflamed synovium (26), perhaps due 
to increased levels of production of chemoattractants for these cells in the synovial fluid (24). 
Moreover, the cytokines interleukin-6 (IL-6), IL-10, IL-12, and tumor necrosis factor   (TNF ), 
which are connected to the type I IFN pathway, have all been suggested to be involved in the 
disease process in RA (27). 
The JAK Tyk-2 is crucial for signaling via the type I IFN receptor. Tyk-2 also interacts with the 
receptors for several other cytokines, such as IL-6, IL-10, and IL-12. A possible role of Tyk-2 in 
RA is more directly indicated by the finding that Tyk-2–deficient mice are resistant to 
experimental arthritis (28). IRF-5 is a transcription factor that is activated by Toll-like receptor 7 
(TLR-7), TLR-8, and TLR-9, which are involved in induction of IFN= genes in human cells 
(29,30). IRF-5 is constitutively expressed in cells of the immune system, including plasmacytoid 
dendritic cells (31), and its expression is regulated by type I IFN (32).  
Given the potential role of the type I IFN system in RA, we hypothesized that genetic variants of 
Tyk2 and IRF5 could be associated with RA, by analogy with our previous findings in SLE (7). 
To test this hypothesis, we genotyped 5 SNPs in the IRF-5 gene and 3 SNPs in the Tyk-2 gene 
in a large cohort of RA patients and controls from Sweden. We found that 4 of the 5 IRF5 SNPs 
and a commonly observed haplotype formed by the rare alleles of these SNPs were strongly 
associated with RA, and that the evidence of association was mainly found in anti-CCP–
negative RA. We replicated the association between IRF5 and anti-CCP–negative RA in an 
unrelated cohort of Dutch patients.  
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Patients & Methods 
Samples 
The Swedish RA patients and controls were from the Epidemiological Investigation of 
Rheumatoid Arthritis (EIRA), a population-based case–control study of incident cases of RA. 
The EIRA included subjects ages 18–70 years who were living in the central and southern parts 
of Sweden during 1996–2003. Briefly, all potential cases were examined and diagnosed by a 
rheumatologist at a study unit. All rheumatology units linked to the public health care system, as 
well as almost all of the few existing privately run rheumatology units, in the relevant geographic 
area participated in the study. In total there were 19 reporting clinics, 15 of which were Early 
Arthritis Clinics. Initially, some centers reported cases that did not satisfy the criteria for RA, in 
order to enable investigations of undifferentiated arthritis, but these subjects were eventually 
excluded from the study. 
For each potential case, a control subject was randomly selected from the study base, with 
consideration of age, sex, and area of residence. Controls were selected using the Swedish 
national population register, which is continuously updated. If a proposed control declined to 
participate, was not traceable, or was reported as having RA, a new control was selected using 
the same criteria. Controls selected to match cases who were eventually excluded because they 
did not fulfill study criteria remained in the study. 
In the present study we used part of the EIRA cohort consisting of 1,530 newly diagnosed 
patients who fulfilled the 1987 American College of Rheumatology (formerly, the American 
Rheumatism Association) criteria for RA (33), and 881 controls who answered a questionnaire 
and provided a blood sample. Among the cases, the mean duration between estimated disease 
onset and study entry was 10 months. Of all participants in the EIRA study, 97% were 
Caucasian. Seventeen controls who were found to be positive for anti-CCP antibodies and 3 
controls with unknown anti-CCP status were excluded from the analysis.  
The replication cohort consisted of RA patients and controls from the Leiden Early Arthritis 
Clinic, as previously described in detail (34). Briefly, in 1993, an Early Arthritis Clinic was 
established at the Department of Rheumatology of the Leiden University Medical Center. 
General practitioners in an area with ~300,000 inhabitants referred patients directly to the clinic 
when arthritis was suspected. All patients were evaluated at the Early Arthritis Clinic within 2 
weeks of referral. Patients were included in the study only if the duration of symptoms was <2 
years, and the mean duration between estimated disease onset and study entry was 7 months. 
Diagnoses were made according to international classification criteria, as previously described 
(35). 
Patients from the Early Arthritis Clinic who were diagnosed as having definite RA, and from 
whom DNA was available, were included in the present study (n = 387). Other anti-CCP–
negative and RF-negative patients from the Early Arthritis Clinic with diagnoses such as gout, 
pseudogout, viral or bacterial reactive arthritis, posttraumatic osteoarthritis, Lyme arthritis, or 
paraneoplastic arthritis made up the control group (n = 181). Patients with undifferentiated 
arthritis, psoriatic arthritis, or SLE were excluded from the control group. All subjects in the case 
and control groups were Caucasian. 
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All subjects in both cohorts gave informed consent, and the local ethics committee approved the 
study. DNA was isolated from EDTA-treated blood by a standard desalting method. 
Autoantibody Analysis 
Patient sera obtained from the EIRA cohort at the time of diagnosis were examined for RF by 
nephelometry and for anti-CCP antibodies by enzyme-linked immunosorbent assay (ELISA) 
(second-generation test; Euro-Diagnostica, Arnhem, The Netherlands). Antinuclear antibodies 
(ANAs) were measured in 194 anti-CCP–positive and 191 anti-CCP–negative patients with RA 
using indirect immunofluorescence on HEp-2 cells (Bio-Rad, Stockholm, Sweden) in a 1:200 
screening dilution with a secondary antibody directed against the  -chain of IgG (Dako, 
Glostrup, Denmark). All sera were interpreted blindly in parallel, by the same investigator (JR). 
Using this procedure, ANAs were detected in sera from 5 (5%) of 100 healthy controls. In the 
Early Arthritis Clinic study, serum anti-CCP antibodies were assessed with a commercial ELISA 
(Immunoscan RA [Mark 2]; Euro-Diagnostica). Anti-CCP antibodies were measured in serum 
collected within 4 months after the first visit (in 94% of the patients) or, when serum was not 
available within this period, in the first stored serum sample available thereafter. 
Genotyping 
In the Swedish EIRA cohort we genotyped 4 SNPs in the promoter and first intron of the IRF-5 
gene (no. rs729302, no. rs2004640, no. rs752637, and no. rs3807306) and 2 SNPs in protein-
coding exons of the Tyk-2 gene (no. rs12720356 and no. rs2304256) for which we had 
observed strong or suggestive signals for joint linkage and association with SLE in a previous 
study (7). We also included in the analysis an additional SNP in the promoter region of IRF5 
(no. rs3757385) and a Tyk2 SNP (no. rs91755) located in intron 9 between the SNPs 
rs2304256 in exon 8 and rs12720356 in exon 15 of Tyk2.  
Six of the SNPs were genotyped by multiplex minisequencing (fluorescence single-base 
extension) with the SNPstream Genotyping System (Beckman Coulter, Fullerton, CA) (36), and 
2 SNPs (rs752637 and rs2304256) were genotyped using a homogeneous single-base 
extension assay with fluorescence polarization detection (FP-TDI; PerkinElmer, Emeryville, CA) 
(37). Four SNPs in the IRF-5 gene (rs729302, rs3757385, rs2004640, and rs3807306) were 
genotyped for replication in samples from the Dutch Early Arthritis Clinic study, using the 
SNPstream System as described above. The SNPs were genotyped at the SNP technology 
platform in Uppsala (www.genotyping.se). The sequences of the polymerase chain reaction and 
minisequencing primers used in the genotyping assays are available from the corresponding 
author upon request.  
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The mean SNP genotype call rate in the EIRA samples was 94% (range 92–97%), and the 
accuracy estimated from 3,700 genotype comparisons between repeated assays (18% of the 
genotypes) was 99.9%. In the Early Arthritis Clinic study samples, the mean call rate was 98% 
(range 95–99%), and the accuracy based on repeated determination of 10% of the genotypes 
was 100%. All SNPs exhibited Hardy-Weinberg equilibrium (P > 0.01 by Fisher’s exact test) in 
both sample sets. 
Statistical Analysis  
Unadjusted 2-tailed P values calculated by Fisher’s exact test were used to compare the SNP 
allele frequencies in the RA patient groups versus the controls and for assessing Hardy-
Weinberg equilibrium of the SNP genotypes. Haploview, version 3.2. (38) was used to construct 
the haplotypes, to calculate pairwise D' and r2 values for linkage disequilibrium, to perform 
haplotype association analysis using a chi-square test, and to perform permutation tests. Odds 
ratios (ORs) were calculated using the formula [i(G1)/i(G2)]/[j(G1)/j(G2)], where i and j are the 
allele counts in patients with RA and in controls, respectively.  
Prior to performing a pooled analysis of the 2 independent cohorts, lack of heterogeneity in the 
populations was confirmed using the Breslow-Day test of homogeneity (39). The EasyMA 2001 
free software package (39) was used for the pooled analysis, using the Mantel-Haenszel test for 
calculating ORs. The EIRA and Early Arthritis Clinic cohorts demonstrated P values for 
homogeneity > 0.01 for all 4 loci tested. The frequencies of ANAs in the EIRA patient and 
control sera were compared using a chi-square test. 
Results 
Association analysis using the genotype data for the individual SNPs from all Swedish patients 
and controls revealed that 4 of the 5 analyzed SNPs in the IRF-5 gene were associated with RA 
(P < 0.05), with SNP rs3807306 exhibiting the strongest association (P = 0.00063) (Table 1). In 
contrast, we did not find evidence of an association between RA and any of the SNPs in the 
Tyk-2 gene (P > 0.05). We also analyzed the genotype data from RA patients stratified into 
subgroups according to presence or absence of RF and stratified into subgroups according to 
presence or absence of anti-CCP autoantibodies, compared with the data from all controls. In 
the RF-positive patients, only SNP rs3807306 showed evidence of association with RA, 
whereas in the RF-negative patients 4 of the IRF5 SNPs showed evidence of association.  
No significant differences in the minor allele frequencies of any of the SNPs were observed 
when RF-positive and RF-negative patients were compared (data not shown). There was a 
slight difference between anti-CCP–positive and anti-CCP–negative patients in the minor allele 
frequency of SNP rs3807306 (P = 0.036). The most striking result of this analysis was the 
strong evidence of association observed for the 4 IRF5 SNPs in the group of anti-CCP–negative 
patients. Despite the fact that this subgroup of patients (n = 590) constituted only approximately 
one-third of all patients with RA, evidence of association for SNP rs3807306 was stronger in this 
subgroup (P = 0.000091) than it was in the original analysis of all patients and controls (Table 
1). This association was also evident in a codominant model (P = 0.0003; data not shown). 
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When the RA patients were stratified into subgroups according to a combination of presence or 
absence of RF and anti-CCP antibodies, most of the evidence of association was found in the 
group of patients who were negative for both anti-CCP and RF. In this group, which included 
only approximately one fifth of all patients (n = 366), the observed P values were 0.0035, 
0.0082, and 0.0026 for SNPs rs3757385, rs2004640, and rs3807306, respectively. Stratification 
of the patients according to anti-CCP and RF status did not reveal any evidence of association 
of the 3 Tyk2 SNPs with RA.  
We did not detect any significant sex-specific differences in Tyk2 or IRF5 SNP allele 
frequencies in the RA patient or control groups (data not shown). The minor allele frequencies 
of the IRF5 SNPs were, however, lower in the male patients who were negative for both anti-
CCP and RF (n = 100) than in the male controls (n = 250), and a significantly lower minor allele 
frequency was noted for SNP no. rs2004640 in this subgroup compared with that in male 
controls (0.35 versus 0.49; P = 0.00091). Table 1 shows the ORs for the 5 IRF5 SNPs in the 
subgroups of anti-CCP–positive and anti-CCP–negative patients. The frequency of the minor, 
variant alleles of the associated SNPs was lower in the RA patient groups than in the controls, 
reducing the risk of RA to 0.7–0.8 compared with carriers of the major alleles. Thus, these 
alleles appeared to be protective against RA.  
 
Table 1. Analysis of the association of individual SNPs in the IRF-5 and Tyk-2 genes with RA in all Swedish patients 
and controls, and in Swedish patients after stratification based on the presence or absence of RF or anti-CCP 
antibodies*
 
* Single-nucleotide polymorphisms (SNPs) rs729302, rs3757385, rs2004640, rs752637, and rs3807306 are in the 
interferon regulatory factor 5 (IRF-5) gene; SNPs rs12720356, rs91755, and rs2304256 are in the Tyk-2 gene. 
Rheumatoid factor (RF) status could not be determined in 85 patients, and anti–cyclic citrullinated peptide antibody 
(anti-CCP) status could not be determined in 21 patients. 95% CI = 95% confidence interval; NS = not significant;  
ND = not determined. 
† Unadjusted 2-tailed P values comparing each patient group with controls were calculated using Fisher’s exact test. 
The empirical P values for association with anti-CCP–negative rheumatoid arthritis (RA) (100,000 permutations 
obtained using Haploview software, version 3.2) were P = 0.024 for SNP rs3757385, P = 0.042 for SNP rs2004640, 
and P = 0.0008 for SNP rs3807306. The P value for SNP rs752637 was not significant. 
‡ Odds ratios (ORs) were calculated using the formula [i(G1)/i(G2)]/ [j(G1)/j(G2)], where i and j are allele counts in 
patients with RA and in controls, respectively. 
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Figure 1 shows the positions of the SNPs in the IRF-5 gene and the pairwise linkage 
disequilibrium values between the SNPs rs3757385, rs2004640, rs752637, and rs3807306 in 
the control samples from Sweden. Table 2 shows the frequencies of the haplotypes formed by 
these 4 IRF-5 SNPs in anti-CCP–negative RA patients, anti-CCP–positive RA patients, and 
controls. The 3 most common haplotypes, H1–H3, accounted for almost 90% of the genetic 
variation conferred by these SNPs in the sample set. The most common haplotype, H1, which is 
formed by the more frequent alleles of the SNPs, appeared to be a risk haplotype for anti-CCP– 
negative RA, with an OR of 1.23 (95% confidence interval [95% CI] 1.06–1.43). The frequency 
of the second most common haplotype, H2, which is formed by the minor alleles of the 4 SNPs, 
displayed the strongest evidence of association with RA (P = 0.000080), and was associated 
with protection against anti-CCP–negative RA, with an OR of 0.71 (95% CI 0.60–0.84). For anti-
CCP–positive RA, the OR for haplotype H2 was 0.85 (95% CI 0.74–0.98). 
 
Figure 1. Location and pairwise linkage disequilibrium values of the single-nucleotide polymorphisms (SNPs) in the 
interferon regulatory factor 5 (IRF-5) gene. Top, Location of the SNPs in the IRF-5 promoter and first intron. P values 
for association with rheumatoid arthritis in Swedish patients who were negative for anti–cyclic citrullinated peptide 
antibodies are shown at the top. Exons 1 and 2 are indicated. NS _ not significant.  
Bottom, Pairwise linkage disequilibrium values for the SNPs in the Swedish control samples. 
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 Table 2. Analysis of the association of IRF-5 haplotypes with RA in Swedish patients* 
 
* Haplotypes were formed by the 4 IRF-5 SNPs rs3757385, rs2004640, rs752637, and rs3807306. The empirical P 
value for association between the AGAC haplotype and RA in anti-CCP–negative patients (100,000 permutations 
obtained using Haploview software, version 3.2) was _0.001. See Table 1 for definitions. 
 
To attempt to replicate the association between the IRF-5 gene and anti-CCP–negative RA, we 
genotyped 4 of the IRF-5 SNPs in an unrelated cohort of Dutch RA patients (Table 3). The SNP 
allele frequencies were similar in the Swedish and Dutch patient and control groups, and 
evidence of association was observed for SNP rs2004640 in the group of anti-CCP– negative 
patients (P = 0.024). Also, P values for SNPs rs729302 and rs3757385 (P = 0.072 and P = 
0.091, respectively) suggested an association in the anti-CCP–negative patients, but, possibly 
due to the small number of individuals in this group, the evidence of this association did not 
reach the formal threshold for statistical significance. 
In a combined analysis of all 741 anti-CCP–negative patients in the cohorts from both 
populations, which were genetically homogeneous (P > 0.01 by heterogeneity test), strong 
evidence of association of SNPs rs2004640 and rs3807306 with anti-CCP–negative RA was 
exhibited (P < 0.001). Table 3 shows the Ors for the 4 IRF-5 SNPs analyzed in the Dutch cohort 
and the combined ORs for all anti-CCP–negative patients in both cohorts. In the Dutch samples 
the haplotypes formed by SNPs rs3757385, rs2004640, and rs3807306 occurred with similar 
frequencies as in the Swedish samples (data not shown). 
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 Table 3. Analysis of association of SNPs in the IRF-5 gene with RA in all Dutch patients and controls, and in Dutch 
and Swedish patients after stratification based on the presence or absence of anti-CCP antibodies* 
 
* SNPs rs729302, rs3757385, rs2004640, and rs3807306 are in the IRF-5 gene. See Table 1 for definitions. 
† Unadjusted 2-tailed P values comparing patient groups with controls were calculated using Fisher’s exact test. 
‡ Fisher’s procedure was used for combining the P values for anti-CCP–negative RA in the Dutch and Swedish data 
sets. P values for the Swedish anti-CCP–negative patients are shown in Table 1. 
§ EasyMA 2001 software was used for the pooled analysis, using the Mantel-Haenszel test to calculate ORs. 
 
The strongest evidence of association with RA in the Swedish cohort was observed for the IRF5 
SNP rs3807306. This SNP is in relatively high linkage disequilibrium with SNP rs2004640 
(Figure 1), which is associated with SLE, and the minor alleles of these 2 SNPs are on the same 
protective haplotype in both SLE and RA. To test for phenotypic similarities between SLE and 
anti-CCP–negative RA, we measured ANAs, which are characteristic of SLE, in a subgroup of 
385 RA patients and 100 age- and sex-matched controls from the EIRA cohort. We noted an 
increased frequency of ANAs in the RA patient samples (78 of 385) compared with the healthy 
control sera (5 of 100) (P = 0.0005), but there was no difference between anti-CCP–positive and 
anti-CCP–negative RA patients with respect to the frequency or staining intensity of ANAs (data 
not shown). 
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Discussion 
The data presented here provide strong evidence of an association between IRF-5 gene 
variants and RA, and show that the IFN pathway can be involved in this disease. Interestingly, 
in both the Swedish and Dutch cohorts we detected the most significant association with the 
IRF5 SNPs in the subgroup of anti-CCP–negative RA patients, which constituted approximately 
one-third of the RA patient population. Previously, no gene, with the exception of the HLA–DR3 
allele (17,40), has been found to be exclusively associated with anti-CCP–negative RA. This is 
particularly important because the pathogenesis of anti-CCP–negative disease is poorly 
understood, and specific drugs for this subset of patients with RA are lacking. 
 Other genes that have displayed an association with RA, such as the shared epitope alleles 
(17) and the PTPN22 gene (18), are associated with anti-CCP–positive RA. Anti-CCP–positive 
and anti-CCP–negative RA patients have clinically similar phenotypes at diagnosis, but can 
differ with respect to the course of the disease, and anti-CCP–negative RA patients usually 
develop a milder form of the disease (41). The results of the present study further support the 
notion that genetic background is important in the differences observed between anti-CCP–
positive and anti-CCP–negative RA. 
The relevant SNPs are located in or close to the first intron of the IRF-5 gene. This region 
contains a CpG island, which is an indication of regulatory activity, and several promoters, 
including one with an IFNstimulated response element site that is activated by type I IFN and 
one with an IRF element site that is activated by IRF-5 and IRF-1 (42). SNP rs2004640 is 
located in a 5' splice donor site of an alternate exon 1, and recent data indicate that there is an 
allele-specific effect of this SNP on the expression pattern of different isoforms of the IRF-5 
gene (8). 
Because IRF-5 is an important mediator of signals from TLR-7–TLR-9 (29,43), we speculate 
that certain expression patterns of the IRF-5 gene can modify IRF-5–dependent induction of 
type I IFN, proinflammatory cytokines (e.g., IL-6, TNF , IL-12, and IL-1!), and several 
chemokines (44,45). Furthermore, the level of TLR-7 expression is increased in RA synovium 
and can contribute to synergistic cytokine production by dendritic cells (46). These cytokines 
can obviously influence the development and expression of inflammatory diseases, both at the 
level of the underlying autoimmune process and by promoting the inflammatory process. 
However, IRF-5 can also increase the expression levels of several genes coding for proteins 
that mediate cell growth arrest and apoptosis (45). Consequently, polymorphisms within the 
IRF-5 gene may affect several cellular functions of importance for RA susceptibility, besides the 
type I IFNs. However, understanding the possible functions of the allele variants of the IRF-5 
gene on the molecular level requires further experimental studies. 
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The clear association of SNPs in the IRF-5 gene with anti-CCP–negative RA that we observed 
in the present study leads us to believe that the pathogenesis of this variant form of RA may be 
similar to the proposed pathogenesis of SLE that we described earlier (2). The findings of the 
present study suggest that future investigations of anti-CCP–negative RA should focus on the 
role of IFN , as well as on the role of environmental agents, such as infections, that may trigger 
IFN -related pathways. In a more general sense, the present clear demonstration of an 
association of an important non-MHC gene with anti-CCP–negative RA, but not with anti-CCP–
positive RA, provides further evidence that appropriate phenotyping of RA patients and inclusion 
of sufficiently large study cohorts are fundamental prerequisites for future genetic and functional 
studies.  
In summary, we now have evidence that in RA one set of genes and environmental triggers 
related to T cell activation and immune reactions against specific types of autoantigens 
(citrullinated proteins) is related to one subset of the disease, the anti-CCP–positive variant, 
whereas other sets of genes appear to be related to the other major subset of the disease, the 
anti-CCP–negative one. Thus, anti-CCP–positive RA and anti-CCP–negative RA should be 
considered as phenotypically distinct subsets of RA with respect to their genetic and 
environmental risk factors, as well as with respect to their molecular pathogenesis. In fact, we 
suggest that these subsets of RA should be regarded as 2 distinct diseases and treated as such 
in future studies.  
Addendum.  
After submission of this manuscript, reports of 2 studies showing no association between RA 
and 2 SNPs in the IRF-5 gene were published (47,48). The reasons for this seeming 
discrepancy could be related to the fact that the sizes of the cohorts used in the present study 
were larger and, perhaps more importantly, that patients in the present study were stratified 
according to anti-CCP antibody status.  
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Abstract 
To identify rheumatoid arthritis risk loci in European populations, we conducted a meta-analysis 
of two published genome-wide association (GWA) studies totaling 3,393 cases and 12,462 
controls1,2. We genotyped 31 top-ranked SNPs not previously associated with rheumatoid 
arthritis in an independent replication of 3,929 autoantibody-positive rheumatoid arthritis cases 
and 5,807 matched controls from eight separate collections. We identified a common variant at 
the CD40 gene locus (rs4810485, P = 0.0032 replication, P = 8.2 x 10-9 overall, OR = 0.87). 
Along with other associations near TRAF1 (refs. 2,3) and TNFAIP3 (refs. 4,5), this implies a 
central role for the CD40 signaling pathway in rheumatoid arthritis pathogenesis. We also 
identified association at the CCL21 gene locus (rs2812378, P = 0.00097 replication, P = 2.8 x 
10-7 overall), a gene involved in lymphocyte trafficking. Finally, we identified evidence of 
association at four additional gene loci: MMEL1-TNFRSF14 (rs3890745, P = 0.0035 replication, 
P = 1.1 x 10-7 overall), CDK6 (rs42041, P = 0.010 replication, P = 4.0 x 10-6 overall), PRKCQ 
(rs4750316, P = 0.0078 replication, P = 4.4 x 10-6 overall), and KIF5A-PIP4K2C (rs1678542, P = 
0.0026 replication, P = 8.8 x 10-8 overall). 
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Introduction 
Rheumatoid arthritis is a systemic autoimmune disease with intraarticular inflammation as a 
dominant feature that affects up to 1% of the population. It can be subdivided clinically by the 
presence or absence of autoantibodies (antibodies to cyclic citrullinated peptide (CCP) or 
rheumatoid factor (RF), both of which are highly correlated to each other). Previous genetic 
studies have identified and validated five risk loci for autoantibody-positive RA: multiple alleles 
within the MHC region (6); a missense allele in the PTPN22 gene (7); two alleles at the 6q23 
locus near the TNFAIP3 gene (4,5); and single alleles in the STAT4 locus (8) and TRAF1-C5 
loci (2). Additional alleles at 4q27 (ref. 9), CTLA4 (ref. 10) and PADI4 (ref. 11) have suggestive 
associations, but have not yet been widely replicated in individuals of European ancestry. 
To identify a collection of unbiased candidate rheumatoid arthritis risk loci for further 
investigation, we carried out a meta-analysis of SNP data from three case-control collections of 
European individuals from two published GWA studies1,2 (Table 1, see Methods for details). 
We investigated a common set of ~340,000 SNPs genotyped by the Wellcome Trust Case 
Control Consortium (WTCCC) with an Affymetrix 500K platform that (i) passed strict quality 
control criteria and (ii) were also present in the Phase II HapMap. 
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Table 1 Sample collections 
 
GWA data from three meta-analysis collections were used to identify candidate SNPs for replication. The replication 
set was divided into two stages: stage 1 replication (three collections) and stage 2 replication (five collections). For 
each collection we list the geographic origin, the source of the controls, the autoantibody status of cases, and the 
number of cases and controls. We also list the genotyping technology used to type SNPs of interest. Finally, we 
specify the strategy used to correct for case-control population stratification. 
 
We used the software package IMPUTE12 to determine genotypes of these SNPs in individuals 
from Sweden (Epidemiological Investigation of Rheumatoid Arthritis, EIRA) and North America 
(North American Rheumatoid Arthritis Consortium, NARAC) on the basis of available Illumina 
platform SNP data (Supplementary Fig. 1 online). To conduct a meta-analysis of SNP 
association with rheumatoid arthritis risk, we used the Cochran-Mantel-Haenszel (CMH) 
statistical test using genotype counts from the WTCCC and imputed probabilistic allele dosages 
in EIRA and NARAC. The CMH test allowed us to conduct a stratified analysis that maintained 
the three case-control collections as separate strata. CMH also allowed for further sub-
stratification of EIRA and NARAC individuals into more homogenous subgroups using identity-
by-state similarity for SNPs across the genome2 to correct for residual population stratification. 
This resulted in improved genomic control inflation for both EIRA ( GC = 1.03) and NARAC ( GC 
= 1.20). As there was little evidence of population stratification in the WTCCC ( GC = 1.06), we 
did not further substratify those individuals.  
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After calculating case-control CMH association statistics in the GWA meta-analysis, we 
observed minimal inflation for SNPs outside the MHC region ( GC = 1.09,  GC = 1.02 after 
normalizing to a 1,000 case and control collection, Supplementary Fig. 2 online). Thus, there 
was little evidence of bias due to technical artifact or population stratification. In Table 2 we 
present association statistics for validated and suggestive rheumatoid arthritis risk loci in 
European populations. Of the confirmed non-MHC risk loci, we observed association at 
PTPN22, 6q23/(containing TNFAIP3), STAT4 and TRAF1-C5. We also observed evidence of 
association at 4q27 (containing the IL2 and IL21 genes) and CTLA4, but not PADI4. The 4q27 
result is an independent replication, suggesting that this is a true-positive association. CTLA4 
replicates in the WTCCC (P = 0.026), providing further support for the role of this locus in 
rheumatoid arthritis, as suggested by previous studies in EIRA and NARAC10. 
 
Table 2 Meta-analysis results from regions previously associated with rheumatoid arthritis 
 
For each SNP, we identified the best proxy in our study and the calculated LD to that proxy on the basis of CEU 
HapMap (reported as r2). We present the w2 score and two-tailed P value in EIRA, NARAC and WTCCC, and in the 
meta-analysis. 
 
For each of the collections we further addressed potential case-control population stratification 
by either (i) using epidemiologically matched samples or (ii) matching cases and controls with 
ancestry informative genetic data; detailed strategies for each collection are described in the 
Supplementary Note online. 
Our replication collection consisted of eight independent casecontrol collections totaling 3,929 
autoantibody (either CCP or RF) positive rheumatoid arthritis cases and 5,807 matched 
controls, all self-described as white and of European ancestry (Table 1). The presence of CCP 
or RF autoantibodies assures specificity for the diagnosis of rheumatoid arthritis and helps to 
minimize clinical heterogeneity across the eight collections. For each of the collections we 
further addressed potential case-control population stratification by either (i) using 
epidemiologically matched samples or (ii) matching cases and controls with ancestry informative 
genetic data; detailed strategies for each collection are described in the Supplementary Note 
online. 
A total of 31 of these SNPs were successfully genotyped in all three stage 1 replication 
collections. The 17 most significant SNPs were genotyped in the stage 2 replication collections. 
For each SNP we calculated the replication P value using a one-tailed CMH statistic across the 
replication collections, and for those that replicated with P < 0.05, we calculated an overall P 
value (replication and the three meta-analysis collections) using a two-tailed CMH statistic. 
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Testing in our complete replication set identified rheumatoid arthritis–associated alleles (Table 3 
and Supplementary Tables 2 and 3 online). In replication genotyping, we observed that 6 out 
of31 SNPs obtained P   0.01; this is significantly more than expected by chance alone (P = 9 x 
10-7 by Poisson). Figure 1 illustrates the observed one-tailed CMH replication z scores, which 
clearly show that our results are enriched for z > 2 values (which corresponds to P < 0.023). 
Also, 4 of the 340,000 SNPs tested initially in the meta-analysis are associated with P < 5 x 10-7 
in joint analysis; this is also significantly more than expected by chance alone (P = 3 x 10-5 by 
Poisson). 
After excluding published risk loci (including those in the MHC region) and correcting for 
residual inflation by  GC, we found that 78 SNPs remained with possible associations at a P < 
10-4 threshold (Supplementary Table 1 online). These SNPs were grouped into 38 independent 
regions on the basis of pairwise linkage disequilibrium (LD) estimates derived from CEU 
HapMap (where SNPs were grouped together if r2 > 0.1). We tested the single most significant 
SNP from each region in a two-staged replication. 
Our replication collection consisted of eight independent casecontrol collections totaling 3,929 
autoantibody (either CCP or RF) positive rheumatoid arthritis cases and 5,807 matched 
controls, all self-described as white and of European ancestry (Table 1). The presence of CCP 
or RF autoantibodies assures specificity for the diagnosis of rheumatoid arthritis and helps to 
minimize clinical heterogeneity across the eight collections. 
 
 
Figure 1 Enrichment of SNPs with z scores 42 in replication samples. 
For each of the 31 SNPs tested, we calculated a one-sided CMH z-score statistic from our two-staged replication 
data. Results were calculated using either stage 1 replication samples only (n = 14 SNPs) or using both stage 1 and 
2 replication samples (n = 17 SNPs). A z score of 0 corresponds to a P value of 0.5, and a z score of 1.65 
corresponds to a P value of 0.05. For a random collection of unassociated SNPs, this histogram should approximate 
a normal distribution (dotted line). 
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Table 3 Newly identified SNPs associated with rheumatoid arthritis susceptibility 
We list results of 6 SNPs (out of 31 tested) that replicated with P   0.01. The first six columns list SNP characteristics. 
The next four columns list GWA meta-analysis results including allele frequencies, a two-tailed P value for SNP 
association, and an odds ratio. The next four columns list similar results for replication genotyping; significance is 
reported on the basis of a stratified one-tailed CMH statistic. The next two columns summarize joint (overall) analysis 
results. Significance is reported on the basis of a stratified two-tailed CMH statistic across all 11 sample collections. 
The final column lists the Breslow-Day test for heterogeneity of odds ratios across all 11 collections. 
 
One SNP, rs4810485 in the 20q13 region, surpasses a conservative level of significance in joint 
analysis (P = 8.2 x 10-9) and thus represents a confirmed rheumatoid arthritis risk variant (Fig. 
2). This SNP is located in the second intron of CD40 and is within an LD block that contains a 
large portion of the CD40 gene and its 5’ intergenic region. A SNP in near-perfect LD with 
rs4810485 (r2 = 0.95, rs1883832) has been associated with autoimmune thyroid disease13, 
although the association has not been confirmed unequivocally14,15. The same allele contributes 
to risk in both diseases. The rs1883832 variant has been shown to influence the efficiency of 
CD40 protein translation by disrupting a Kozak sequence13. The CD40 protein is expressed on 
the surface of multiple immune cells, including B cells, monocytes and dendritic cells, whereas 
its ligand, CD154, is expressed by activated CD4+ T cells. CD40-CD154 interactions play a 
pivotal role in provision of helper activity by CD4+ T cells in immune reactions including 
immunoglobulin class switching, memory B-cell development and germinal center formation16. 
Null mutations in CD40 are known to cause a rare B cell–dependent hyper-IgM 
immunodeficiency syndrome17.  
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Figure 2 CD40 region and association with rheumatoid 
arthritis. 
(a) Observed association within a 400-kb region 
surrounding the CD40 locus in meta-analysis of three 
GWA datasets. We plot the meta-analysis P value on the y 
axis versus genomic position on chromosome 20 on the x 
axis. Best associated SNP was rs4810485 (large red 
diamond). Other data points are shaded with increasing 
red intensity to suggest LD to rs4810485: dark red signifies 
r
2
   0.8, orange 0.8 > r
2
   0.5, gray 0.5> r
2
   0.2, and white 
r
2
 < 0.2. In two-tailed joint analysis including all 11 
collections, the SNP was strongly associated with risk of 
rheumatoid arthritis (P= 8.2 x 10
-9
, large blue diamond). 
Along the bottom of the figure we plot the recombination 
rate with the CEU HapMap (light blue line) and have 
indicated known human genes (black arrows). (b) The LD 
structure for a 200-kb region (indicated by dark blue bar 
along the x axis in a) surrounding the rs4810485 SNP (red 
arrow).. 
 
 
 
 
 
The rs4810485 SNP is located in the second intron of CD40. LD between SNPs is indicated by the redness of 
individual spots in the triangular graphic, the most intense red spots have a D’= 1. (c) Forest plot for rs4810485 
association across 11 collections. For each sample collection we plot the odds ratio (small diamond) and the 95% 
CI. A light dashed line indicates the final odds ratio across all collections. The top three bars (green) represent GWA 
data and the diamond below them summarizes their meta-analyzed effect. The next eight bars (red) represent 
replication data and the diamond below them summarizes their meta-analyzed effect. The final diamond at the 
bottom of the page (clear) represents the final meta-analysis odds ratio and the 95% CI for all 11 collections. 
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Figure 3 CCL21 region and association with rheumatoid 
arthritis. 
(a) Observed association in the 400-kb region 
surrounding the CCL21 locus in meta-analysis of three 
GWA datasets; plot characteristics are similar to those in 
Figure 2.  
 
Best associated SNP was rs2812378 (large red 
diamond). In two-tailed joint analysis including all 11 
collections this SNP was associated with rheumatoid 
arthritis at P =2.8x10
-7
  (large blue diamond). (b) The LD 
structure for a 200-kb region surrounding the rs2812378 
SNP (red arrow).  
The rs2812378 SNP is located close to the 5’ end of the 
CCL21. (c) Forest plot for rs2812378 association across 
11 collections. 
 
 
The rs2812378 SNP in the 9p13 region replicates convincingly (P = 0.00097) and has a highly 
suggestive level of significance with an overall P = 2.8 x 10-7 (Fig. 3). The SNP is located ~0.1 
kb from the 5’ untranslated region of the CCL21 gene, and is near a cluster of other genes 
including CCL19 and CCL27. However, it is in an LD block that fully includes the CCL21 coding 
sequence and not the other genes. The CCL21 protein is a chemokine that is involved in 
homing lymphocytes to secondary lymphoid organs. Expression of this chemokine is associated 
with ectopic lymphoid structures and has been implicated in the organization of lymphoid tissue 
affected by rheumatoid arthritis18.  
Most of the four other SNPs with P   0.01 in our combined stage 1 and 2 genotyping probably 
represent true rheumatoid arthritis susceptibility alleles, although additional validation in large 
sample collections is required. Of the four regions, each contains genes that are known to be 
critical to the immune system. The rs42041 SNP on chromosome 7 maps to a CDK6 intron; 
CDK6 is a ubiquitous cyclin-dependent kinase that regulates cell cycle progression, and it has 
been identified as a key mediator in the rapid proliferation of B cells and CD8 memory cells19,20. 
The rs1678542 SNP on chromosome 12 is ~20 kb away from the PIP4K2C locus, which has 
been implicated in signalling through the B-cell antigen receptor21. The rs3890745 SNP on 
chromosome 1 is ~60 kb away from TNFRSF14, which is similar to CD40 in that it is a member 
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of the TNF receptor super-family; it is known to bind TRAF family members including TRAF1 
and is involved in activation of the transcription factors NF- B and AP-1 (ref. 22). The 
rs4750316 SNP on chromosome 10 is ~100 kb away from the 3’ end of the PRKCQ gene, 
which encodes a kinase required for the activation of the transcription factors NF- B and AP-1, 
and may link the T-cell receptor signalling complex to the activation of the transcription factors23. 
A parallel UK study in this issue investigating the most significantly associated SNPs within the 
WTCCC study1 provides additional evidence for associations with rs4750316 (PRKCQ), 
rs1678542 (KIF5A-PIP4K2C) and rs10910099 (with r2 = 0.96 to rs3890745 in the MMEL1-
TNFRSF14 locus)24. 
Population stratification is unlikely to account for these observed effects, despite the modest 
effect sizes observed for rheumatoid arthritis risk (0.87 ! OR ! 1.12). We were careful to control 
for stratification individually in each of the meta-analysis GWA studies and also in each of the 
eight replication collections. Furthermore, the WTCCC collection contributed the greatest 
number of samples to the meta-analysis, and careful investigation across 12 subregions in the 
UK showed little evidence of case-control stratification1. Each of the associations presented 
here is notably significant in the WTCCC alone (P < 0.001). We found no evidence that different 
effects were present for these six loci across the five collections with genetically matched 
controls and the six collections with epidemiologically matched samples (Breslow-Day P > 0.31, 
Table 2). Technical artifact cannot explain the associations, as all SNPs passed strict quality 
control criteria (Supplementary Table 4 online). 
These associations provide strong evidence for the importance of the CD40 signaling pathway 
in autoantibody-positive rheumatoid arthritis. Our study implicates a putative functional variant 
that affects protein translation of the CD40 receptor. Established associations near TRAF1 and 
TNFAIP3 (also known as A20) already suggest the possibility that the CD40 signaling pathway 
mediates rheumatoid pathogenesis through NF-kB activation25, although the rheumatoid arthritis 
risk variants have not yet been proven to modulate function of these genes. In particular, TRAF1 
binds the CD40 receptor and cooperates with TRAF2 to activate NF- B26. TRAF1 also binds 
TNFAIP3, which is a negative regulator of NF- B signaling27. Furthermore, CD40 stimulation 
results in B-cell proliferation through regulation of CDK6 expression19. The CD40 signaling 
pathway has been investigated in drug development, and mouse models have demonstrated 
that its disruption could prevent development of immunemediated arthritis and diabetes28,29. 
In conclusion, our study has identified a rheumatoid arthritis–associated variant for European 
populations at the CD40 locus, provided strong evidence for association at the CCL21 locus, 
and also suggests association at four other loci. It also provides empirical data suggesting that 
additional common alleles with odds ratios ~1.15 remain to be discovered. Even under the 
assumption that all of these variants are true risk factors, their total percent variance explained 
is only 0.6% (Supplementary Note). In this study, we estimate that the total percent variance 
explained for all known non-MHC common genetic variants is just 3.6%. Considering that ~60% 
of rheumatoid arthritis risk is thought to be genetic, and one-third of this risk is from the MHC 
locus30, this indicates that less than half of genetic variation can be explained by the known 
rheumatoid arthritis risk alleles. One possibility is that there are other non-MHC common 
variants that have not yet been detected. All of the variants identified in our study have very 
modest effects and the rheumatoid arthritis case collections used in the meta-analysis were 
underpowered to screen for these effects at a modest level of significance (P < 10-4). For 
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example, assuming the observed odds ratios and allele frequencies, simulations show that the 
rs4810485 SNP in the CD40 gene only had a 53% chance of meeting the P < 10-4 significance 
criteria that we used to initially select SNPs. The other SNPs that replicate would have had only 
a 19–36% chance of being selected for further replication. Together, this suggests that other 
common alleles of modest effect size should be identified with additional GWA studies and 
deeper replication in large autoantibody-positive rheumatoid arthritis sample collections. 
Methods 
Subject groups 
Subject groups are described in detail in Table 1 and in the Supplementary Note. Subjects were 
subdivided into three separate sets: (i) meta-analysis set, (ii) stage 1 replication set, and (iii) 
stage 2 replication set. Each collection consisted only of individuals that were self-described 
white and of European descent, and all cases either met 1987 ACR diagnostic criteria or were 
diagnosed by board-certified rheumatologists. Informed consent was obtained from each 
individual, and the institutional review board at each collecting site approved the study.  
We used three subject groups to conduct the rheumatoid arthritis GWA meta-analysis. The 
groups used in the meta-analysis have been described elsewhere, and include those from the 
WTCCC, NARAC and EIRA. All of the cases in EIRA and NARAC and >80% of cases in 
WTCCC are CCP positive. For the WTCCC collection, we used an expanded collection of 
controls drawing from five non-autoimmune diseases that were genotyped as part of the larger 
study.  
We used eight subject groups in our replication set. These collections consisted entirely of 
cases that were autoantibody positive (CCP or RF). For most of the collections, control samples 
were collected along with case samples as part of the same study. For some of the collections, 
control samples were unavailable; we matched these case collections to publicly available 
shared controls that had been genotyped on compatible platforms. The stage 1 replication set 
consisted of three subject groups: (i) CCP- or RF-positive cases identified by chart review from 
the Nurses Health Study (NHS) and matched controls based on age, gender, menopausal 
status, and hormone use; (ii) CCPpositive cases from the Brigham Rheumatoid Arthritis 
Sequential Study (BRASS) and controls from the National Institutes of Mental Health (NIMH); 
and (iii) CCP-positive cases drawn from North American clinics and controls from the New York 
Cancer Project (together this collection is called NARAC-II). The stage 2 replication set 
consisted of five collections: (i) CCPpositive cases drawn from North American clinics (NARAC-
III) (P.K.G., unpublished data) and publicly available controls taken from a Parkinson’s study 
and study 66 and 67 of the Illumina Genotype Control Database; (ii) North American RF-positive 
cases and controls matched on gender, age and grandparental country of origin from the 
Genomics Collaborative Initiative;(iii) CCP- or RF-positive Dutch cases and controls from Leiden 
University Medical Center (LUMC); (iv) CCP-positive cases from Sweden and epidemiologically 
matched controls (EIRA-II); and (v) CCP-positive Dutch cases and controls collected from the 
greater Amsterdam region (GENRA).  
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Genotyping 
Detailed description of genotyping is provided in the Supplementary Note. All GWA meta-
analysis genotyping was previously described. We directly genotyped 38 SNPs in stage 1 
replication samples with the Sequenom iPlex platform at the Broad Institute (for NHS case-
control samples and BRASS case samples) and National Institutes of Health (for NARAC-II and 
NYCP samples). We obtained NIMH genotypes from previously generated GWA data on the 
Affymetrix 500K platform through a formal application process. We genotyped stage 2 
replication samples with (i) the Illumina 317K array at the Feinstein Institute (for the NARAC-III 
samples; unpublished data); (ii) using the kinetic PCR platform at Celera Diagnostics (for the 
GCI and LUMC samples); and (iii) with the Sequenom iPlex platform at the Broad Institute (for 
the EIRAII and AMC/UVA samples). We obtained publicly available genotype data for shared 
controls for NARAC-III cases after an official application to a Parkinson’s Disease consortium 
and Illumina Genotype Control Database. All stage 2 SNPs were directly genotyped in the GCI, 
LUMC, EIRA-II and GENRA samples, and individually imputed in NARAC-III case-control 
samples to determine genotype probability, as in our GWAS meta-analysis (see below).  
In stages 1 and 2 we required that each SNP pass the following criteria for each collection 
separately: (i) genotype missing rate <10%, (ii) minor allele frequency >1%, and (iii) Hardy-
Weinberg equilibrium with P > 10-3. We also excluded individuals with data missing for >10% of 
SNPs. Of the 38 SNPs advanced into stage 1, 6 SNPs failed genotyping in Sequenom iPlex at 
either the Broad or NIH, and 2 failed in the NIMH dataset. The remaining SNPs had <4% 
missing data for each collection. All 17 SNPs passed stage 2 replication in NARAC-III, 2 failed 
in GCI and LUMC, and 4 failed in EIRA-II and GENRA.  
Imputation and GWA meta-analysis 
We conducted a GWA meta-analysis on a set of SNPs genotyped in the WTCCC study 
(Supplementary Note). We selectedWTCCC SNPs on the basis of strict quality control criteria: 
(i) genotype missing rate <1% in cases and controls separately, (ii) minor allele frequency >1% 
in cases and controls separately, (iii) Hardy-Weinberg equilibrium with P > 10-4 by a 2 degree-
of-freedom test in cases and controls separately and (iv) availability of Phase II HapMap data. 
This resulted in a total of 336,721 SNPs. We imputed these SNPs in the EIRA and NARAC 
collections with IMPUTE. We used EIRA and NARAC data that had been filtered and imputed 
genotypes separately. We conducted separate runs for each chromosome using default 
parameters. As IMPUTE provides probabilistic confidence scores that track with prediction 
accuracy, we elected to use probabilistic dosages in our statistical analysis rather than hard 
genotype calls. This approach accounts for some uncertainty in imputation, and avoids bias. 
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To address case-control stratification we used identity-by-state to cluster EIRA cases and 
controls on the basis of Illumina 317K SNP data into 165 substrata, and then to cluster NARAC 
cases and controls similarly on the basis of Illumina 550K SNP data into 396 substrata. This 
strategy was identical to that used to effectively control stratification previously in this dataset. 
As previous investigations revealed minimal case-control stratification in the WTCCC data, we 
placed all cases and controls from the WTCCC into a single stratum.We calculated association 
statistics using genotype counts available online for the WTCCC (see URLs section below) and 
probabilistic allele dosages for EIRA and NARAC. We calculated a CMH 1 degree of freedom 
test on the basis of allele frequency across 562 strata, and then after correcting  2 scores by 
genomic control inflation (!GC), we assigned P values. 
Population stratification in replication samples.  
For each replication collection we corrected for possible case-control stratification by either (i) 
using only epidemiologically matched samples when cases and controls were drawn from the 
same population, or (ii) matching at least one control for each case on the basis of ancestry 
informative markers (see Supplementary Note for details). As the cases in the NHS, GCI, 
LUMC, EIRA-II and GENRA collections were well matched to controls, we did not pursue further 
strategies to correct for case-control stratification. For the BRASS, NARAC-II and NARAC-III 
collections, we matched cases and controls with ancestry informative markers and placed them 
into a single stratum. For the BRASS cases and NIMH controls, GWA data on Affymetrix 6.0 
(unpublished data) and Affymetrix 500K platforms were available, respectively. A total of 57,417 
SNPs overlapped both datasets that had 0% missing data across all individuals; we used these 
as SNPs to derive ancestry information. For NARAC-II cases and NYCP controls, cases and 
controls were matched using genotype data on 760 ancestry informative markers. Finally for the 
NARAC-III cases (unpublished data) and shared controls, we used available Illumina 317K 
GWA data for 269,771 SNPs passing stringent quality control criteria. For each case-control 
collection, we used these SNPs to define the top ten principal components and to remove 
genetically distinct outliers (" threshold = 6 with five iterations) with the software program 
EIGENSTRAT. We eliminated vectors that correlated with known structural variants on 
chromosomes 8 and 17, demonstrated minimal variation, or did not stratify cases and controls. 
After mapping cases and controls in the space of eigenvectors, we matched cases to controls 
that were nearest in Euclidean distance. A total of 814 of the available 1,498 NIMH controls 
were included (matching along the top two principal components), a total of 637 of the available 
1,153 NARAC-II controls were included (matching along the top principal component), and a 
total of 1,303 of the available 2,189 NARAC-III shared controls were included (matching along 
the top two principal components).  
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Stage 1 and 2 replication analysis  
We selected SNPs for replication by (i) identifying all SNPs that achieve P < 10-4 significance in 
meta-analysis, (ii) grouping SNPs with r2 < 0.1 into regions, and (iii) forwarding the SNP 
showing strongest association from each region for replication (Supplementary Note). We 
excluded SNPs from regions that had already demonstrated association in other studies. We 
forwarded 38 SNPs for stage 1 replication. The most significant SNPs from a preliminary 
statistical analysis conducted without correcting for possible case-control stratification were 
forwarded for stage 2 replication. For only those SNPs that replicated with P < 0.05, we 
genotyped EIRA samples and replaced imputed genotypes with genotype data for our final 
analysis (Supplementary Table 5 online). For each SNP we conducted three statistical tests. 
First, we conducted a onesided CMH statistical test across eight strata to assess whether 
rheumatoid arthritis association was reproducible in the replication collections in the same 
direction as the GWAS meta-analysis used to select the SNPs of interest. Second, we 
calculated a 570 strata joint analysis across all meta-analysis strata and substrata and 
replication strata; the eight replication collections were each placed into their own strata and the 
GWAS samples were partitioned into 562 strata, as described above. We considered P < 5 x 10-
8 as a reproducible level of significance. Third, we calculated a Breslow-Day test of 
heterogeneity of odds ratios. We performed all analyses in MATLAB. 
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Chapter 16 
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Rheumatoid arthritis is an autoimmune-disease with a prevalence of ~1% world wide. The 
etiology of RA is largely unknown; however it is thought that both genetic as well as 
environmental factors play a role in the pathogenesis of the disease. Genome wide association 
studies (GWAS) as well as candidate gene approaches have led to the association of a number 
of genetic susceptibility loci (1-7). The Wellcome Trust case-control consortium (WTCCC), the 
first GWAS in RA, identified a number of loci reaching genome-wide significance including the 
HLA-region and the PTPN22 gene (5). To identify new genetic risk factors, Thomson et al. 
investigated whether tier 2 single nucleotide polymorphisms (SNPs) (P=1x10-5-1x10-7) in the 
WTCCC-GWAS showed association with RA in an independent validation study of 5063 
patients and 3849 healthy controls(8). Of the nine loci investigated, significant association with 
rs6920220 in the TNFAIP3-OLIG3 region was identified (OR 1.23, 95%CI-1.15-1.33, P=1.1x10-
8). Association of RA with this region was independently identified by Plenge and coworkers (2) 
and a recent meta-analysis of GWAS data from three independent case-control populations of 
European descent confirmed these results(3). To further investigate these tier 2 SNPs, the 
control group of the validation study was enlarged from 3849 to 11487 individuals by including 
non-RA disease groups consisting of bipolar disorder, Type 2 Diabetes, hypertension and 
coronary artery disease(9). In addition to association with rs6920220, other statistically 
significant SNPs surfaced, located in MMEL1, IL2RA and IL2RB. Furthermore, investigation of 
forty-nine tier 3 loci (P=1x10-4-1x10-5) from the original WTCCC-GWAS, identified significant 
RA-associated SNPs located in PRKCQ and KIF5A (8). Three of these regions, encoding 
MMEL1, KIF5A and PRKCQ, were also identified in a large independent study of RA samples of 
European descent (3), suggesting that these regions harbor true RA susceptibility loci. 
In the present study we addressed the contribution of the two IL-2-pathway SNPs, specifically 
rs743777 located in IL2RB and rs2104286 in IL2RA, to RA risk in an independent Dutch case-
control study. This is of relevance, not only because additional replication would strengthen the 
putative contribution of IL-2-receptor-positive cells to RA, but also because only a trend towards 
association for the IL2RA SNP, was observed after correction for multiple testing using the 
Bonferroni-method (P<0.0056). 616 Dutch patients and 545 healthy, ethnically and 
geographically matched controls were genotyped by allele specific kinetic PCR as previously 
described(10). In this study, significant association with RA for both rs743777 and rs2104286 
was observed (OR 1.26, 95%CI 1.06-1.50, P=0.009; OR 0.81, 95%CI 0.67-0.98, P=0.026 
respectively) (Table1). Combining the data from our study with the UK data strengthened the 
evidence for association (rs743444: OR 1.12, 95%CI 1.06-1.18, P=8.6x10-6; rs2104286: OR 
0.92, 95%CI 0.87-0.97, P=1.2x10-3) (Table1). To bypass the phenomenon of the ‘winners 
curse’, in which effect sizes are often overestimated in the original study(13), we opted to 
analyze the data without the original WTCCC data to provide an estimate of the most likely 
effect size. In conclusion, this study provides additional evidence for the association of IL2RB 
and IL2RA with RA by independent replication in a Dutch population, underlining the importance 
of the IL-2 pathway in RA. Recently the IL2RA region was also found to be associated with 
other autoimmune diseases(11;12), specifically multiple sclerosis and type 1 diabetes, which 
suggests a possible common functional pathway. 
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Table 1. Analysis of rs743777 and rs2104286 with RA in two populations of northern-European descent. Allele 
frequency data of RA cases versus controls was compared using a fixed effects (Mantel-Haenszel) meta-analysis. No 
significant heterogeneity or deviation from Hardy-Weinberg (HW) equilibrium was observed among the studies. 
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Chapter 17 
 
 
 
 
Summary & Discussion 
Rheumatoid Arthritis (RA) is a complex disease with unknown etiology. Genetic as well as 
environmental risk factors are both thought to play a role in disease onset and/or progression1, 2.  
At the immunological level, the role of the adaptive immune system in autoimmune diseases is 
largely accepted. Based on both mouse models and data from human studies, it has become 
clear that T cells and B cells, amongst other immune cells, are likely to play a major role in RA. 
Examples of such studies include the clear role of T cells in the development of RA in the SKG 
mouse model where a mutation in the ZAP-70 molecule (a key signal transduction molecule in T 
cells) leads to spontaneous arthritis3. Additional evidence for the relevance of T cells in arthritis 
comes from the very strong association of the human leukocyte antigen (HLA) region with RA in 
human genetic studies4, 5. The products of the HLA-DRB1 alleles that associate the strongest 
with RA share a 5 amino-acid sequence in a peptide-binding pocket called Shared Epitope (SE). 
The prediction has been that these DRB1 molecules would bind and allow the presentation of 
RA inducing peptide(s) to T cells6. Although these peptides remain elusive, the well-established 
association of the SE with RA provides evidence of the role of T cells in RA development. 
However it is becoming increasingly clear that it is not simply a case of SE-positive alleles 
predisposing to disease. The presence of the SE alleles is highly correlated with the presence of 
autoantibodies indicating that SE alleles likely do not predispose to the development of the 
disease as such7, 8. Additionally, there may also be HLA-DRB1 protective alleles and also a 
number of other important associations to polymorphisms in this gene-rich region of the 
genome6, 9-11.  
The role of B cells in RA is highlighted by the presence of autoantibodies in patients. These 
autoantibodies including rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) 
have been consistently described12, 13. The emergence of ACPA years before onset of clinical 
symptoms indicates that it possibly lies in a causal pathway for the development of the disease 
although no conclusive evidence could be obtained from mouse models14. In 2006, Kuhn and 
colleagues showed that ACPA can exacerbate disease progression in a collagen-induced 
mouse model15. In 2009, a recent report suggests that these autoantibodies specific to 
citrullinated proteins do play a role in both the onset and progression of autoimmunity in the 
same mouse model16. However, it still takes years before clinical symptoms are apparent in 
patients who already harbour these autoantibodies, indicating that other genetic as well as non-
genetic factors likely play a role in the onset of the disease.    
Despite the rather large genetic component in RA (approximately 60%), it has been very difficult 
to identify the precise genetic markers responsible for the onset of the disease4, 17. The 
increased risk of disease in siblings of patients with RA compared with that of the general 
population ( s) has been estimated to be between 2 and 174. However, recent developments in 
genetics and genomics, heavily influenced by technological innovations, are overcoming the 
prior limitations within the field.  
Genetic variations are sometimes referred to as “polymorphisms”, meaning that the gene or 
locus (the gene region) occurs in several “forms” within the population. Most loci that are 
polymorphic have no direct influence on disease risk or human traits, while those that are 
associated with a difference in risk of disease or a human trait (however subtle) are termed 
“disease-associated polymorphisms”. Although the clinical significance and causality of these 
disease-associated polymorphisms are currently difficult to establish, these variations may 
account for a genetically susceptible individual predisposed to an aberrant immune profile, who, 
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combined with other non-genetic factors eventually develops diseases like RA18. In line with this 
concept, human genetic studies offer prima facie evidence that a biological pathway is critical in 
disease pathogenesis. Since there are no drugs yet proven to cure RA or other chronic 
inflammatory/autoimmune diseases, research into the principle mechanisms underlying the 
disease process are crucial for disease management, new diagnostics and ultimately cure. 
In advance of large-scale techniques, which have now become widely available, we took a 
hypothesis-driven approach to determine whether candidate genes, namely complement 
component 5 (C5) and interleukin 10 (IL10), both immune related genes, may be involved either 
in the development and/or progression of RA. This approach has been highly rewarding as 
exemplified identification of one of the few widely-confirmed genetic risk factors for RA, namely 
the Tumour Necrosis Factor (TNF) receptor associated factor 1 (TRAF1) – Complement 
component 5 (TRAF1/C5) locus on chromosome 9q33 (part I of this thesis) and by our 
functional characterization of the mRNA regulation at the interleukin 10 (IL10) locus (part II of 
this thesis). In part III, we have also investigated the role of several candidates in relation to 
disease as well as specific disease phenotypes. 
Genetic Risk factors in RA 
Prior to 2007, only two genetic risk factors had been identified. The first and most robust genetic 
risk factor to date was identified three decades ago and is confined to the HLA region on 
chromosome 64, 5. The second largest risk factor in RA, the protein tyrosine phosphatase non-
receptor type 22 (PTPN22) gene, was identified by using a largescale approach in 2004 and 
has now been widely replicated as an autoimmune locus19-22.  
In collaboration with our Swedish and American colleagues, we successfully identified a novel 
genetic risk factor in RA in 2007 in the 9q33 region of the genome containing TRAF1/C5 by 
taking a candidate gene approach (chapter 2)23.  Interestingly, this region was also concurrently 
detected in a genome-wide approach by Plenge and colleagues24. Although the original genome 
wide association study (GWAS) performed by the Wellcome Trust Case-Control Consortium 
(WTCCC) in 2000 patients and 3000 controls did not originally identify this locus, a follow-up 
post-genome study performed in the UK now also provides evidence of association at this 
region25, 26. 
Our data revealed that although the case–control allele frequency increase in different sample 
sets ranged from 4% to 9%, the frequency ranged from 38% to 46% in control groups of 
European ancestry. Data from HapMap (www.hapmap.org) support these observations with the 
G allele (minor allele in Caucasians) frequency of rs3761847 (perfect proxy of rs10818488) 
varying from 48% in Caucasians of European descent, 31% in Gujarati Indians in Texas, 42% in 
Japanese in Tokyo, 66% in Mexicans in Los Angeles, 59% in Yorubans in Nigeria and 74% in 
Luhya in Kenya. Given that association studies compare the frequencies in patients versus 
healthy individuals, unknown biases in control frequencies may lead to spurious associations. 
To address this issue and to further complement our data, we have also reproduced this 
association in 1356 individuals from 452 trio families with RA (chapter 3)27. Interestingly, an RA 
association of the opposite allele has been reported in the Japanese population but no 
association has been found in a Korean population, reflecting possible ethnic diversity in the 
associations at this locus28, 29. A more recent fine-mapping of this region now indicates that a 
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third gene, PHD finger protein 19 (PHF19), may be part of the haplotype block involved in 
disease susceptibility30. While TRAF1 and C5 being immune-related molecules represent ideal 
candidates as biological mediators in RA, relatively little is currently known about PHF19 to infer 
its possible role in the disease process. 
Our work has now also shown that the TRAF1/C5 region is not only relevant for RA but is also 
relevant in patients with a polyarticular form of juvenile arthritis (Odds ratio 1.46, p=0.004) 
(chapter 4)31. Behrens and colleagues have also independently reported an association of a 
perfect proxy to JIA further supporting our findings32. In recent years, several common variants 
associated with RA have been convincingly associated with multiple autoimmune diseases 
including the PTPN2233 and signal transducer and activator of transcription 4 (STAT4)34 genes.  
In line with these observations, one widely accepted pattern across the genes loci identified is 
the overlap of genetic risk factors across various autoimmune diseases. To test this hypothesis 
we investigated the TRAF1/C5 locus in a well-powered study including four additional 
autoimmune diseases including 735 Type I Diabetes (TID), 1049 Celiac Disease (CD), 367 
Systemic Sclerosis (SSc), 746 Systemic Lupus Erythematosus (SLE) patients and a common 
set of controls consisting of 3494 healthy individuals. In combination with the previously 
unpublished data from the SLEGEN consortium, we observe an overall association to SLE in 
1577 patients and 4215 healthy individuals (OR 1.22, p=1.02x10-6). We found suggestive 
evidence for T1D and did not observe any evidence of association to CD and SSc (chapter 5)35.  
With these studies, we have provided considerable evidence that the TRAF1/C5 region is not 
only relevant to RA but that the frequency of the same allele is increased in JIA and SLE. It is 
therefore highly likely that the TRAF1/C5 region is a genetic risk factor involved in a shared 
pathway underlying multiple autoimmune diseases. It now seems that most of the RA 
susceptibility loci identified so far have an association with other autoimmune diseases36.  
Interestingly, the association with SLE is absent in a well-powered Japanese case-control study 
and small study in the Columbian population37, 38. As with many genetic loci, it is highly likely 
that ethnic differences exist in the contribution of this locus to SLE. Since, TRAF1 is suggested 
to be a negative regulator of TNF-Receptor and/or CD40 signaling and C5 is a central 
component of the complement pathway and they are both highly involved in the immune 
system, they both represent likely candidates for further functional studies. Current efforts are 
geared towards the functional relevance of the genetic variants in the TRAF1/C5 region by 
determining the expression levels and function of each gene in primary lymphocytes from 
healthy individuals to tease apart the influence of these genetic variants on biological function.  
In addition to the identification of the TRAF1/C5 locus, the year 2007 saw the discovery and 
replication of two additional risk loci, more than doubling the number of genes known to play a 
role in RA39. The STAT4 gene region on chromosome 2q was identified following a mapping of 
genes under a linkage peak and so far represents the only linkage study to have successfully 
pinpointed the gene of interest in RA in Caucasians40. The other locus, identified by the WTCCC 
as well as Plenge and colleagues using a genome wide association study (GWAS) with 100,000 
markers is located on chromosome 6q23 and encompasses a very interesting candidate gene 
TNF-  induced protein 3 (TNFAIP3)25, 41.  
Unprecedented progress however has been witnessed in 2008 when a meta-analysis of three 
genome-wide association studies from the US, Sweden and the UK was performed (chapter 
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15)42. Comprised of 3,393 patients who were predominantly ACPA positive and 12,460 healthy 
individuals, our study enabled the confirmation of previously associated RA loci (HLA, PTPN22, 
TRAF1/C5, STAT4 and 6q23 containing TNFAIP3)39 and also provided suggestive evidence 
towards previous associations with Cytotoxic T Lymphocyte associated 4 (CTLA4) and 
interleukin 2/interleukin 21 (IL2/21)43, 44. By genotyping these variants in our Dutch cohort, we 
have now independently replicated three of these loci (STAT4, IL2/21 and CTLA4) in the Dutch 
population further confirming the suggested role of IL2/21 and CTLA4 in RA (chapter 12)45. It is 
of note to mention that an overall estimate of the effect size of the CTLA4 locus results in an 
odds ratio of ~1.10, highlighting that lack of power of most previous studies is the likely culprit in 
the controversy of this locus in RA over the past few years. Both IL2/21 and CTLA4 have now 
been reported in a large UK cohort36. In addition, our data also provides evidence of the 
association of IL2/21 in juvenile arthritis (chapter 13)46. 
The above-mentioned meta-analysis of three GWAS of European-ancestry populations 
identified 31 regions of interest outside of the known RA risk loci (P<10-4). Following replication 
in 3,929 autoantibody positive individuals (ACPA and/or RF) and 5,807 matched controls, six 
additional loci were identified with the most significant finding localized in the CD40 gene region, 
more recently complemented by independent replication47. The five additional signals were 
found in regions harboring the following genes, membrane metallo-endopeptidase-like 1-Tumor 
necrosis factor receptor superfamily member 14-TNF receptor superfamily 14 (MMEL1-
TNFRSF14), cyclin-dependent kinase 6 (CDK6), Chemokine (C-C motif) ligand 21(CCL21), 
Protein kinase C theta (PRKCQ), and Kinesin family member 5A- Phosphatidylinositol-5-
phosphate 4-kinase type II gamma (KIF5A-PIP4K2C). A parallel study investigating suggestive 
hits from the WTCCC study provides additional evidence for associations with PRKCQ, KIF5A-
PIP4K2C and MMEL1-TNFRSF14 regions in an independent UK sample set48. Despite the fact 
that CDK6 and CCL21 have not as yet been independently replicated by other groups, recent 
data from our group suggests that CDK6 predisposes to a more severe disease course in ACPA 
positive patients (Manuscript in Press,A&R). However, additional replication from independent 
groups will be required to establish whether the CDK6 and CCL21 regions are genuine RA loci. 
Interestingly a recent UK study provides suggestive evidence for CCL21 but no association with 
CDK647. Barton and colleagues have also suggested a possible role of IL2RA and IL2RB48. We 
have now confirmed these two loci in our independent Dutch sample set (chapter 16) leading to 
a three-fold increase in the number of RA risk loci in 2008 (Table 1). It will be highly relevant to 
determine whether gene-gene or gene-environment exists among these loci. 
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Table 1. Non-HLA susceptibility genes for RA 
Gene locus Chromosomal region Year of confirmation Method of identification
PTPN22 1p13 2004 Largescale missense SNP screen
TRAF1-C5 9q33 2007 Candidate Gene Study, GWAS
STAT4 2q33 2007 Linkage
TNFAIP3-OLIG3 6q23 2007 GWAS
IL2-IL21 4q27 2008 Candidate Gene Study
CTLA4 2q33 2008 Candidate Gene Study
CD40 20q13 2008 GWAS
MMEL1-TNFRSF14 1p36 2008 GWAS
KIF5A 12q13 2008 GWAS
PRKCQ 10p15 2008 GWAS
CCL21 9p13 - GWAS
CDK6 7q21 - GWAS
IL2RA 10p15 2008 GWAS
IL2RB 22q13 2008 GWAS  
Genetic risk factors in phenotypes of RA 
RA, which remains a clinical diagnosis based on classification criteria, is most likely not a single 
entity. This point has been clearly illustrated by dichotomy of ACPA-positive versus ACPA-
negative RA with the disease course being more severe in ACPA-positive individuals as 
compared to ACPA-negative individuals49. From a genetic perspective, loci identified seem to 
also differ between these two disease categories. For example, HLA SE alleles seem to 
predispose to the development of these autoantibodies themselves while the PTPN22 locus 
predominantly predisposes to the development of ACPA-positive disease7, 50. However, most 
studies have so far been underpowered to detect a conclusive distinctive pattern between the 
two subgroups. The HLA-DR3 alleles have been consistently associated with ACPA-negative 
RA51, 52. Similar associations have now been suggested for the interferon regulatory factor 5 
(IRF5) locus, a gene region identified as a risk factor for SLE. In our studies we have shown that 
IRF5 has a stronger association with ACPA-negative disease (chapter 14), a finding which is 
also supported by a recent report by Eguez-Gonzalez and colleagues53, 54. A recent report 
suggests a considerable genetic component in the development of ACPA-negative RA as well55. 
It is therefore anticipated that with increasing collaborations between groups this particular 
question can be addressed with relative ease in the near future.  
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From these studies it is clear that multiple loci of modest effect are involved in the onset of RA. 
However, despite our understanding that the subclassification of RA patients based on their 
autoantibody profile results in a more homogeneous subgroup, RA remains a syndrome 
comprising several phenotypes. For example, following diagnosis of early RA, approximately 
10% of patients undergo natural remission while others develop either mild or severe joint 
damage over time56.   
Data linking newly identified genetic polymorphisms to disease outcome in RA are only 
beginning to emerge. Since the early arthritis cohort in Leiden possesses a wealth of 
information on these particular disease phenotypes, we can ask the clinically relevant question 
regarding genetic loci that associate with remission as well as severity of joint damage. One of 
the interesting candidates that has been consistently investigated in radiographic damage in RA 
is the TNF-  locus. Historically, this cytokine has been of high relevance in RA with TNF-  
blockers in use for years already57. However at a genetic level, several inconsistent reports exist 
between this locus and both the susceptibility and severity of RA. Recent GWAS have not 
identified this region as a susceptibility factor for RA and our recent investigation reveals that it 
does not predispose to a more severe disease course after stratification for autoantibody status 
(chapter 10)42, 58. This is most likely due to the linkage disequilibrium between TNF-  and HLA-
DR3 with the latter being highly correlated to ACPA-negative RA generally following a less 
severe disease course.  
More recently we have highlighted the relevance of taking into account these disease 
phenotypes in genetic studies of RA (chapter 11). Two SNPs on chromosome 6q23 near 
TNFAIP3 have been associated with susceptibility to rheumatoid arthritis (RA)25, 41, 59. While the 
initial associations were detected in patients with long-standing RA, no association was found in 
a Swedish early arthritis cohort. Since these sample sets are well controlled for population 
stratification issues, a likely explanation for this discordance could be the overrepresentation of 
patients with severe disease in cohorts with long-standing RA. To this end, we analyzed the 
effect of the 6q23 region (TNFAIP3) on the rate of joint destruction in our early arthritis cohort 
with a mean duration of follow-up of 5 years. Our data are unique as they cover a long period of 
radiographic follow-up and have been scrutinized for artefacts such as secular trends in 
treatment intensity. Albeit based on relatively low patient numbers, our data suggest a 
contribution of the 6q23 region to the rate of joint destruction in ACPA-positive RA, thereby 
further refining our understanding of the effects exerted by this locus. Replication of our findings 
in other cohorts is needed. Nonetheless, this is the first study demonstrating such an effect for 
genetic polymorphisms located outside the HLA-region in ACPA-positive RA patients. More 
recently, one additional independent protective allele has been described at this locus and 
requires further confirmation60. It would be highly relevant to investigate this additional signal in 
relation to the joint damage of RA patients.  
In part II of this thesis, we have also revisited an old cytokine, repeatedly suggested to be 
associated with radiographic progression in RA. IL10 is a cytokine with key regulatory and anti-
inflammatory function involved in the pathogenesis of various diseases61-64. Although the large 
interindividual differences in the production of IL10 have been extensively associated with 
polymorphisms and haplotypes of the IL10 gene, surprisingly little evidence existed that this 
variation was actually dictated by IL10 haplotypes65.  
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Using the technique of allele-specific transcript quantification, the ratio between two alleles (A 
and G) of the IL10 gene was characterized in 15 healthy heterozygous individuals. Two groups 
were identified whereby donors in group 1 exhibited a 1:1 ratio, whereas those in group 2 
exhibited a ratio>1 (P<0.0017). We found that donors heterozygous for haplotype IL10.2 (one of 
the four ancient IL10 haplotypes) were only prevalent in the group that showed higher allelic 
expression ratios. In our study we show that IL10 alleles are indeed differentially transcribed in 
cells from heterozygous individuals and that IL10 haplotypes dictate production of IL10. These 
findings showed, for the first time, that interindividual differences in IL10 protein levels could be 
partially explained at the allele-specific transcriptional level (chapter 7)65. More recently, 
Sharma and colleagues have reported the post-transcriptional regulation of IL10 via the binding 
of microRNA hsa-miR-106a to the 3’ UTR in several cell lines66. It would be interesting to 
determine whether this microRNA has an allele-specific effect in primary cells and whether this 
post-transcriptional regulation of IL10 is functionally relevant in diseases like RA. 
In a previous study, an increased risk of familial osteoarthritis (OA) at multiple site was detected  
in subjects with a low innate production of IL10 as measured by the same ex vivo whole blood 
assay using lipopolysaccharide stimulation as in several other studies67, 68. This finding 
implicating IL10 in cartilage destruction led us to investigate whether genetic variation in IL10 
contributes to the susceptibility of OA (chapter 6). Our study has failed to detect those 
differences. However, due to the highly limited power of the study, we can only preclude a large 
effect size of this locus in the development of osteoarthritis. To enable more conclusive results 
with regards to modest effect sizes, more extensive studies with larger sample sizes will have to 
be conducted.   
In RA, the -A2849G (rs6703630), an IL10 promoter SNP, was shown to be associated with 
differences in titres of autoantibodies (RF and ACPA). Moreover the rate of joint destruction in 
RA patients from the early arthritis cohort was twice as high in patients that were –2849G carrier 
to those who were not (median rate per year 8 versus 4 Sharp van der Heijde units on X-rays of 
hand and feet)69. However, none of the known IL10 promoter polymorphisms alone could be a 
causal variant as shown from our functional study. A more likely possibility of causal mutations 
is either unknown or untyped SNP(s) located on haplotype IL10.2. As the length of the 
haplotype block around IL10 is highly relevant to the search for the functional polymorphism(s), 
we characterized the level of linkage disequilibrium in a region of 217 kb, encompassing IL10 as 
well as its neighbouring homologues (IL19, IL20 and IL24). We successfully excluded the 
neighboring genes as potential candidates for harboring the functional cis-acting variants 
(chapter 8)70. We further fine-mapped the immediate IL10 region by genotyping 43 SNPs in 57 
healthy unrelated individuals of European descent. One haplotype block was identified restricted 
to 17 kb encompassing the coding region of the IL10 gene (5kb) as well as 5’and 3’ untranslated 
regions. HapMap data showed similar linkage disequilibrium patterns. Six tagging SNPs, 
explaining 93% of the variation in the IL10 region were identified in our study. We have now 
genotyped these SNPs in our extensive and clinically well-defined RA cohort to determine their 
relevance to phenotypes of RA. However, our data show no significant differences in the rate of 
joint damage and remission with respect to the IL10 genotypes and haplotypes irrespective of 
their ACPA status (chapter 9). These data suggest that IL10 polymorphisms most likely do not 
play a major role in phenotypes of R 
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More recently however, a GWAS in ulcerative colitis and a meta-analysis of T1D GWAS has 
identified a signal in the IL10 gene (rs3024505) located in the 3’ UTR71, 72. Unfortunately, this 
polymorphism was not tagged in our fine-mapping approach. While it is clear from the lack of 
association of this region in the recent GWAS meta-analysis that IL10 most likely does not 
predispose to the development of RA as such, it remains important to perform a more extensive 
sequencing and genotyping effort of this region to definitively exclude any potential role of this 
locus in RA phenotype. 
Translating genetic findings into functionally relevant pathways 
One common theme across most loci identified is the fact that most loci either contain multiple 
genes or they are located in regions devoid of any known genes. However, most loci do harbor 
at least one candidate gene involved in immune function and thereby do provide important 
information in potential biological processes. For example, in RA the role of T and B cell 
functions in general have been highlighted as well as a significant indication of the involvement 
of the NF-kB signalling pathway. The genes involved in those pathways are discussed below. 
We believe that many of the proteins encoded by these genes either represent drug targets that 
have been or will be of high therapeutic potential in the near future. Given the overlap of genetic 
risk factors across various autoimmune genes, these drug targets may prove useful for more 
than one disease entity18, 73.  I have attempted to outline the potential biological relevance of the 
genetic regions identified by the likely candidates in each region as we know it now but fully 
aware that this landscape is rapidly evolving.  
T cell function 
The strongest genetic risk factor for RA is the SE alleles from the HLA locus. Activation of the T 
cell occurs via the engagement of the T cell receptor (TCR) and CD28 on the T cell to the HLA-
complex presenting the specific peptides as well as the B7 molecules. In these initial steps, 
PRCKQ, also known as protein kinase C theta (PKC ) and involved in the phosphorylation of a 
wide variety of protein targets may play an essential role in relocating to the immunological 
synapse between the T cell and the antigen-presenting cell (APC) during antigen specific 
interactions74, 75. PTPN22, the second strongest genetic risk factor in RA, is involved in 
regulating the threshold of T cell activation through increased phosphatase activity of 
downstream proteins that associate with the TCR21. CTLA4 is known to compete with CD28 to 
limit the extent of T cell activation76, 77. Once a T cell is activated, IL2RA is induced, enabling the 
trimerisation of the IL2RA, IL2RB and IL2RG to form the high affinity IL2 receptor78. IL2 binds 
this receptor and through further downstream signaling enhances the proliferation and survival 
of T cells79. Interestingly, STAT4 and IL21 are involved in T helper 1 and T helper 17 cells, 
which are T cell lineages involved in inflammatory reactions80-82. IL21 as well as CDK6 also 
seem to play a role in the proliferation of activated T cells83, 84. More importantly, in the last 
couple of years, a key role for IL21 in the differentiation of B cells into antibody secreting cells 
has been reported as a result of T-B cell interaction85-87. Interestingly, CCL21 is also a molecule 
involved in the homing of lymphocytes to secondary lymphoid organs88. Expression of this 
chemokine is associated with ectopic lymphoid structures and has been implicated in the 
organization of lymphoid tissue affected by rheumatoid arthritis89. 
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Taken together, it seems that these genetic risk factors now identified in RA play a crucial role in 
the regulation of T cell receptor activation and proliferation, migration as well as differentiation of 
T cells. It will therefore be interesting to determine how these genetic variations alter their 
respective gene functions. In the case of PTPN22, strong indications already exist that the 
susceptibility allele results in a higher threshold of T cell activation which may reduce the 
negative selection of autoreactive T cells in the thymus22. In line with these findings and the fact 
that T cells may play a more regulatory role by providing help for the activation of B cells, it is 
not surprising that therapies targeted towards T cells have so far not been proven to be highly 
effective in RA patients90. However, gaining insight into the biological implications will inevitably 
lead to a better understanding of disease processes. 
B cell function 
B cells are an integral part of our immune system which is geared towards responses against 
invading antigens. The genes identified by human genetic studies have now also highlighted a 
role of certain molecules that play an important role in the activation of B cells through the 
regulation of both the B cell receptor (BCR) function as well as the second signal required to 
activate B cells i.e the CD40 signalling cascade. In addition to its role in the increased threshold 
for T cell activation, the PTPN22 susceptibility allele has recently been implicated in the 
reduction of BCR signaling91, 92. Associations near TRAF1, TNFAIP3 (A20) and CD40 itself 
already suggest the possibility that the CD40 signaling pathway mediates rheumatoid 
pathogenesis through NF-kB activation93. In particular, TRAF1 binds the CD40 receptor and 
cooperates with TRAF2 to activate NF-kB94-97. TRAF1 also binds TNFAIP3, which is a negative 
regulator of NF-kB signaling98, 99. Furthermore, CD40 stimulation results in B cell proliferation 
through regulation of CDK6 expression100. The CD40 signaling pathway has been investigated 
in drug development, and mouse models have demonstrated that its disruption could prevent 
development of immune-mediated arthritis101. In addition, the production of RF autoantibodies 
have been shown to be dependent on CD40 signalling102. More recently, the NF-kB family of 
transcription factors (also known as REL) has been implicated in RA by an extensive GWAS 
performed by Gregersen and colleagues103. The various members of REL are c-Rel, p65 (Rel-
A), Rel-B, p50 (NFkB-1) and p52 (NFkB-2) and they have been shown to play important roles in 
immune responses and autoimmunity104. Notably, c-Rel has been reported to physically interact 
with nuclear CD40 and results in the transcriptional regulation of several target genes105. These 
data further uphold the crucial role of the NFkB pathway as well as the CD40 pathway in RA. 
Another potential role of the TNF receptor superfamily has been highlighted by the identification 
of TNFRSF14, the cytoplasmic region of which was found to bind to several TRAF family 
members, which may mediate the signal transduction pathways that activate the immune 
response106.   Although the specific functions of phosphatylinositol 4 phosphate 5 kinase type II 
, PIP4K2C, remain largely uncharacterized, it is known that it forms part of a family of kinases 
which are also thought to play a role in the phosphorylation of proteins downstream of the TNF-
receptor signaling cascade107, 108. The protein is found in sera from RA patients as well as 
healthy individuals109.  
In addition to its function as a homing signal for T cells to the lymph nodes, it has been 
suggested that CCL21 may also play a role in B cells as it is the high-affinity ligand for CCR7, a 
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molecule also expressed by B cells, although its precise role in these cells remain to be 
investigated thoroughly88.  
Taken together, the genes identified seem to play important roles in B cell function, either by 
regulating the first signal which is the BCR activation or by affecting the second signal which is 
the signaling cascade resulting from TNF-receptor signaling, in particular via the CD40 receptor.  
Altogether, several processes have been highlighted involving antigen recognition, lymphocyte 
migration, receptor activation, cell fate of T and B cells and NFkB signaling. While the 
identification of these genetic risk factors have provided considerable insight into the crucial role 
of the adaptive immune system in RA, we realize that much work lies ahead in the identification 
of the actual causal variants through sequencing, fine-mapping and functional experiments.  
The next step 
Common Variants 
While pinpointing these gene regions has been a monumental advancement on our previous 
knowledge of genetic risk factors for RA, the exact common causal mutation(s) is not known for 
most of these genetic regions. It is therefore paramount to now take steps to characterize the 
regions of association in more detail, especially since only one out of three common 
polymorphisms in the human genome have so far been identified110, 111. Additionally, recent 
studies have highlighted the existence of multiple signals at one locus indicating the complexity 
of associations with disease. One particular example in RA are the multiple alleles at the 
TNFAIP3 locus which shows complex haplotypic associations41, 59, 60 . To resolve these issues 
across loci identified in RA, we will need to sequence all the regions identified to capture all 
unknown variations, followed by an in-depth evaluation of association signals conferred by 
these polymorphisms. Undoubtedly, applying this strategy across multiple autoimmune diseases 
as well diverse ethnic populations will be invaluable tools in identifying causal alleles and 
understanding pathways. 
Rare variants 
The entirety of RA susceptibility variants identified so far does not explain the entire genetic 
burden of RA, indicating that more remain to be discovered. While current studies in RA are 
biased towards common variants, increasing evidence points towards the relevance of rare 
mutations in other complex diseases.  Examples of such rare variants influencing common traits 
exists in Systemic Lupus Erythematosus (TREX1)112, Inflammatory Bowel Disease (NOD2 and 
IL23R)113-115, disorders of cholesterol metabolism (PCSK9, ANGPTL4, among others)116-119 and 
deregulated blood pressure levels (SLC12A3, SLC12A1 and KCNJ1)120. Notably, numerous 
examples of non-RA genes exist containing both common mutations of small effect size 
together with independent rare functional mutations of larger effect size.  The most compelling 
example includes the rare gain- and loss-of-function missense mutations in PCSK9 which cause 
deregulated levels of cholesterol while common PCSK9 variants reproducibly associate with 
plasma LDL cholesterol levels116, 121, 122. An additional 18 loci containing common variants 
influencing levels of LDL/HDL cholesterol and/or triglycerides was recently reported123. 
Strikingly, rare variants at 9 of these loci have been shown to cause rare Mendelian forms of 
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dyslipidemia. It is therefore likely that rare mutations contributing to the RA phenotype exist and 
contribute significantly towards disease pathogenesis. To enable their discovery, sequencing of 
exon-coding regions in thousands of patients and controls will be required. Compared with 
common variants, the technologies to detect these rare variants, termed next-generation 
sequencing, have only recently become available. Hence, our ability to assay them reliably is 
still maturing but holds great promise for future investigations of our complex genome124-126. 
Structural variations 
Unlike single nucleotide polymorphisms, structural variations have largely been ignored in the 
genetic mapping of common diseases. Although these have been historically difficult to assay 
until recently, sequencing of several human genomes have now revealed that they comprise 
over 20% of genetic variants in the human genome127. According to Frazer and colleagues, 
structural variation refers to all base pairs that differ between individuals and that are not single 
nucleotide variants. These variations include insertion–deletions (indels), block substitutions, 
inversions of DNA sequences and copy number differences. Interestingly, recent studies that 
have looked for associations between rare structural variants and autism and schizophrenia 
have identified specific deletions involved in both of these diseases128-130. Additionally, recent 
technological developments have also generated the possibility of interrogating the genome for 
copy number variation in disease131. Copy numbers in Fc gamma receptor genes have been 
implicated in SLE as well as RA132, 133. We therefore expect that the coming years will provide 
insight into the relevance of these structural variations in RA and hopefully explain some of the 
large proportion of the genetic variance in this disease that remains unexplained.  
Functional characterization of both common and rare variants 
The next frontier lies in the functional characterization of the myriad of sequence variations that 
influence disease susceptibility. For common variants as well as rare variants, most focus will 
likely be on candidate protein coding genes and their putative regulatory regions. Experiments 
are currently being conducted that simultaneously assay global gene expression and genome-
wide variation in a large number of individuals to map genetic factors underlying differences in 
expression levels134. While these data sets may undoubtedly be valuable tools for identifying the 
causative variants and biological bases for many loci associated with a complex trait, they will 
primarily serve as a prioritization tool for candidate genes and will aid in the hypothesis-
generating exercise prior to functional testing. In my opinion, each gene region will require tailor-
made experiments in the relevant cell-types to enable a successful translation of genetic 
findings to biology. Additionally, since each region often encompasses large regions of linkage 
disequilibrium, there is every possibility that many of these variations will alter the interactions 
between regulatory (non-coding) RNAs and their targets, a prospect that should not be excluded 
from future functional analyses135. 
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Shared genetic risk factors across diseases and phenotypes – a powerful tool 
While sequencing, fine-mapping and identifying common and rare functional variants in RA are 
the obvious steps the genetic community needs to take, there is one theme in common 
diseases that can immensely enrich our understanding of the pathways underlying disease. A 
recent review by Zhernakova and colleagues has recently highlighted the importance of 
investigating which genetic risk factors are shared by several immune-mediated diseases. The 
authors investigated genes involved in ankylosing spondylitis, asthma, Graves’ disease, celiac 
disease, Crohn’s disease, multiple sclerosis, psoriasis, RA, SLE, type 1 diabetes, and ulcerative 
colitis and observed that the most likely function of the shared genes were two common 
pathways involving T cell differentiation and signaling as well as the innate immune response73.  
In addition, a study performed by Smyth and colleagues has highlighted common as well as 
distinct genetic risk factors between type 1 diabetes and celiac disease136. Of the fifteen 
previously validated susceptibility alleles in type 1 diabetes, at least two contributed to a risk of 
celiac disease with five showing highly suggestive associations. Interestingly two shared alleles 
actually had opposite effects in the two diseases: the minor alleles of IL18RAP on chromosome 
2q12 and TAGAP on chromosome 6q25 conferred protection against type 1 diabetes but 
susceptibility to celiac disease. The authors suggest that common biologic mechanisms, such 
as autoimmunity related tissue damage and intolerance to dietary antigens may be etiologic 
features of both diseases.  
The concept of shared autoimmunity is now well-established and represents an opportunity not 
only to study which mechanisms are relevant to several diseases but also which phenotype of a 
particular disease may have distinct or common pathways. In RA, most of the genetic loci also 
associate with at least one other autoimmune disease, implying that once a systematic search 
for these loci has been performed in other immune-related conditions, we can begin to dissect 
the various overlapping and common mechanisms involved. More recently, suggestions have 
been made for a multi-step process involving the study of risk factors for specific common sub-
phenotypes in diseases, the study of isolated subphenotypes as well as a meta-analysis of 
these to maximize statistical power in fine-mapping efforts (Huizinga and Grondal, in press at 
A&R). Therefore combining datasets with well defined phenotypes of each disease may lead to 
new understanding of disease pathogenesis.         
In summary, the advent of technological advances enabling the study of hundreds of thousands 
of markers across the genome in thousands of cases and controls has significantly changed the 
genetic landscape of diseases like RA. Now with the sequencing of a thousand genomes 
(www.1000genomes.org) the genetic community can expect advances on the evaluation of 
previously unaddressed rare and structural variants in health and disease potentially leading to 
an even greater understanding of the role of variation in common diseases. In addition, great 
progress is expected in the coming years in translating these genetic findings into functionally 
relevant targets for therapeutic interventions.  
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Reumatoïde artritis (RA) is een chronische auto-immuunziekte met een prevalentie van één 
procent onder de Nederlandse bevolking. Ondanks dat de etiologie van RA nog grotendeels 
onbekend is, is bekend dat zowel erfelijke als genetische factoren betrokken zijn bij ontstaan en 
progressie van ziekte. Het onderzoek beschreven in dit proefschrift heeft zich geconcentreerd 
op kandidaat genen die mogelijk een rol spelen bij RA; dit om meer inzicht te krijgen in de 
erfelijke factoren die ten grondslag liggen aan het ziekteproces. Het identificeren van deze 
risicofactoren zal uiteindelijk leiden tot een beter begrip van het ziekteproces, en kan daardoor 
bijdragen tot een betere behandeling. Genetische risicofactoren worden gevonden doordat de 
natuurlijk voorkomende genetische variatie in een andere frequentie voorkomt in patiënten dan 
in personen zonder RA. 
Het eerste deel van dit proefschrift (Hoofdstukken 2-5) beschrijft de ontdeking van een 
genetische risicofactor voor RA op chromosoom 9. Deze variatie ligt op een stukje DNA, dat 
voor twee genen codeert: Tumour Necrosis Factor Receptor Associated Factor 1 (TRAF1) en 
Complement factor 5 (C5). Deze ontdekking is inmiddels bevestigd in duizenden patiënten uit 
Nederland, Zweden, de VS, Frankrijk en Engeland. Echter, dit is een van de weinige 
risicofactoren waarvan ook in 1356 familieleden uit 452 families is aangetoond dat hij 
preferentieel met RA overerft. Deze variatie is niet alleen geassocieerd met RA maar ook met 
juvenile arthritis (JIA) en systemic lupus erythematosus (SLE). Dit toont aan dat deze 
risicofactor mogelijk in een biologische route ligt die een bijdrage levert aan deze verschillende 
auto-immuunziekten.  
In het tweede deel van dit proefschrift wordt onderzoek beschreven over het interleukine-10 
(IL10) gen. IL10 is een belangrijk ontstekingonderdrukkend cytokine en is bij vele aspecten van 
de immuunreactie betrokken. Uit voorafgaand onderzoek is gebleken dat DNA varianten in dit 
gen mogelijk verantwoordelijk zijn voor de verschillen in het maken van IL10 tussen mensen. 
Een lage IL10 produktie is geassocieerd met het ontwikkelen van familiale osteoartritis. In het 
kader hiervan heeft dit onderzoek het verband tussen genetische variaties van IL10 en 
osteoartritis bekeken. De bevindingen laten geen associatie tussen IL-10 en deze ziekte zien 
(Hoofdstuk 6).  
Omdat IL10 zo’n belangrijke rol speelt bij het immuunsysteem is het onderzoek naar de invloed 
van ons DNA op het maken van dit cytokine zeer interessant. Wij hebben het gebied op het 
DNA waar de erfelijke variaties, geassocieerd met verschillen in IL10 produktie, gelegen kunnen 
zijn, nauwkeurig in kaart gebracht. Tevens hebben we aangetoond dat een haplotype in dit 
gebied gecorreleerd is met allel-specifieke transcriptie van het gen (Hoofdstuk 7). In 
hoofdstuk 8 zijn de resultaten beschreven over een associatie van drie polymorfismen van het 
IL10 gen die mogelijk betrokken zijn bij de ontwikkeling van restenose. Restenose is het 
opnieuw vernauwen van een ader, nadat deze met een klein ballonnetje op een katheter is 
opgerekt om een verstopping op te heffen. IL10 is een interessante kandidaat voor verbetering 
van anti-restenose therapie, aangezien dit een van de meest bestudeerde anti-inflammatoire 
cytokinen is. IL10 is een risico marker voor het ontwikkelen van restenose. Een therapie gericht 
op IL-10 zou mogelijk kunnen bijdragen tot het verbeteren van individuele therapie, aangezien 
de cytokinen zoals IL-10 kunnen worden aangepakt door middel van een drug-eluting stent. In 
Hoofdstuk 9 wordt de rol van genetische varianten in het IL10 gen in relatie tot RA beschreven. 
Dit lijkt geen belangrijke rol te spelen voor respectievelijk de ernst en de remissie van RA 
patienten. 
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In het derde deel van dit proefschrift wordt onderzoek gedaan naar de rol van verschillende 
andere genetische risicofactoren. In Hoofdstuk 10 wordt de associatie tussen TNF  en de 
ernst van RA beschreven. Ondanks het feit dat RA patienten vaak grote hoeveelheden TNF  
eiwitten maken en dat het gebruik van anti-TNF therapie in de kliniek effectief is, hebben wij 
geen correlatie tussen genetische varianten in dit gen en het verloop van de ziekte kunnen 
aantonen. Recentelijk is er een gen-gebied ge dentificeerd dat een TNF-gerelateerd molecuul in 
kaart brengt. In Hoofdstuk 11, wordt de link tussen TNF -induced protein 3 (TNFAIP3) en de 
ernst van RA beschreven. Onze studie laat een correlatie zien tussen TNFAIP3 en het krijgen 
van een ernstigere vorm van de ziekte.  
In Hoofdstuk 12 wordt de onafhankelijk replicatie in de Nederlandse populatie en een meta-
analyse van drie beschreven genetische risico factoren (STAT4, CTLA4 en IL2/21) 
bediscusci!erd. Wij laten zien dat CTLA4 inderdaad geassocieerd is met RA maar dat deze 
associatie alleen gevonden wordt in een deel van de patiëntenpopulatie; de autoantilichaam 
positieve pati!nten. In Hoofdstuk 13, wordt de bevinding dat het IL2/21 gebied niet alleen een 
rol speelt bij RA, maar ook bij JIA, beschreven. In Hoofdstuk 14, worden genetische varianten 
in het IRF5 gen beschreven. Deze lijken voornamelijk geassocieerd met het krijgen van een 
autoantilichaam-negatieve vorm van RA. In Hoofdstuk 15 worden zeer recent gevonden 
genetische risco-factoren beschreven. Deze studie is verricht in het kader van een grote 
consortium studie, waarbij een significante associatie met een polymorfisme in CD40 is 
gevonden. Omdat CD40 een centrale rol vervult binnen het immuunsysteem, is het hoogst 
waarschijnlijk dat het gevonden gen belangrijk is voor de ontwikkeling en instandhouding van 
RA. In Hoofdstuk 16 wordt de replicatie van twee belangrijke genen in de IL-2 route (IL2RA en 
IL2RB) beschreven. Deze route is nauw betrokken bij de totstandkoming van specifieke 
afweerreacties tegen antigenen. Deze studie geeft aan dat naast de CD40 signaleringscascade, 
de IL2-receptor signaleringscascade ook een belangrijk rol zou kunen spelen bij het 
ontwikkeling van RA. 
De resultaten die worden beschreven in dit proefschrift hebben geleid tot nieuwe inzichten in de 
rol van vaak-voorkomende genetische varianten in een complexe ziekte als RA. Deze 
bevindingen zullen zeker leiden tot een beter begrip van het ziekteproces, wat in de toekomst 
mogelijk toegepast kan worden bij het ontwikkelen van nieuwe behandelingen voor RA. 
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